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ABSTRACT 
Irving Coy Allen, Jr. 
G Protein-Coupled Receptors in the Neuropathophysiology of Asthma 
(Under the direction of Dr. Beverly H. Koller, PhD) 
 
Asthma is a complex genetic disorder with environmental influences and is 
characterized by airway inflammation, reversible airflow obstruction, and airway 
hyperresponsiveness (AHR).  The arachidonic acid metabolite thromboxane A2 (TXA2), is a 
potent lipid mediator released by platelets and inflammatory cells and is capable of inducing 
bronchoconstriction.  In the airways, it has been postulated that TXA2 causes airway 
constriction by direct activation of TP receptors on airway smooth muscle (ASM) cells.  Here 
we demonstrate that although TXA2 can mediate a dramatic increase in ASM constriction, 
this response is largely dependent on vagal innervation of the airways and is highly sensitive 
to muscarinic acetylcholine receptor (mAChR) antagonists.  Further analyses demonstrate 
that TP-dependent ASM constriction requires M3 mAChR expression.  To further define the 
mechanism underlying TXA2 meditated airway constriction, mice carrying a Tp receptor 
locus that is sensitive to disruption by cre recombinase were generated.  These mice were 
crossed with nestin-cre transgenic mice, which express cre recombinase throughout the 
nervous systems.  Here we demonstrate that loss of the TP receptor throughout the nervous 
system does not significantly affect TXA2 airway reactivity.  To assess ASM TP receptor 
function, we crossed the floxed Tp receptor mice with SM22-cre transgenic mice, which 
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express cre recombinase in smooth muscle.  The resultant smooth muscle TP receptor 
deficient animals demonstrate attenuated airway responses following aerosol challenges with 
TXA2.  Together, these findings suggest that TXA2 mediates airway reactivity and AHR 
through collaborations between ASM Tp receptors and the M3 mAChR.  
In addition to TXA2, we also evaluated the role of NPSR1 (GPRA), a newly 
deorphanized G protein-coupled receptor that has been shown to be a promising candidate 
gene associated with asthma in human populations.  We report here that the change in airway 
resistance in response to methacholine was identical in control and NPSR1 deficient mice 
and the development of allergic lung disease in NPSR1 deficient mice is unaltered.  In 
contrast to previously published data, our analyses also failed to detect expression of NPSR1 
in human lung tissue or in mice with allergic lung disease. Taken together, our studies fail to 
support a direct contribution of NPSR1 to asthma pathogenesis.   
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CHAPTER I 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Nature and Significance Of Asthma 
Asthma is a complex genetic disorder with environmental influences and is defined 
by the presence of chronic airway inflammation, airway hyperresponsiveness (AHR), and 
reversible airflow obstruction.  The presence of these three cardinal features, distinguishes 
asthma from other obstructive airway diseases, such as chronic obstructive airway disease 
(COPD), cystic fibrosis (CF), and viral wheeze (159).  The chronic airway inflammation 
associated with asthma is eosinophillic in nature and typically involves mucus 
hypersecretion, airway smooth muscle (ASM) hypertrophy, collagen deposition, and mast 
cell degranulation.  In addition to airway inflammation, the presence of AHR is a common 
finding in asthmatic individuals and is characterized by an exaggerated response to an 
otherwise mildly provoking aerosol stimulus, such as methacholine (MCh).  The degree of 
the resultant AHR has been demonstrated to correlate with asthma severity (108).  While a 
matter of contention, it seems likely that incessant exposure of the airway smooth muscle 
(ASM) to inflammatory mediators is likely to modify the physiology of the smooth muscle, 
thus contributing to the AHR.  ASM constriction also contributes to the reversible airflow 
obstruction that sets asthma apart from the other obstructive airway diseases.  In the 
asthmatic airway, airflow obstruction in highly variable and can reverse either spontaneously 
or with treatment.  Clinically, this reversible airflow obstruction is the target of most fast 
acting and emergency asthma therapies, such as the β-agonists that relax ASM constriction 
by signaling through norepenepherin receptors. Norepenepherin signaling is the primary 
dilatory mechanism in the airways.  
For the past 20 years, a worldwide asthma epidemic has been underway, with 
morbidity and mortality associated with this disease increasing throughout industrialized 
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nations (2, 45).  In the United States, asthma is now the most prevalent disease of early 
childhood and affects approximately 20 million people.  Of these affected individuals, 
approximately 5 million are children under the age of 18 (1).  Asthma is considered to be a 
potentially fatal disease that results in approximately 1.9 million emergency room visits 
annually and 4000 deaths per year (3). Asthma morbidity is disproportionately higher among 
inner-city residents and continues to increase in all age groups, sexes, and across all racial 
and ethnic backgrounds (127).   The cost of asthma in the United States, in the year 2000, has 
been estimated at 13.8 billion dollars (160).  This figure represents both direct costs (such as 
inpatient and outpatient medical care, physician services, and short-term and long-term 
treatment regimes) and indirect costs (such as absence from work and school, time waiting 
for care, and death).  However, the costs associated with a diminished quality of life (such as 
increased anxiety, pain, and suffering) are not included in this estimate because they are 
difficult to accurately assess in economic terms. 
The heterogeneity of the therapeutic responses to treatment and the variable 
underlying genetic and environmental factors that influence the risk of developing the 
disorder, suggests that asthma is probably not a single disease but rather a syndrome 
comprised of multiple diseases with a set of similar symptoms (15, 41).  This syndrome has a 
complex heritable pattern that is influenced by a number of genes that can contribute to an 
individual’s susceptibility to developing asthma.  Previous studies have shown that children 
who have one parent with asthma have approximately a 25% chance for disease 
development, while those with both parents affected have a 50% risk of disease (109).  In 
general, data from twin studies suggest that the concordance rate of asthma is higher among 
monozygotic twins compared with dizygotic twins.  For example, a study involving a large 
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cohort of Norwegians found a concordance of asthma of 17.9% in monozygotic twins for the 
relative risk for development of disease versus only 2.3% for fraternal twins (59).   
In general, large-scale linkage analysis projects have only recently revealed 
promising candidate genes for asthma and atopy.  One of the earliest linkage studies for 
asthma susceptibility and atopy was initiated in the late 1980’s and early 1990’s by Cookson 
et al. and ultimately demonstrated linkage on chromosome 11, in a region later mapped to the 
β chain of the high affinity IgE receptor (30).  However, over a decade later, the first 
positionally cloned gene associated with asthma susceptibility was identified as ADAM33 on 
chromosome 20p (152).   This gene, a disintegrin and metalloproteinase homologue with 
functional relevance in the airways, demonstrated a powerful association in UK and US 
populations.  However, subsequent attempts to replicate the original observations in other 
populations or to observe allelic association between asthma and ADAM33 polymorphisms 
have failed to confirm a role for this gene in asthma susceptibility (65, 74, 87, 93, 117).  In 
the 4 years since ADAM33, no fewer than 119 other promising candidate genes have been 
identified through linkage analysis and/or positional cloning (Table 1.1).  Over 50 of these 
genes have demonstrated a strong association with the asthmatic phenotype in several 
different human populations (reviewed in (112)).  As for the asthmatic phenotype, it should 
also be noted that segregation analyses have demonstrated that airway hyperresponsiveness 
and atopy are both genetically distinct, but clinically correlated (116).  While all of these 
genes appear to confer a moderate risk of asthma and variable effects on pathophysiology, in 
most cases the biological mechanisms by which these genes influence asthma and atopy 
remains uncharacterized.   
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Table 1.1.  Genes associated with asthma or atopy (modified from Ober, 2006)  
 
Gene Chromosomal location Gene
Chromosomal 
location Gene
Chromosomal 
location
CLCA1 1p22 CD14 5q31 AICDA 12p13
VCAM1 1p21 UGRP1 5q32 VDR 12q13
GSTM1 1p13 SPINK5 5q32 STAT6 12q13
CHIA 1p13 ADRB2 5q32-34 IFNG 12q15
DAP3 1q22 IL12B 5q31-33 NOS1 12q24
SELP 1q24 HAVCR1 5q33 FLAP 13q12
COX2 1q31 HAVCR2 5q33 CYSLTR2 13q14
IL10 1q32 CYFIP2 5q33 PHF11 13q14
AGT 1q42 LTC4S 5q35 TCRA/D 14q11
CHRM3 1q43 EDN1 6p24 CMA1 14q11
ACP1 2p25 HLA-G 6p22 PTGDR 14q22
KCNS3 2p24 LTA 6p21 PTGER2 14q22
IL1RL1 2q11 TNF 6p21 AACT 14q32
IL1A 2q13 HLA-DRB1 6p21 IL4RA 16p12
IL1B 2q13 HLA-DQA1 6p21 CARD15 16q12
IL1RN 2q13 HLA-DQB1 6p21 NOS2A 17q11
DPP10 2q14 TAP1 6p21 CCL2 17q12
HNMT 2q22 HLA-DPB1 6p21 CCL11 17q12
STAT4 2q22 HLA 6p21 CCL5 17q12
CTLA4 2q33 PAFAH 6p12 STAT3 17q21
ICOS 2q33 IFNGR1 6q23 CRHR1 17q21
IL8RA 2q35 NOD1 7p15 ITGB3 17q21
IL5RA 3p26 GPRPA 7p14 TBX21 17q21
CCR3 3p21 CCL26 7q11 ACE 17q23
CCR5 3p21 CCL24 7q11 TBXA2R 19p13
TLR9 3p21 CFTR 7q31 C3 19p13
TLR10 4p14 NOS3 7q36 IL12RB1 19p13
TLR6 4p13 DEFB1 8p23 TGFB1 19q13
MUC7 4q13 NAT2 8p22 SCCE 19q13
IL8 4q13 IKAP 9q31 ADAM33 20p13
PGDS 4q22 TLR4 9q33 IFNGR2 21q22
IL15 4q31 C5 9q33 MIF 22q11
EDNRA 4q31 GATA3 10p14 GSTT1 22q11
TLR2 4q31 CXCL12 10q11 TIMP1 Xp11
IRF2 4q35 ALOX5 10q11 CXCR3 Xq13
IL3 5q23 FCER1B 11q12 IL13RA1 Xq24
CSF2 5q23 CRTH2 11q12
IRF1 5q23 CC16/CC10 11q12
IL5 5q23 GSTP1 11q13
IL13 5q23 IL18 11q23
IL4 5q23 C3AR1 12p13
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The History of Asthma:  From Antiquity to the Modern Era 
The term “Asthma” is derived from the Greek verb aazein, meaning “to exhale with 
open mouth or pant” and was first used in the Iliad of Homer to describe the breathing of a 
warrior who died at the end of a battle with “asthma and perspiration” (Iliad 0 241; reviewed 
in (100)).  However, the history of asthma actually begins much later in Egypt in the 1870s 
with the discovery of the Georg Ebers Papyrus.  This document, produced around 1500 BC, 
chronicles the lives of the Ancient Egyptians in hieroglyphics and in particular describes the 
use of powdered mixtures containing sesame, balsam apple, and frankincense to treat 
diseases of the respiratory system (which would have included asthma).  This document 
details the placing plant extracts on heated stones and covering the extracts with a jar, which 
has a reed inserted through the bottom.  Individuals suffering from respiratory distress would 
be instructed to place their mouths around the reed and swallow the aromatic fumes (43).  
Thus, this papyrus describes the first use of inhalational therapy as a treatment for respiratory 
diseases.  While the Ebers Papyrus is the oldest medical document to reference therapies for 
respiratory diseases, historical records indicate that the Ancient Chinese were actually 
treating the symptoms of these diseases almost 1500 years prior to the Egyptians (Table 1.2).  
Around 160 BC, The Yellow Emperor’s Canon of Internal Medicine appeared and describes 
the ancient use of the herb Ma Huang for respiratory ailments (129).  In the 1900s, the active 
chemical of Ma Huang was isolated and identified as “ephedrine”.   
Almost a thousand years after Hippocrates first used the word asthma as a medical 
term to describe difficult or labored breathing, Moses Maimonides, a medieval Jewish 
physician and rabbi, described the first successful treatment of a patient with asthma in his 
Treatise on Asthma.  In this volume, Maimonides was summoned to care for an unnamed 
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Table 1.2.  The History Of Asthma From Antiquity To The Renaissance 
 
 
  
 
 
 
  
 
 
  
 
 
 
 
  
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
3000 BC Historical records suggest the Ancient Chinese treated asthma symptoms with Ma 
Huang.  In the 1900’s scientists identified the active chemical of Ma Huang and called 
it “ephedrine”. 
1500 BC In Ancient Egypt, sufferers of asthma symptoms were treated with a powdered mixture 
of figs, grapes, beer, frankincense, and animal dung.  Hieroglyphics from the period 
describe a treatment in which plant extracts are heated on stones and the patient would 
inhale the rising vapors. 
718 BC The term “Asthma” is first used as a descriptive term for shortness of breath in The 
Iliad of Homer.  It is derived from the Greek verb aazein, which means to exhale with 
open mouth or to pant. 
460-360 BC Asthma is first used as a medical term in the writings of Hippocrates.  However, the 
term asthma was used interchangeably with dyspnea, tachypnea, and orthopnea.  The 
Hippocratics noted that adults were considered more prone to asthma then children, 
conditions worsened in warmer districts, and symptoms were more prevalent during 
the fall and summer months. 
509 BC – 476 AD The Ancient Romans adopted many of the medical beliefs of the Ancient Greeks and 
were the first to recognize the connection between dirt and disease. However, little 
progress was made in treating asthma, with medical texts referring to the use of 
vinegar, millipedes, and homogenized fox lungs 
140 AD The Greek physician Aretaeus Cappadox wrote accurate descriptions of the disease 
symptoms and progression.  He was also the first person to characterize asthma as an 
autonomous clinical entity. 
130 – 200 AD Claudius Galen further characterized the symptoms of asthma and then systematically 
confirmed his theoretical and clinical observations with experiments on animals.  In his 
treatise On Anatomical Operation, he demonstrates that surgical severing of specific 
muscles and nerves can induce forceful and labored breathing.     
476 AD The Middle Ages begins with the Collapse of the Roman Empire, with much of the 
previously learned medical knowledge lost.  Asthma remedies revert back to primitive 
treatments such as animal bones and dung.  In the Byzantine Empire, chemical burning 
and skin blistering was used to pull the irritating substances from the body.  Arab 
physicians promoted arsenic based therapies as a cure for asthma. 
625 – 690 AD Bleeding was advocated as an asthma therapy in the writings of the Byzantine 
physician, Paulus Aegineta.  This practice continued on into the 17th century. 
1135 - 1204 AD Moses Maimonides, a Jewish physician and rabbi, composes his Treatise on Asthma, in 
which he suggests that asthma may be related to environmental factors and 
recommended patients move to dry climates, outside of cities, with ample fresh air, 
clean water, and a healthy diet. 
1552 AD Gerolamo Cardano, an Italian physician was summoned to Scotland to attend to John 
Hamilton, Archbishop of St. Andrews who had suffered from asthma for over 10 years. 
Cardano determined that the Archbishop was sick because he was too hot and thus 
instructed the patient to go out into fresh air as often as possible and stay away from 
smoky fires.  He also directed the Archbishop to no longer sleep on feather mattresses, 
as they would make him to hot.  Physicians at the time did not realize the existence of 
allergies.  In retrospect, it is likely that the Archbishop’s asthma symptoms were a 
result of his being allergic to feathers.  Thus, Cardino’s approach was instantly 
successful, making him the most celebrated European physician of his day. 
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patient who suffered from severe headaches, which did not allow him to wear his turban.  
The patient’s symptoms were similar to the common cold and always appeared during the 
rainy season, which forced him to gasp for air until phlegm was expelled (128).  In his 
writings, Maimonides outlined the benefits of proper diet and the minimal use of powerful 
remedies.  Most notably, he provides a description of the various climates of the Middle East 
and discusses the improvements observed in asthma suffers who relocate to the drier climates 
of Egypt, as well as, the benefits of fresh air, clean water, and rural living (128).  
While widespread pharmacological therapy for respiratory diseases was still centuries 
away, by the end of the Renaissance the most common therapy for asthma focused on 
lifestyle changes including improved hygiene, balanced diet, fresh air, and relocation to dry 
climates. The Italian physician Gerolamo Cardano, who had been summonded from Italy to 
Scotland to attend to John Hamilton, Archbishop of St. Andrews, first described this 
treatment strategy in 1552 AD.  The Archbishop had been severely afflicted with asthma for 
over a decade and because of his powerful status, his condition had attracted a lot of attention 
from the medical community of the period.  Upon arriving Cardano assessed the 
Archbishop’s condition and ultimately determined that his patient was sick because he was 
too hot.  Cardano instructed the Archbishop to stay away from smoky fires and spend 
extended time in the fresh air.  Almost serendipitously, Cardano also reasoned that the 
feather beds the Archbishop was sleeping on was making him too hot at night and thus, 
instructed his patient to avoid feather beds and only sleep upon spun silk.  The Archbishop 
rapidly recovered and was a prominent figure throughout Scotch politics until he was hung 
15 years later (39).  In retrospect, the Archbishop’s asthma symptoms were likely the result 
of his being allergic to feathers.  While described throughout history, the connection between 
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animals and the symptoms of asthma were not fully realized until the early 1900s with S.J. 
Meltzer’s work with antigen induced anaphylaxis in guinea pigs (Table 1.3).   
Expanding upon Cardano’s work, Sir John Floyer, an English physician who was also 
an asthma sufferer, published A Treatise of the Asthma in 1697.  In this book, he provides a 
detailed account of the disease taken from 30 years of carefully documenting his own 
symptoms.  The factors that he noted induced asthma exacerbations included exercise, air 
pollution, tobacco smoke, some occupations, and prior disease exposure.  Floyer was the first 
to introduce the possibility that heredity plays some role in asthma and provides the first 
detailed description of the pathological changes that occur in the lungs caused by 
emphysema.  As human autopsies were still taboo, his observations were taken from a 
broken-winded mare. 
During the mid-nineteenth and early twentieth century, asthma was formally 
described as a psychoneurosis, involving both vascular and neural mechanisms.  The 
foundation for this description was based on the early work of Henry Hyde Salter, a London 
physician who published his ‘Treatise on Asthma; Its Pathology and Treatment’ in 1860 
(Table 1.3).  Although the concept of allergy had not yet been introduced, Salter discussed 
the relationship between animal emanations and increased episodes of asthma.  Salter also 
alludes to the hereditary nature of the disease and also appreciated the importance of 
emotional disturbances in asthma (63).  One of Salter’s major contributions to the 
understanding of asthma was the production of a comprehensive classification of the stimuli 
associated with exacerbations.  These stimuli included exercise, cold air, animal/plant 
emanations, and chemical and mechanical irritants.  By characterizing the mechanisms by 
which these stimuli induced acute episodes, Salter proposed that inflammation or congestion 
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Table 1.3:  The History Of Asthma From The Scientific Revolution To Modern Era 
 
 
  
 
 
 
 
  
 
 
  
 
 
  
 
  
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
1656 Pierre Borel developed the first diagnostic skin test.  He applied egg extracts to patient’s skin 
to demonstrate egg sensitivities. 
1697 Sir John Floyer, an English physician who was also an asthma sufferer, published A Treatise 
of the Asthma.  In this book, he provides a detailed account of the disease taken from 30 years 
of carefully documenting his own symptoms.  The factors that he noted induced asthma 
exacerbations included exercise, air pollution, tobacco smoke, some occupations, and prior 
disease exposure.  He also introduced the possibility that heredity plays some role in asthma.  
Floyer provides the first detailed description of the pathological changes that occur in the 
lungs caused by emphysema.  As human autopsies were still taboo, his observations were 
taken from a broken-winded mare. 
1811 Reports from England suggest that smoking the leaves of Datura stramonium provides relief 
from asthma symptoms.  Both the leaves and seeds of this plant contain atropine.  Smoking 
atropine and ingesting anticholinergic powders remained a common therapy well into the 20th 
century. 
1816 R.T. H. Laennec invents the stethoscope. 
 
1819 John Bostock, a London Physician, describes a seasonal nose infection that becomes known 
as hay fever 
1833 Atropine, an anticholinergic alkaloid, is isolated from the Atropa belladonna (Nightshade) 
plant 
1844 John Hutchinson invents the Spirometer 
 
1860 Henry Hyde Salter, a physician and asthmatic, provides a comprehensive classification of the 
stimuli associated with acute episodes; however, he also realized that external stimuli were 
not the sole cause of exacerbations.  He hypothesizes that inflammation, functioning through 
nerves of the air tubes, could be the stimulus that induces airway muscles to contract. 
1861 The methylxanthine of coffee is isolated and named “caffeine”.  Use of strong coffee as an 
asthma therapy is often attributed to Henry Hyde Salter; however, evidence suggests that Sir 
John Floyer actually initiated this practice. 
1888 The methylxanthine of tea is isolated and named “theophylline’.  In 1940, published in Cecil’s 
Textbook of Medicine, the use of theophylline as a bronchodilator is encouraged and the 
practice continues to the present day. 
1892 Sir William Osler, in his first edition of Principles and Practice of Medicine, connects the 
reduced airway function of asthma with physiological changes in the lungs that include 
airway hyperresponsiveness, bronchial mucosal oedema, inflammation, mucus production and 
the presence of octahedral crystals (Charcot-Leyden crystals) in the sputum.  Osler’s 
description of exacerbations being induced by psychogenic stimulation leads to asthma being 
characterized as a psychoneurosis and thus, sedatives become a common therapy.  
1900 Adrenal extracts are used in the treatment of asthma. 
1906 Austrian Pediatrician Clemens von Pirquet first uses the word allergy, from the Greek word 
‘alol’ meaning change in the original state, to describe the non-disease related symptoms that 
developed following treatment with a horse serum antitoxin. 
 
1910 B. Melland injects adrenaline into asthma patients and describes dramatic improvements 
 
1910 S.J. Meltzer proposes that asthma in humans and anaphylaxis in guinea pigs are equivalent 
phenomena.  From this point forward, asthma was no longer considered a neurosis. 
 
1911 Henry Dale and Patrick Laidlaw found that histamine created effects similar to those 
described for anaphylaxis. 
 
1914 Inhaled or injected anticholinergics become the first line asthma therapy. 
 
1916 Isaac Chandler Walker describes positive dermal reactions of asthmatics to proteins derived 
from animals, foods, and bacteria. 
 
1921 Parusnitz and Kuster identify a “reaginic antibody” that passively transfers the acute response 
from one individual to another.  This antibody is later identified as IgE. 
 
1922 Huber and Koessler report on the eosinophilic nature of the inflammation associated with 
asthma. 
 
1920-1930 Theophylline deriviatives begin routine use as bronchodilators. 
 
1937 Cortisone is identified as compound E from the adrenal glands 
 
1940–1950 The anti-inflammatory actions of glucocorticosteroids were recognized. 
 
1946 J.J. Curry characterizes the bronchial hyperresponsiveness to graded challenges of histamine. 
 
1950 Corticosteroids become available as an inhaled asthma therapy. 
 
1953 Riley and West propose the connection between allergens, mast cells, and histamine. 
 
1960s β2-adrenergic agonists are developed for rescue bronchodilation. 
 
1967 The Middle East herbal remedy Khellin had been used for centuries as an antispasmonic. 
Roger Altounyan developed the synthetic khellin analogue, disodium cromoglycate, which is 
safe and effective at controlling bronchospasm when inhaled.    
 
1972 Ipatropoium bromide, a quaternary atropine derivative, is developed as an inhaled 
anticholinergic therapy for asthma and other obstructive airway diseases. 
 
1975 Bengt Samuelsson describes the generation of prostaglandins and leukotrienes from 
arachidonic acid. 
 
1997 The first new class of asthma drugs in 30 years appears.  The 5-lipooxigenase inhibitor 
(zileuton) and leukotriene receptor (CysLT1) antagonists are shown to reduce asthma 
exacerbations and significantly improve lung function. 
 
1997 Anti-IgE therapies are introduced in an attempt to reduce the amount of circulating IgE.  
Thus, this new therapy may be able to reduce the amount of corticosteroids required to control 
asthma exacerbations. 
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was capable of stimulating airway nerves to induce muscle contractions (101).  The use of 
anticholinergic and methylxanthine-containing herbal remedies as antispasmodics dates back 
to antiquity; however, Salter is typically credited with characterizing the successful 
management of asthma with either atropine or strong coffee ((130, 131); reviewed in (26)).   
Anticholinergic agents, including the modern preparations of ipratropium bromide 
and tiotropium bromide, have proven to be effective bronchodilators and are utilized in the 
management of acute asthma.  However, their use as therapies in mild intermittent asthma 
has not been approved in the United States, despite successful clinical trials and the reported 
improvement of conditions in the subsets of patients who demonstrate adverse effects to 
adrenergic bronchodilators (70); reviewed in (22)).  The recognition that the active xanthines 
in coffee and tea could actually be useful as bronchodilators was not realized until the 1920s; 
however, by the 1940s aminophylline (the ethylene diamine salt of theophylline) was widely 
used in the management of acute asthma (reviewed in (26)).  Theophylline is currently used 
in asthma therapy as a third-line drug (analogous to long-acting inhaled β2-agonist) and is 
utilized in difficult to treat asthma where rescue β2-agonist and corticosteroid treatments 
demonstrate reduced efficiency in controlling exacerbations (26). 
As the twentieth century progressed, research shifted from viewing asthma as a 
disease of the nervous system to a disease of smooth muscle dysfunction with substantial 
research efforts being shifted towards understanding the pathobiology of the disease.  In 
1946, J.J. Curry characterized the airway reactivity (excessive airway narrowing and 
bronchial hyperresponsiveness) to dose response challenges of histamine in asthmatics 
(reviewed in (101)).  Subsequently, in 1947 the Middle Eastern herbal remedy and anti-
spasmodic Khellin, was reported to have efficacy as an asthma therapeutic (5); reviewed in 
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(26)). However, Khellin is relatively insoluble and has a variety of undesired side effects.   
Its mainstream use as an asthma therapy was due to the persistence of Roger Altounyan, a 
physician of Middle Eastern decent, who happened to be severely asthmatic in response to 
guinea pig dander.  Altounyan tested extracts from the active ingredients of several anti-
asthmatic folk remedies on himself after inhalation of guinea pig dander and through this 
process identified the safe and effective synthetic khellin analogue, disodium cromoglycate 
(reviewed by (22, 26)).  While the mode of action of this class of compounds is still 
incompletely understood, the cromones are useful asthma therapies that inhibit exercise-
induced and allergen-induced bronchospasms (26).         
During the 1970’s and 1980’s multiple lines of research clearly demonstrated that 
airway smooth muscle is the key effector of acute airway narrowing in asthma exacerbations.  
However, to date, investigators have not been able to conclusively identify a specific 
functional abnormality of smooth muscle derived from asthmatic individuals that correlates 
with the bronchial hyperresponsiveness observed in the diseased airway.  With few 
exceptions, smooth muscle tissues isolated from asthmatics and assessed by isometric force 
generation have demonstrated normal contractile function (140).  This absence of functional 
ASM abnormalities has lead to the development of alternative hypotheses, which attempt to 
explain bronchial hyperresponsiveness and airflow obstruction including: 1) excessive ASM 
constriction in asthma is due to decreased airway elastance; 2) increased ASM mass in the 
asthmatic airway is capable of generating greater total force and increased airway narrowing; 
and 3) airway remodeling, airway edema, and/or increased cellular infiltration amplifies 
luminal narrowing, regardless of ASM dysfunction (140).  Despite the complete 
understanding of the underlying mechanisms behind airway obstruction and bronchial 
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hyperresponsiveness, the foundation of the current approach to asthma pharmacotherapy is 
based on fast acting adrenergic bronchodilators to relax ASM constriction.  This class of 
bronchodilators was introduced to western medicine during the 1900s in the form of 
adrenaline injections (102) and by the 1950s, metered dose inhalers became available to 
deliver epinephrine and isoproterenol (22, 26).  Today, the use of the relatively specific β2-
adrenergic agonists, such as albuterol, is the primary treatment of acute asthmatic airway 
obstruction due to the rapid onset of action, relatively minor adverse side effects, and the 
resultant bronchodilation lasts approximately 4 to 6 hours. 
Concurrent with advances in understanding mechanisms of smooth muscle 
involvement in airway pathophysiology, mechanisms underlying airway inflammation were 
also being pursued.  Airway inflammation had been observed in the lungs and sputum of 
asthmatic patients since the late nineteenth century.  The histologic features and eosinophilic 
nature of this inflammation was recognized and characterized by Huber and Koessler in 1922 
(67).  Subsequent characterization of lung biopsies and bronchoalveolar lavage fluid (BALF) 
revealed that chronic inflammation was a cardinal feature of asthma pathology during all 
stages (reviewed in (23)).  Expanding upon these studies, mast cells, eosinophils, 
macrophages, and specific subpopulations of T-lymphocytes were shown to have critical 
roles in the immunobiology of asthma (40).  These leukocytes were subsequently shown to 
regulate allergic inflammation and establish disease chronicity through the release of 
inflammatory mediators, such as prostaglandins, leukotrienes, histamine and IgE, which may 
act either directly on airway cells or indirectly through neural mechanisms.  Simultaneous to 
the discovery of the inflammatory aspects of asthma, the anti-inflammatory characteristics of 
the glucocorticoids were also being recognized.  Cortisone was initially identified from 
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adrenal gland extracts in 1936 and was subsequently used to treat the weakness and fatigue 
often suffered by asthmatics (26).  The anti-inflammatory aspects of glucocorticoids were not 
recognized until the 1940s; however, once recognized, corticosteroids were utilized as 
therapies for a wide variety of inflammatory conditions.  Both adrenal corticotropic hormone 
(ACTH) and cortisone injections were used as asthma therapies during the early 1950s, 
ultimately leading to the development of the synthetic corticosteroid analogue 
beclomethasone dipropionate in 1972 (10).  With the increased recognition and 
understanding of the underlying airway inflammatory mechanisms associated with asthma, 
inhaled corticosteroid therapy has become the cornerstone of chronic asthma management.   
 
Is Asthma A Uniquely Human Disease? 
Animal modeling has been vital to elucidating the pathophysiological mechanisms 
underlying multitudes of chronic human diseases and have been essential to the development 
of therapeutics to ease human suffering.  The use of animal experimentation when studying 
the simple physiological processes associated with pulmonary disorders is well established.  
However, many would argue that the complexity of the human airway and the extensive 
structural, physiological, pharmacological, and neuronal changes that are associated AHR 
can not accurately be assessed in model organisms (17, 75).   Indeed it appears that only 
humans and a limited number of other mammalian species have been shown to 
spontaneously develop asthma, as determined by the presence of chronic airway 
inflammation and eosinophilia, AHR, and reversible airflow obstruction.  Of these other 
species, both horses and cats spontaneously develop syndromes that closely mimic the 
human condition.  Horses develop heaves, a naturally occurring equine asthma related to 
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sensitization and exposure to moldy hay.  Heaves is an obstructive pulmonary disease that is 
characterized by chronic airway inflammation, AHR, and airflow obstruction that can 
spontaneously reverse or be reversed following therapy.  The standard of care for heaves is 
similar to that for human asthma, with corticosteroid therapy utilized to manage the 
underlying airway inflammation and β2-adrenergic agonists to relieve ASM constriction (90, 
96).  It has also been demonstrated that horses demonstrate high levels of IgE in response to 
inhaled molds and dust and also demonstrate a positive passive cutaneous anaphylaxis test.  
The airway obstruction associated with heaves has been observed to reverse in situations 
involving only brief exposures to the hay; however, continued or extended exposures can 
lead to an irreversible reduction in airflow (60).  This suggests that, as observed in asthmatic 
humans, the pathogenesis of heaves may also include the remodeling of airway smooth 
muscle (ASM).  Unlike human asthma, the airway inflammation associated with heaves is 
dominated by the infiltration of neutrophils, rather than eosinophils, into the lung tissue of 
affected horses (86, 90).  Similar to heaves in the horse, feline asthma is a naturally occurring 
syndrome in pet cats that closely mimics the features of human asthma.  Affected animals 
demonstrate excessive airway reflexes, mucus secretion, wheezing, and increased AHR (42).  
Like horses and humans, felines respond well to β2-adrenergic agonists and corticosteroid 
therapy.  However, unlike the neutrophilic inflammation observed in horses, the airway 
inflammation observed in feline asthma is eosinophilic in nature and therefore provides a 
more accurate model of the human condition.  To date, the major reluctance to use the feline 
asthma model is the prohibitive cost of maintaining and propagating colonies of asthmatic 
cats (48).  
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Unlike the horse and cat, no laboratory mouse strain spontaneously develops asthma.  
However, allergic lung disease as a surrogate model of asthma can be induced in mice by 
sensitization and challenge with simple protein antigens (e.g. OVA), complex 
microorganisms (e.g. Aspergillus), or chemical compounds (e.g. TDI). Environmentally 
relevant protein antigens derived from cockroaches and house dust mites have also been 
employed (16, 32, 168).  Short-term exposure models utilizing these antigens, in particular 
OVA, have been evaluated extensively and reproduce many features observed in human 
asthma including increases in antigen-specific IgE, increases in Th2 cytokines IL-4, IL-5, 
and IL-13, eosinophilic lung inflammation, goblet cell metaplasia, and airway 
hyperresponsiveness (reviewed in(149).   However, it is important to recognize that these 
short-term exposure models also show many important differences from human asthma 
including: 1) acute peribronchiolar and perivascular inflammation in the lung parenchyma 
(rather than inflammation within the airway wall); 2) lack of activation, degranulation, or 
intra-epithelial accumulation of eosinophils; 3) significantly less plasma exudation in murine 
vs. human airways; 4) lack of structural changes in the airway other than goblet cell 
metaplasia (reviewed in(81)).   
The major advantage of utilizing mouse models to assess changes in airway 
physiology and pathology is the ease at which the mouse genome can be manipulated.  It is 
now a relatively straightforward process to either induce or inhibit gene expression in the 
lungs, either constitutively or in a spatial/temporal manner (Figures 1.1 and 1.2).  These 
methods have been used extensively to determine the function of various genes of interest in 
respiratory disease development and pathogenesis.  Tables 1.4-1.7 list mouse lines, each 
carrying a null mutation in a particular gene, which have been examined in allergic asthma 
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models.  Physiological and histopathological phenotyping of genetically altered mice is now 
commonly used to determine the contribution of candidate genes to asthma pathogenesis.  
Despite their small size, a variety of techniques have been recently introduced to allow 
accurate in vivo assessments of the physiological changes that mediate airflow obstruction 
and AHR in the mouse and are summarized in Table 1.8.  In addition to assessing airway 
function, histopathological phenotypeing is also conducted in these animals and routinely 
includes assessments of bronchoalveolar lavage fluid (BALF) cellularity, relative cytokine 
and chemokine levels present in the BALF and serum, the total and specific immunoglobin 
levels in the serum, the extent of leukocyte infiltration into the lung tissue, and the level of 
mucus hypersecretion. 
 
Allergic Airway Inflammation and Asthma 
Airway obstruction and hyperresponsiveness represent cardinal features of asthma 
and their contribution to the disease process has been recognized for a considerable amount 
of time.  However, the appreciation of the role of airway inflammation in asthma pathology 
is still relatively new.  Several current models suggest that the underlying airway 
inflammation likely plays a critical role in airway obstruction and hyperresponsiveness; 
however, the relationship between inflammation and AHR is still poorly understood.  The 
heterogeneity of the pathophysiology observed in asthmatic individuals has presented 
significant hurdles in understanding the underlying mechanisms affecting airway 
inflammation.  Allergic airway inflammation is a complex process that involves a multi-step 
inflammatory cascade that can be grouped into seven categories:  sensitization; stimulation; 
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Figure 1.1.  Common strategies for the creation of knockout mice.  A) Schematic 
illustration for the development of IL-4Rα deficient mice.  A targeting construct is designed 
containing the gene for neomycin resistance (Neo).  Arms of homology are amplified from 
the endogenous locus from sites immediately 5’ and 3’ to a region critical to proper IL-4Rα 
functioning.  These amplification products are positioned adjacent to the Neo cassette.  
Following homologous recombination, the targeted IL-4Rα region will be replaced with the 
Neo cassette.  B) Schematic illustration of the generation of a lung specific IL-4Rα deficient 
mouse line.  A transgene is designed containing the gene for Cre recombinase under the lung 
specific CCSP promoter.  A second mouse is generated in which critical regions of the IL-
4Rα gene are flanked by loxP sites.  In cells carrying an integrated copy of the loxP2-IL-4rα 
cassette, Cre mediated recombination results in excision and subsequent loss of the flanked 
region.   
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Figure 1.2.  Common strategies for the creation of transgenic mice.  A) Schematic 
illustration of an IL-4 transgene construct.  A generic promoter drives expression of the IL-4 
cDNA.  Intronic regions and a polyadenylation sequence are included to augment transgene 
expression and enhance stability.  B) Schematic illustration of a lung specific IL-4 transgene 
construct.  The CCSP promoter facilitates lung specific constitutive expression of IL-4.  C) 
Schematic illustration of a temporal specific IL-4 transgene construct.  The CCSP promoter 
facilitates lung specific constitutive expression of the reverse tetracycline transactivator 
(rtTA).  rtTA requires the tetracycline derivative, doxycyline, for specific DNA binding to 
the tetracycline operator (tetO).  Once bound, this drives the expression of IL-4.  The 
cytomegalovirus promoter (Pcmv) further augments expression.  D) Schematic illustration of 
a temporal lung specific tTS “on/off” transgene construct.  The CCSP promoter facilitates 
lung specific constitutive expression of both the reverse tetracycline transactivator (rtTA) and 
the tetracycline-controlled transcriptional silencer (tTS).  In this situation, tTS binds to the tet 
operator in the absence of doxycycline.  When doxycycline is administered, the silencer 
releases, allowing the rtTA to facilitate IL-4 expression.  This system was designed to control 
for leaky transgene expression commonly encountered during the use of rtTA alone. 
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Table 1.4.  Cytokine and Cytokine Receptor Deficient Mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cytokine Mouse Strain
Inflammation 
Model AHR Eosinophilia
Airway 
Remodeling References
IL-1α BALB/c OVA ↓ ↓ na Nakae 2003
IL-1β BALB/c OVA ↓ ↓ na Nakae 2003
IL-1 α/β BALB/c OVA ↔ ↓ na Nakae 2003
IL-1R1* Mixed OVA na ↓ na Broide 2000
IL-1R1* BALB/c OVA na ↓ ↓ Schmitz 2003
IL-1Ra BALB/c OVA ↑ ↑ na Nakae 2003
IL-1R1* BALB/c AF ↓ na na Kurup 1999
IL-4* C57BL/6 OVA na ↓ ↑ Herrick 2000
IL-4* BALB/c OVA ↓ ↓ ↓ Leigh 2004
IL-4* C57BL/6 OVA ↓ ↓ na Hamelmann 2000
IL-4Rα BALB/c OVA na na ↓ Whittaker 2002
IL-5 C57BL/6 OVA ↓ ↓ na Hamelmann 2000
IL-5 C57BL/6 OVA ↓ ↓ ↔ Foster 1996
IL-5 C57BL/6 OVA na ↓ ↓ Cho 2004
IL-5 BALB/c IL-13 na ↓ ↔ Pope 2001
IL-5Rα BALB/c OVA na ↓ na Tanaka 2004
IL-5Rα Mixed OVA ↓ ↓ na Tanaka 2000
IL-6 C57BL/6 OVA ↑ ↑ na Wang 2000
IL-6 BALB/c OVA ↔ ↑ ↓ Qiu 2004
IL-8R BALB/c OVA ↓ ↔ ↔ De Sanctis 1999
IL-9 BALB/c OVA ↔ ↔ ↔ McMillan 2002
IL-10* C57BL/6 RW ↓ ↑ na Justice 2001
IL-10* C57BL/6 OVA na ↔ na Ameredes 2001
IL-10* Mixed AF ↔ ↑ na Grunig 1997
IL-10* C57BL/6 OVA ↔ ↑ na Tournoy 2000
IL-12 C57BL/6 OVA na ↑ na Zhao 2000
IL-12p35 C57BL/6 OVA na ↓ na Wang 2001
IL-12p40 
(homodimer) C57BL/6 OVA na ↓ na Wang 2001
IL-13* BALB/c OVA ↑ ↔ ↓ Webb 2000
IL-13* BALB/c OVA ↓ ↑ ↓ Walter 2001
IL-13* BALB/c OVA na na ↓ Whittaker 2002
IL-13* Mixed OVA na ↓ na Herrick 2003
IL-4/IL-13 BALB/c OVA ↓ ↓ ↓ Walter 2001
IL-17 BALB/c OVA ↔ ↔ na Nakae 2002
 
* Conflicting Data
↓ Reduced AHR or Eosinophilia compared with the wildtype animals
↔ No difference in AHR or Eosinophilia compared with the wildtype group
↑ Increased AHR or Eosinophilia compared with the wildtype animals
na not assessed
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Table 1.5.  Chemokine and Chemokine Receptor Deficient Mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemokine Mouse Strain
Inflammation 
Model AHR Eosinophilia
Airway 
Remodeling References
TNF-α C57BL/6 OVA ↑ ↑ na Kanehiro 2001
TNFR1 (p55) C57BL/6 OVA ↓ ↓ na Kanehiro 2002
TNFR2 (p75) C57BL/6 OVA ↔ ↓ na Kanehiro 2002
TNFR1/ TNFR2 C57BL/6 OVA ↔ ↔ ↑ Rudman 2000
INF-γ BALB/c OVA ↔ ↓ na Hofstra 1998
FCεR1α Mixed OVA ↔ ↓ na Mayr 2002
CCR1 Mixed AF ↔ ↔ ↓ Blease 2000
CCR2 Mixed OVA ↔ ↔ na MacLean 2000
CCR2 Mixed OVA ↑ ↑ ↑ Kim 2001
CCR2 Mixed AF ↑ ↑ ↑ Blease 2000
CXCR2 (IL-8r) not listed AF ↑ ↓ ↔ Schuh 2002
CXCR2 (IL-8r)  BALB/c OVA ↓ ↔ ↔ DeSanctis 1999
CXCL10 129/SV OVA ↔ ↓ na Medoff 2002
CCR5 Mixed AF ↓ ↓ ↓ Schuh 2002
CCR6 C57BL/6 CR ↓ ↓ na Lukacs 2001
eotaxin BALB/c IL-13 na ↔ ↔ Pope 2001
eotaxin not listed AF ↓ ↓ na Schuh 2002
IL-5/ eotaxin BALB/c IL-13 na ↓ ↔ Pope 2001
 
 ↓ Reduced AHR or Eosinophilia compared with the wildtype animals
↔ No difference in AHR or Eosinophilia compared with the wildtype group
↑ Increased AHR or Eosinophilia compared with the wildtype animals
na not assessed
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Table 1.6. Th2 Cytokine Signaling Pathway Deficient Mice  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Th2 
Cytokine 
Signaling 
Pathway
Mouse 
Strain
Inflammation 
Model AHR Eosinophilia
Airway 
Remodeling References
Fgr C57BL/6 OVA na ↓ na Vicentini 2002
Hck C57BL/6 OVA na ↔ na Vicentini 2002
PKCζ 129/SVJ OVA na ↓ na Martin 2005
Jak3 Mixed OVA na ↓ na Verbsky 2002
Stat 5α BALB/c OVA na ↓ na Kagami 2000
Stat 5β BALB/c OVA na ↓ na Kagami 2000
Stat6 C57BL/6 OVA na ↓ na Miyata 1999
Stat6 C57BL/6 OVA ↓ ↓ na Akimoto 1998
Stat6 Mixed OVA na ↓ ↓ Herrick 2000
Stat4 BALB/c CR ↓ ↓ ↓ Raman 2003
T-Bet 
(Tbx21) not listed OVA ↑ ↑ ↑ Finotto 2002
TGF-β1 C57BL/6 (HET) OVA ↔ ↑ ↑ Scherf 2005
 ↓ Reduced AHR or Eosinophilia compared with the wildtype animals
↔ No difference in AHR or Eosinophilia compared with the wildtype group
↑ Increased AHR or Eosinophilia compared with the wildtype animals
na not assessed
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Table 1.7.  Prostaglandin and Leukotriene Deficient Mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prostaglandin/ 
Leukotriene
Mouse 
Strain
Inflammation 
Model AHR Eosinophilia
Airway 
Remodeling References
PGHS-1 (Cox-1) Mixed OVA ↑ ↑ ↑ Gavett 1999
PGHS-1 (Cox-1) Mixed OVA ↑ ↑ na Carey 2003
PGHS-2 (Cox-2) Mixed OVA ↓ ↑ ↑ Gavett 1999
PGHS-2 (Cox-2) Mixed OVA ↔ ↑ na Carey 2003
PGHS-2 (Cox-2) C57BL/6 OVA ↓ ↑ ↔ Nakata 2005
DP C57BL/6 OVA ↓ ↓ ↓ Matsuoka 2000
IP C57BL/6 OVA na ↑ na Takahashi 2002
BLT1 BALB/c OVA ↓ ↔ ↓ Miyahara 2005
5-LO Mixed OVA ↓ ↓ na Irvin 1997
 
 ↓ Reduced AHR or Eosinophilia compared with the wildtype animals
↔ No difference in AHR or Eosinophilia compared with the wildtype group
↑ Increased AHR or Eosinophilia compared with the wildtype animals
na not assessed
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Table 1.8.  In vivo physiological assessments of the mouse airway 
 
 
 
 P
 
 
 
 
 A
 
 
 
 E
Method Advantages Disadvantages
Whole Body
lethysmography
(WBP)
Parameters
irway Pressure
Time Index
(APTI)
quation of Motion –
Single Compartment
Model
Forced Oscillation
Technique (FOT) –
Constant Phase 
Model
Penh
Airway Resistance
Resistance   (RL)
Elastance     (Edyn)
Compliance  (Cdyn)
Airway Resistance  (RAW)
Tissue Resistance  (G)
Tissue Elastance    (H)
1) Capacity To Measure 
Serial Changes Over Time
2) Evaluation of Mice During 
Normal Physiological 
Conditions
3) High Throughput and 
Ease of Measurement
1) Lack of Specificity of the 
Penh Parameter
2) Inability to Distinguish 
Contributions of the Upper 
Airway vs Lower Airway
1) Direct Monitoring of 
Respiratory Mechanics 
2) Can Simultaneously Assess 
the Level of Airway 
Resistance, the Ease at 
Which the Lungs Can Be 
Extended, and Lung Rigidity  
Capable of Distinguishing 
Between Central and 
Peripheral Respiratory 
Mechanics
Only Requires Measures 
of Respiratory Pressures, 
Not Volumes or Flows
Pressure Measured Reflects 
Both Airway and Tissue 
Resistance; Thus This Is 
Actually An Assessment of Total 
Respiratory System Impedance
The Single Compartment Model 
Is Based On an Oversimplified 
Model of the Lung; Thus, This 
Method Lacks the Ability to 
Differentiate Between 
Physiological Changes 
Occurring In Various Parts of the 
Respiratory Tree
Similar to Other Methods 
Requiring Anesthesia, Airway 
Modulation by Neural 
Components May be Suppressed
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cell signaling; leukocyte migration into the airways; activation of inflammatory cells; tissue 
stimulation/damage; and resolution.  The following sections discuss the roles of key 
inflammatory cells and mediators involved in this inflammatory cascade. 
 
Lymphocytes 
 The current paradigm to explain T-lymphocyte function in asthma has suggested that 
T helper type 2 (TH2) cells mediate IgE synthesis through the activation of B-lymphocytes by 
IL-4, which results in the subsequent activation of mast cells (Figure 1.3).  In addition to IgE 
synthesis, T-cells are also able to directly initiate eosinophil recruitment thorough IL-5, IL-
13, and GM-CSF production (reviewed by (85)).  The resultant eosinophil infiltration results 
in epithelial damage and ultimately results in ASM remodeling and AHR (Figure 1.3).  The 
evidence for this is supported by the observation that asthmatic individuals present a Th2-
type T-cell cytokine profile, which includes elevated levels of IL-4, IL-5, and IL-13 (125).  
Likewise, association studies have clearly demonstrated that increased levels of T-cell 
activation are associated with asthma severity, the degree of AHR, and airway eosinophil 
influx (123, 124, 157).  
Despite the multitudes of human and animal models of allergic disease, the 
mechanism by which Th2 cytokines affect the cardinal features of asthma remains to be 
elucidated.  The biological roles of IL-4 and IL-5 in vivo were first assessed using transgenic 
mice overexpressing these cytokines in lymphocytes.  In 1990, Tepper et al. used an 
immunoglobulin promoter/enhancer to drive IL-4 transgene expression in lymphocytes (12, 
151). Mice constitutively expressing increased amounts of IL-4 developed a marked increase 
in serum IgE and IgG1 levels, as well as, allergic inflammation in the eyes.  In the same year, 
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Dent et al. reported their findings with transgenic mice over-expressing IL-5 (38).  The 
expression of IL-5 was driven by its own promoter.   IL-5 transgenic mice exhibited 
eosinophilia in the bone marrow, bloodstream, spleen, lymphoid organs, gut, and the lung.  
While these experiments demonstrated an in vivo role for these cytokines in IgE production 
and eosinophilia, two classic phenotypic features of asthma, it was the development of lung-
specific tissue expression systems that has helped elucidate the effects of IL-4, IL-5, and 
other inflammatory mediators on the lung itself.  
Initial studies in IL-4 deficient mice demonstrated that IL-4 was essential for the 
development of allergic airway inflammation, as these mice failed to demonstrate a 
phenotype in response to allergen challenge (11).  Supporting this finding, antibody 
neutralization of IL-4 prior to allergen sensitization prevents the development of allergic 
airway inflammation; however, if the same treatment was given after sensitization but prior 
to allergen delivery to the lung, the antibody treatment was ineffective (31).  These studies 
suggest that IL-4 is essential for the initial development and expansion of antigen specific 
Th2 polarized cells; however, it is not essential for the effector phase of the response.  Prior 
studies of the IL-4 receptor-signaling cascade had demonstrated that this receptor and its 
downstream effectors were essential for the development of disease (53, 83); thus these 
findings suggested that another ligand could signal through the IL-4α receptor.   
IL-13 has been shown to be a potent inducer of AHR, eosinophilic inflammation, and 
mucus hypersecretion in naïve mice when added exogenously or following targeted 
overexpression in the lungs (55, 165, 169).  Based on the similarity of structures between IL-
4 and IL-13, it was hypothesized that IL-13 may also function through the IL-4α receptor.  
Studies conducted with IL-13 deficient mice demonstrated that antigen sensitization and 
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Figure 1.3.  Allergic Airway Inflammation.  Allergic airway inflammation is initiated by 
ction.  
l 
and IL-
xact 
 
allergen presentation at the airway surface by dendritic cells, which results in Th2 cell 
differentiation, cytokine production (IL-4, 5, 9, and 13) and allergen specific IgE produ
Resident lymphocytes, macrophages, and mast cells orchestrate the ensuing inflammatory 
response ultimately characterized by an influx of eosinophils into the airways.  CD4+ T-cel
derived IL-5, IL-13, and GM-CSF facilitates the maturation of eosinophils from CD34+ 
progenitor cells.  Once cells have committed to the eosinophil lineage, IL-5 mediates 
migration from the bone marrow into the vasculature.  Subsequent production of IL-4 
13 at sites of inflammation, induce expression of vascular cell adhesion molecule-1 (VCAM-
1), which binds to the VLA-4 receptors on the eosinophil surface.  This interaction facilitates 
the preferential extravasation of eosinophils through the vessel walls and subsequent release 
of eosinophil chemotactic substances, such as RANTES and eotaxin, from responding 
leukocytes mediate the migration of eosinophils to sites of inflammation.  Though the e
role eosinophils in allergic airway disease in poorly defined, once on site, eosinophils likely 
contribute to the pathogenesis of allergic asthma by acting on fibroblasts, smooth muscle, 
and epithelial cells to ultimately cause airway hyperresponsiveness and remodeling. 
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challenge failed to elicit AHR or significant mucus hypersecretion, despite having increased 
e 
-4 is 
by the IL-4 and IL-13 released 
ently 
  
ease of 
osinophils 
 factors mediate eosinophil recruitment to the inflamed lungs including 
proinfla .  
ule-
levels of IL-4 and IL-5.  These experiments were verified following the observation that 
increased AHR and mucus hypersecretion occurred following reconstitution of IL-13 
deficient mice with recombinant IL-13 (158).  Together, these data demonstrate that th
biological actions of both IL-4 and IL-13 are mediated through the IL-4α receptor and IL
essential for the initiation of the Th2 polarized response to allergens, while IL-13 likely 
mediates the primary pathophysiological immune responses. 
 B-lymphocytes are the primary effector cells targeted 
by T-lymphocytes.  Antigen specific IgE is produced by B-cells following the isotype 
switching from IgM to IgE in response to either IL-4 or IL-13.  IgE antibodies subsequ
bind to the carboxylic fragment of the ε heavy chain of the specific high affinity FcεRI 
receptor, which is predominately expressed on mast cells, basophils, and dendritic cells.
Following allergen exposure, cross-linking occurs between adjacent antigen binding 
components of IgE on mast cells, which induces degranulation and the subsequent rel
mast cell derived mediators (see Mast Cells below).  Since its discovery, the IgE antibody 
has been viewed as a potential target for asthma drug discovery.  Therapeutic approaches 
have included attempts to desensitize atopic subjects to the triggering allergen, as well as, 
attempts to stimulate the anti-IgE production in the patient (reviewed in (33)).       
 
E
Many
mmatory cytokine (IL-4, IL-5 and IL-13) and chemokine (Eotaxin) expression
Increasing levels of IL-4 and IL-13 induce the expression of vascular cell adhesion molec
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1 (VCAM-1) along the pulmonary vasculature at sites of inflammation.  VCAM-1 binds to 
the eosinophil VLA-4 receptor and leads to the extravasation of eosinophils through vessel 
walls into sites of inflammation (Figure 1.3) (164).  Even the unique and complex structure 
of the pulmonary capillary bed and local hemodynamic factors can influence airway 
eosinophilia (98). While airway eosinophilia is a cardinal symptom of asthma, the 
mechanisms underlying eosinophil migration into the inflamed lung is quite comple
completely understood.  Likewise, the actual significance and function of eosinophils in the 
lung tissue and their effects on AHR is poorly defined.  Recent eosinophil deficient mouse 
models have provided unique, yet divergent, insights into the role of airway eosinophilia 
following allergen-mediated respiratory inflammation (68, 88).  Using a knockout mouse 
model lacking a specific high-affinity binding site for the transcription factor GATA-1, 
Humbles et al. demonstrated that eosinophil deficient mice have reduced features of alle
lung disease, such as airway remodeling, but are still capable of developing airway 
hyperreactivity and mucus hypersecretion (68).  On the other hand, Lee et al. demon
that their eiosinophil deficient mice, which are transgenic mice that express the diphtheria 
toxin A chain under the control of the eosinophil peroxidase promoter (PHIL), do not 
develop airway hyperreactivity and demonstrate attenuated mucus hypersecretion (88)
Strain variations and differences in the methods utilized to generate the eosinophil defici
mice could reconcile the apparent discrepancies observed between these two studies.  
However, despite the availability of eosinophil deficient mice, many questions still rem
regarding the mechanism behind, and significance of, the recruitment of eosinophils into the
airways of asthmatic individuals.   
x and not 
rgic 
strated 
.  
ent 
ain 
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 Mast Cells 
Mast cells are the primary effector cells of acute allergic reactions and likely play a 
critical role in the early phase of allergic airway disease.  During the sensitization period, 
allergen specific IgE is generated by B-lymphocytes and attach to mast cells at the high 
affinity FcεRI receptor.   Subsequent allergen exposure induces cross-linking between 
adjacent antigen binding fragment components of IgE on the mast cells, which in turn induce 
degranulation and the secretion of mediators such as histamine, serotonin, chymase, tryptase, 
and various lipid mediators such as prostaglandins and leukotrienes.  These mast cell 
mediators induce airway obstruction by inducing smooth muscle constriction, vascular 
leakage, and mucus hypersecretion (33).  Mast cell derived cytokines and chemokines, such 
as IL-4, IL-5, and IL-6 can further perpetuate the inflammatory cascade through the local 
recruitment and activation of eosinophils and lymphocytes (33).   
The exact role of mast cells in chronic airway inflammation, including the late phase 
responses of AHR, airway eosinophilia, and airway remodeling is controversial (148, 163).  
Mast cell deficient mice develop eosinophilic airway inflammation and AHR at levels similar 
to those observed in wild type mice (82, 111, 148, 163).  However, as Williams and Galli 
have demonstrated, based on the OVA model employed (i.e. with or without adjuvant) 
conflicting data has been generated with regards to mast cell function in allergic airway 
disease.   These data further suggest that the most likely function of mast cells in allergic 
airway disease is as a local amplifier of antigen-dependent inflammation through the release 
of proinflammatory mediators such as histamine, prostaglandin D2, and platelet activating 
factor (163).   
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 Lipid Mediators and Associated GPCRs 
The Arachidonic Acid Pathway 
Prostanoids, along with leukotrienes and HETES, belong to a family of mediators 
termed eicosanoids.  Eicosanoids are formed in the organism from arachidonic acid (AA) and 
other polyunsaturated 20 carbon fatty acids (110). They are generally not stored free in 
tissue, but are synthesized as a result of membrane perturbations that cause the release of free 
fatty acids, generally AA, from esterified lipid sources.  Release of AA from the sn-2 
position of glycerol by one of several phospholipases, particularly by the action of cPLA2, is 
the first step in the production of all eicosanoids (105).  Phospholipase A2 activity can be 
stimulated by complement fragments, IgE receptor activation, immune complexes, opsonized 
particulate matter, and microorganisms.  The eicosanoid produced from the released AA 
depends on the expression and activity of various enzyme pathways within the cell (Figure 
1.4).  Prostanoids are produced when the released AA is converted into the bis-oxygenated 
intermediate PGH2, a reaction catalyzed by prostaglandin endoperoxide synthase (PGHS), 
commonly referred to as cyclooxygenase (COX)(139).  Two isoforms of this enzyme, COX-
1 and COX-2, encoded by two different genes, have been characterized (138, 139).  The 
regulation of expression of these two genes is very different.  COX-1 expression can be 
detected at low levels in virtually all cells.  However, while the expression of COX-1 differs 
in various cell populations, in general, the level of COX-1 changes little in response to 
physiological stress.  In contrast, dramatic changes in the expression of COX-2 can be 
induced by a number of different stimuli (47, 137).  
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Figure 1.4.  The generation and metabolism of arachidonic acid.   
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This simple classification of these two enzymes may be considered an over-
simplification that is not applicable to all cells and organ systems.  For example, expression 
of COX-2 has been detected in unstimulated cultured human tracheal epithelial cells, and was 
actually reported to be expressed at higher levels than COX-1 (156).  Immunohisto-chemical 
examination of biopsies of airway epithelium obtained from healthy subjects also indicates 
that both COX-1 and COX-2 are expressed in the unchallenged airways (37).  Even though 
expression of both COX-1 and COX-2 was detected in samples prepared from airways of 
stable asthmatic patients, surprisingly these studies did not demonstrate increased expression 
of either synthase (37).  This might indicate that the increased prostanoids present in the 
BALF of asthmatics might be due to other factors such as increased substrate availability or 
production by recruited inflammatory cells.  
 
Thromboxane 
PGH2 produced by COX is further metabolized to form PGE2, PGF2α, PGD2, 
prostacyclin (PGI2), and thromboxane (TXA2), all of which have diverse biological actions 
(Table 1.9).  Thromboxane is formed by further metabolism of PGH2 by thromboxane 
synthase (TXAS)(135).  In aqueous solutions, TXA2 is rapidly hydrolyzed to TXB2, a stable 
and inactive metabolite.  Because of its short half-life, TXA2 functions primarily as an 
autocoid and its actions are limited to tissues in close proximity to the source of its synthesis. 
Because of the instability of TXA2, most studies utilize the stable analogue U46619. 
Thromboxane synthase is present in a broad spectrum of cells and tissues, including the lung 
and immune cells. Elevated levels of thromboxane and other prostanoids have been measured 
in the BALF from asthmatic airways (94, 113, 150). 
  35
Table 1.9.  Prostaglandins and Their Biological Actions 
                 Biological 
Synthase    Expression     Prostaglandin   Receptor     G-Protein    Expression          Actions___   
  TXS        Platelet          TXA2             Tp      Gq      VSM; ASM     Constriction 
                Platelet       Aggregation 
 
  PGIS      Endothelium         PGI2               Ip    Gs      VSM; ASM     Relaxation 
                 Platelet      Declumping 
 
  PGFS        Uterus           PGF2α         Fp    Gq          USM      Contraction 
                 USM      Parturition 
 
PGDS      Mast Cells           PGD2         Dp1    Gs           Lung       Allergic 
               Asthma 
              Dp2*    n/a     Lymphocytes   Chemotaxis 
 
PGES       Various           PGE2         Ep1    Gq         Neurons      Pain Response 
             Ep2    Gs           Ovary         Maturation 
             Ep3    Gi         Neurons      Fever  
             Ep4    Gs        Osteoclast      Bone 
               Resorption 
 
*  Dp2 is a member of the chemoattractant subgroup    
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The actions of TXA2, as well as other prostanoids, are mediated through binding to 
specific G protein coupled receptors, which are named after the native prostaglandin that is 
the receptors most potent agonist (Ip is the receptor for PGI2, Tp for TXA2) (reviewed in (28, 
107)).  All of the known activity of TXA2 is mediated via a single receptor termed Tp.  In 
humans, alternative splicing of the carboxyl-terminal tail results in two isoforms of the Tp 
receptor, Tpα and Tpβ (28, 57, 58, 107).  The significance of the two isoforms is still 
unknown; however, it appears both isoforms similarly activate PLC but differently regulate 
adenylyl cyclase activity (61).  The Tp receptor is coupled to the Gq family of proteins, and 
many of its physiological actions have been attributed to Gq associated activation of PLC and 
increases in intracellular calcium (66). Recently, it has been suggested that in airway smooth 
muscle cells, coupling to Gi can occur and that this coupling may be important in the growth 
response of smooth muscle cells to thromboxane (24).  Total RNA analysis indicates that the 
receptor is broadly expressed throughout the mouse.  A variety of cell types are known to 
maintain high levels of Tp receptor expression, including thymus, lung, endothelial cells, 
brain, and kidney (6). Tp receptor expression has also been documented on airway smooth 
muscle cells and expression on neurons has been implied from pharmacological studies. 
 
Airway Smooth Muscle and Asthma 
 While many lung diseases have symptoms that are similar to asthma, this disease can 
be distinguished by variable and reversible airflow obstruction, AHR, and eosinophilic 
airway inflammation.   However, the relationship between inflammation and asthma is 
complex, with no clear correlation between the severity of inflammation and the severity of 
airflow obstruction and AHR.  While inflammation is almost always present in asthma, it is 
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not sufficient to explain all of the pathophysiological features of disease. In addition to the 
accumulation of eosinophils and lymphocytes in the airway, asthma pathophysiology also 
demonstrates altered smooth muscle and epithelial cell function, thickening of the sub-
epithelial collagen layer, mucus cell hyperplasia/metaplasia, and smooth muscle hypertrophy 
and hyperplasia (77).  In many cases of fatal asthma, a substantial increase in the thickness of 
the airway wall was observed throughout the bronchial tree, which was at least partly due to 
smooth muscle hypertrophy (72).  Asthmatic individuals who have experienced symptoms 
for an extended period of time often develop a certain degree of fixed airflow obstruction, 
which cannot be reversed.  The pathological basis for this phenomenon is largely unknown 
but likely involves smooth muscle hypertrophy, rather than the destructive obliterative 
bronchitis and emphysema that characterize the fixed airflow obstruction associated with 
chronic obstructive pulmonary disease (COPD).  
 
Smooth Muscle Myogenesis 
 Smooth muscle cells in mature animals are highly specialized cells whose principle 
function is contraction.  These cells typically express a unique range of contractile proteins, 
ion channels, and signaling molecules, which regulate the cell’s contractile functions.  The 
plasticity of smooth muscle cells allow the smooth muscle to undergo remarkable phenotypic 
adjustments in response to changes in the local environment and differentiates these cells 
from the terminally differentiated skeletal and cardiac muscle (114).  In addition to profound 
phenotypic changes, smooth muscle cells can also undergo relatively minor changes such as 
alterations in calcium sensitivity and handling, which can have dramatic effects on 
physiology (141).  During development, smooth muscle cells can exhibit a wide range of 
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phenotypes and exhibit very high rates of synthesis of extracellular matrix components 
including collagen, elastin, proteoglycans, cadherins, and integrins (115).  In contrast, 
smooth muscle cells in mature organisms are dedicated to carrying out their contractile 
functions and typically demonstrate low rates of turnover/proliferation and a significantly 
slower rate of synthesis of extracellular matrix components (115).  A variety of smooth 
muscle selective or specific genes and gene products have been identified that serve as useful 
markers of the state of smooth muscle differentiation including SM22α and the smooth 
muscle myosin heavy chain (SM-MHC) (50, 52, 97). In fact, the promoters for these genes 
have been particularly useful in directing targeted expression or deletion of various genes in 
smooth muscle. These promoters has been shown to produce high levels of EGFP expression 
in smooth muscle cells at various embryonic time points and in adult tissues (64, 119).  These 
transgenic mice display strong vascular and airway smooth muscle specific fluorescence and 
there appears to be excellent overlap between fluorescence and Cre activity (64, 166). 
 
ASM Constriction and Relaxation 
 Airway smooth muscle (ASM) constriction is considered to be the primary mediator 
of both the airway hyperresponsiveness and reversible airflow obstruction observed in the 
asthmatic airway (Figure 1.5).  ASM is highly innervated by postganglionic parasympathetic 
nerves, emanating from the vagus nerve, which release endogenous acetylcholine (ACh).  
This endogenous ACh release activates M3 muscarinic acetylcholine receptors (mAChRs) 
located directly on the smooth muscle cells. Ligand binding induces a conformational change 
in the M3 mAChR, which results in a high affinity for the Gq protein associated with GDP.  
Upon binding the M3 mAChR, the Gq protein releases GDP, which exposes the binding site 
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to either GTP or GDP.  The cytosolic concentration of GTP is significantly higher than GDP, 
resulting in the reaction favoring it’s binding to the Gq protein.  Following GTP binding to 
Gq, this complex dissociates from the M3 mAChR and activates Phospholipase C (PLC).  
Activated PLC catalyzes the hydrolysis of phosphoinositol 4,5-bisphosphate (PIP2) into 1,2-
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3).  IP3 binds IP3 receptors on 
sarcoplasmic reticulum Ca2++ stores leading to the release of Ca2++ into the cytosol and 
subsequent binding to calmodulin.  The Ca2++/calmodulin complex activates myosin light 
chain kinase (MLCK), which subsequently phosphoryates myosin light chains.  This 
phosphorylation promotes the ATPase activity of myosin, which is required for cross-bridge 
cycling and subsequent smooth muscle contraction.  In addition to the M3 mAChR, other Gq 
protein coupled receptors are expressed on ASM and can similarly mediate contraction 
(Table 1.10) (reviewed in (8, 9)). 
GPCRs located directly on the smooth muscle cells can also mediate ASM relaxation 
or suppression of constriction (Figure 1.5).  The Gs-coupled β2-adrenergic receptor (β2-AR) 
mediated signal transduction pathway, provides an example of a well-characterized ASM 
relaxation mechanism.  Endogenous norepinephrine or exogenously administered beta-
agonists bind to and activate the β2-AR leading to a high affinity for Gs-proteins coupled 
with GDP.  Ligand binding induces a conformational change in the β2-AR, which results in a 
high affinity for the Gs protein associated with GDP.  Once bound to the activated receptor, 
as previously described for Gq-coupled receptors, the Gs protein undergoes a conformational 
change, which releases the GDP and allows GTP access to the binding site.  Once bound, the 
Gs protein/GTP complex dissociates from the β2-AR and binds to membrane bound adenylyl 
cyclase (AC).  Activated AC catalyzes the conversion of ATP into cAMP, which can then  
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Figure 1.5. 
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Figure 1.5.  Airway Smooth Muscle Constriction and Relaxation.  A) Model of Gq 
mediated airway smooth muscle constriction.  The respective ligand activates the appropriate 
Gq protein coupled receptor.  Once activated, the Gq+GTP complex dissociates from the 
GPCR and activates Phospholipase C (PLC).  Activated PLC catalyses the hydrolysis of PIP2 
into DAG and IP3.  IP3 then binds IP3 receptors on sarcoplasmic reticular calcium stores 
causing the release of calcium into the cytosol.  The increase in calcium promotes calcium 
binding to calmodulin.  The resultant calcium/calmodulin complex activates Myosin Light 
Chain Kinase (MLCK).  Activated MLCK phosphorylates myosin light chains and thereby 
promotes the ATPase activity of myosin, which is required for cross-bridge cycling and 
contraction.  B) Model of airway smooth muscle relaxation by protein kinase activation via a 
Gs protein coupled receptor.  Activated PKA can phosphorylate certain Gq coupled 
receptors, as well as PLC, both of which inhibits the Gq mediated generation of IP3.  
Activated PKA also phosphorylates IP3 receptors, which lowers their affinity for IP3, 
thereby decreasing the ability of IP3 to increase intracellular Ca levels.  Activated PKA also 
phosphorylates MLCK, which decreases its affinity for the calcium/calmodulin complex, 
further reducing the contractility of airway smooth muscle. 
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Table 1.10.  GPCRs Associated With Airway Smooth Muscle Function (modified from 
Billington, 2003) 
 
Ligand                      GPCR            G protein  Smooth Muscle Function  
 
Acetylcholine   m2  Gi  Inhibition of Relaxation* 
    m3  Gq  Constriction  
   
Serotonin                     5HT2a  Gq  Constriction      
 
Adenosine   A1  Gi  Inhibition of Relaxation*  
               A2b  Gs  Relaxation      
 
Histamine   H1  Gq  Constriction      
        Potentiation of Growth  
 
Bradykinin   BK  Gq  Constriction      
 
Endothelin                   ET-A/B  Gq  Constriction      
        Potentiation of Growth 
 
Neurokinin                   NK-1/2  Gq  Constriction      
        Potentiation of Growth 
 
Norepinephrine                  β2-AR  Gs  Relaxation      
        Growth Inhibition 
        Cytokine/Chemokine Regulation 
 
CysLT                    CLT1R  Gq  Constriction      
        Potentiation of Growth 
 
PGE                      EP2  Gs  Relaxation      
                  Growth Inhibition 
        Cytokine/Chemokine Regulation 
 
PGI               IP  Gs  Relaxation      
        Growth Inhibition 
 
TXA2              TP  Gq  Constriction      
        Potentiation of Growth 
 
*  The mechanism behind Gi mediated ASM constriction is possibly mediated through 
inhibiting adenylyl cyclase or activating Ca2++ activated potassium channels 
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activate Protein Kinase A (PKA).  Activated PKA inhibits ASM constriction through 
phosphorylation of Gq-coupled receptors, PLC, IP3 and MLCK.  In addition to the β2-AR, 
other G-protein coupled receptors are expressed on ASM and can similarly mediate 
relaxation (Table 1.10) (reviewed in (8, 9)). 
 
Thromboxane Mediated Constriction of Smooth Muscle and Airway Responsiveness   
Ellis et al. reported in 1976 that when human platelets aggregate, material is released 
that rapidly contracts strips of coronary artery and that this response was indomethacin 
sensitive and was similar to that induced by thromboxane (46).  Svenssen confirmed these 
findings by showing that thromboxane could contract guinea pig trachea (143).  TXA2 is also 
a potent bronchoconstricting agent in humans.  Pharmacological evidence suggests that the 
Tp receptor not only mediates TXA2 constriction but also that at least some of the 
constricting actions of PGF2a, PGD2, and 8-epi-PGF are the result of the cross-reactivity of 
these eicosanoids with the Tp receptor (27).   
Very early studies examined the effect of a thromboxane synthesis inhibitor on 
bronchial responsiveness to acetylcholine in asthmatics.  The provocative doses of 
acetylcholine produced a 20% fall in FEV1, which was increased in asthmatics receiving the 
thromboxane synthase inhibitor (51).  Studies in dogs reported that transient exposure to 
U46619 caused substantial augmentation of the contractile response induced by efferent 
vagus nerve stimulation.  These data suggested that thromboxane had a direct effect in 
augmenting the airway contractile response to efferent vagus nerve stimulation that was not 
related to generalized mechanical contraction of airway smooth muscle (106).  More recent 
studies in the dog suggest that the interactions between the cholinergic pathways and 
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thromboxane might be more complex.  Takata et al. report that the response of tracheal strips 
to acetylcholine was not affected by pretreatment with U46619, whereas subthreshold levels 
of U46619 enhanced the response of bronchial rings (147).  This difference in the action of 
thromboxane at different levels of the airways is of clinical interest.  In humans, Jones et al. 
exposed healthy and asthmatic patients to TXA2 (73).  They reported that U46619 was a 
potent in vivo bronchoconstrictor.  They also report that subthreshold concentrations of 
U46619, but not histamine, increased methacholine airway responsiveness.  More recently, a 
similar interaction has been described in the guinea pig.  Airway hyperresponsiveness to 
acetylcholine was dose dependently enhanced by locally inhaled PGD2, U46619, LTD4, and 
LTE4 (133). 
 
Neural Mechanisms and Asthma 
 The nervous system is divided into the somatic nervous system and the autonomic 
nervous system.  Organs under the control of the somatic nervous system are considered to 
be under voluntary control, while the autonomic nervous system regulates involuntary organ 
function and maintains homeostasis.  The autonomic nervous system predominantly 
functions as an efferent system transmitting signals from the central nervous system (CNS) to 
the peripheral nervous system (PNS) and effects physiological functions such as heart rate 
and contraction, smooth muscle constriction, visual accommodation, and secretions from 
exocrine and endocrine glands.  With few exceptions, autonomic nerves constitute all of the 
efferent fibres exiting the CNS; however, some afferent autonomic fibres, which mediate 
vasomotor and respiratory reflexes, are carried to the CNS by major autonomic nerves such 
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as the vagus, splanchnic, or pelvic nerves.  The actual cell bodies of these afferent nerves sit 
just outside of the CNS in a ganglion defined as the nodose ganglion. 
The autonomic nervous system is divided into the parasympathetic nervous system 
(PNS) and sympathetic nervous system (SNS) on the basis of anatomical and functional 
differences.  Both systems consist of myelinated preganglionic fibres, which form synapses 
with unmyelinated postganglionic fibres that innervate the effector organs.  These synapses 
typically occur in clusters and are defined as ganglia.  Most organs are innervated via both 
sympathetic and parasympathetic nerves, which typically generate opposing actions.  The 
SNS evokes responses such as pupil dilation, muscle vasculature dilation, and heart rate 
increases, which are all characteristics of the so-called “fight-or-flight” response.  Opposing 
these actions “post-threat”, the PNS has several specific functions that include stimulating 
the gut, constricting the pupils, and slowing the heart. The physiological state of the body at 
any given time represents a balance between the PNS and SNS.  In fact, a long-standing 
hypothesis regarding asthma states that it is a disorder of the autonomic nervous system and 
represents an imbalance between the sympathetic and parasympathetic nervous systems 
(146).   
 
Airway Afferent Innervation 
Gas exchange is a dynamic and demanding process facilitated by the airways and 
lungs, which must adapt and respond to the demands for oxygen by tissues throughout the 
body.  To maximize and promote efficient gas exchange, the lungs and airways rely on 
various afferent nerve subtypes to monitor respiration and facilitate defensive reflexes.  
These pulmonary afferent nerves are conducted by the vagus nerve and can be classified by 
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their receptor sensitivities and responses to various stimuli and individual fiber conduction 
velocities.  The primary afferent nerves in the larynx are characterized into pressure, cold, 
drive, irritant, and C-fiber endings, while the afferent nerves of the trachea and bronchi are 
characterized into slowly adapting receptors (SARs), rapidly adapting receptors (RARs), C-
fibre endings, and sensory receptors in neuroepithelial bodies (NEBs)(reviewed in (161)).    
Morphologic studies have shown that approximately 75% of the afferent fibers in the 
bronchopulmonary vagal branches are unmyelinated C-fibers, which span the entire 
respiratory tract, innervating from the lung parenchyma to the large conducting airways (4).  
Activation of these afferents can mediate bronchospasm and facilitate the coughing reflex in 
humans (76).  In most species, tachykinins, calcitonin gene-related peptide (CGRP), and 
other neuropeptides are synthesized in the cell bodies of these sensory neurons that are 
located in the nodose and jugular ganglia.  Bronchopulmonary C-fibers are nociceptors and 
possess polymodial sensitivity to distinct chemical stimuli, which can be roughly divided into 
either exogenous chemical substances or endogenously released mediators.  Capsaicin, a 
pungent ingredient of hot peppers, is the most extensively characterized exogenous C-fiber 
specific stimulant, and is often used to identify the presence of these afferent endings in 
tissues and organs. 
Capsaicin functions through the activation of the vanilloid receptor subtype 1 (VR1), 
a ligand-gated, non-selective cation channel belonging to the TRP channel superfamily.  In 
addition to capsaicin, VR1 is also responsive to acidic solutions with a pH of 5-6 and 
temperatures above 43oC, which correspond to the acidic microenvironment produced during 
inflammation and ischemia, and to the threshold temperature for pain perception (84, 118).  
In support of these observations, naïve VR1 receptor deficient mice exhibit altered 
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behavioral responses to heat (>52.5oC) and thermal hyperalgesia, and these mice exhibit 
reduced thermal hyperalgesia induced by inflammation.  Likewise, isolated nerve 
preparations isolated from the knockout mice demonstrate significantly reduced current 
activity in response to acidic in vitro conditions (pH 5-5.3)(21, 34).  Airway assessments 
have revealed that exposure to aerosolized capsaicin does not effect the breathing patterns of 
VR1-/- mice; however, capsaicin significantly reduces the breathing rates in wild type 
C57BL/6 mice (144).  In addition to capsaicin, a number of other inhaled chemical irritants 
including ozone, sulfur dioxide, ammonia, smoke (cigarette and wood), and volatile 
anesthetics can have a stimulatory effect on bronchopulmonary C-fibre afferents (reviewed in 
(89)).  Interestingly, no role was identified for the VR1 receptor in response to various 
airborne irritants such as acetic acid (acidic), acrolein (electrophilic), and styrene (lipophilic 
solvent).  All of which induced similar sensory irritation responses, as evidenced by 
decreased breathing rates in wild type mice, VR1-/- mice, and wild type mice pretreated with 
the VR1 antagonist I-RTX (144).  While no endogenous ligand for the VR1 receptor has 
been found, lipoxygenase and many other unsaturated fatty acids, bradykinin, ATP, PKC, 
and PLC all have the potential to either activate or sensitize the receptor (reviewed in (69)).   
Slowly adapting pulmonary stretch receptors (SARs) are another class of afferent 
nerves that innervate the tracheobronchial tree and are mechanoreceptors that respond to 
increases in airway wall tension, while not displaying significant chemosensitive properties.  
During rhythmic breathing, this increase in airway wall tension leads to SAR discharge, 
which slowly adapts and maintains airway wall tension.  In the airways, these afferent nerves 
innervate the smooth muscle via a complex network of nerve endings and are stimulated by 
vagal nerve-induced smooth muscle constriction.  SARs are typically found in close 
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proximity to regions of dense collagen and elastic fibers, and are associated with myelinated 
afferent nerves ((167); reviewed in (161)).  Excessive stimulation of these afferent nerves 
leads to shortened inspiratory time, decreased tidal volume, prolonged expiration, reflex 
bronchodilation, tachycardia, and systemic vasodilation.  While these receptors are not 
considered to be chemosensory, elevated venous CO2 results in the inhibition of SARs, 
which has been shown to be independent of changes in pulmonary mechanics (reviewed in 
(134)).  This is of specific relevance to exercise induced asthma, because pulmonary arterial 
PCO2 levels increase during exercise and can easily reach levels capable of SAR inhibition 
(20).  Thus, this could facilitate increased inspiration, reduced expiration, and enhanced 
bronchoconstriction.  Conversely, in guinea pig models of allergic airway inflammation, 
SAR activity is increased following allergen challenge; thus resulting in significantly reduced 
inspiratory rates and tidal volumes (79). In addition to modest roles in asthma, altered SAR 
activity has been shown to dramatically affect other pulmonary disorders, particularly those 
involving altered elastance and compliance, such as emphysema and pulmonary fibrosis 
(reviewed in (134)).  
Rapidly adapting pulmonary stretch receptors (RARs) are a third class of afferent 
nerves that innervate the respiratory tract from the nasopharynx/larynx to the bronchi.  
Unlike SARs, RARs are thinly myelinated afferent fibers (Aδ) that display an irregular 
discharge, and can be activated by mechanical, chemical, pathological, and inflammatory 
stimuli.  While SAR terminals are restricted to the smooth muscle, RAR terminals are located 
throughout the submucosa and airway epithelium. Most importantly, RARs are stimulated by 
an increase in tidal volume and frequency, and a fall in compliance (162); thus RARs and 
SARs perform opposing motor actions in the airways of humans and guinea pigs.  However, 
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many mammalian model organisms have SARs but lack RARs, such as mice and ferrets, and 
consequentially lack the ability to generate a cough reflex.  Likewise, significant species 
differences exist in response to various RAR stimulants.  For example, cigarette smoke is a 
potent RAR stimulate in rabbit airways, but relatively ineffective in the canine, whereas the 
opposite is true for other stimulants (reviewed in (132)).   It is also likely that functional 
subpopulations of RARs exist, as suggested by the observation that no single chemical 
stimulant is capable of activating all RAR receptors (161).   
 
Airway Efferent Innervation 
 Airway smooth muscle is innervated via both sympathetic and parasympathetic 
nerves which mediate bronchoconstriction and dilation.  Parasympathetic nerves are the 
predominate contractile innervation and mediate smooth muscle function through cholinergic 
mechanisms.  Cholinergic mediated airway smooth muscle constriction, as well as mucus 
hypersecretion, is mediated by muscarinic acetylcholine receptors (mAChRs) expressed by 
smooth muscle and submucosal glands.  Muscarinic receptors on neurons are also believed to 
provide a feedback mechanism to modify the activity of cholinergic pathways (Figure 1.6).  
To date, five different muscarinic receptors have been identified (M1-5).  Three of these, M1, 
M2 and M3, are expressed in the lung, and each of these contributes uniquely to 
parasympathetic regulation of airway physiology.  The M3 mAChR is a Gq coupled protein 
receptor, expressed abundantly on airway smooth muscle, and likely to mediate the major 
contractile effects of acetylcholine (44).  The M2 mAChR is a Gi coupled protein receptor 
and is also abundantly expressed by smooth muscle, where it could contribute to smooth 
muscle contraction by inhibiting adenylyl cyclase or activating Ca2++ activated potassium  
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Figure 1.6.  Airway Innervation and Muscarinic Receptor Expression 
In the airways the vagus nerves are the primary source of acetylcholine.  Acetylcholine 
affects most airway functions including smooth muscle constriction, mucus hypersecretion, 
and sensory nerve activation.  Muscarinic acetylcholine receptors are the primary mediators 
of acetylcholine function in the airways.  Both inhibitory subtypes (M2 receptors) and 
excitatory subtypes (M1 and M3 receptors) have been definitively localized to 
parasympathetic ganglia, prejunctional receptors of cholinergic nerves, and along airway and 
vascular smooth muscle. 
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channels (80).  However, this receptor is also expressed prejunctionally on nerves, and 
pharmacological studies in humans and guinea pigs suggest that it provides a negative 
feedback loop limiting acetylcholine release (103).  The M1 mAChR is also a Gq coupled 
protein receptor expressed on parasympathetic ganglia and is thought to filter the 
transmission of neural signals.  The M1 and M3 mAChRs also localize to the submucosal 
gland in human bronchi, where they each contribute to mucus secretion (99, 126).   In human 
and mouse systems, the M4 and M5 mAChRs are not thought to have a role in airway 
smooth muscle function. 
 Elucidating the physiological and pathophysiological roles of the muscarinic 
receptors has been complicated by the lack of subtype specific pharmacological antagonist.  
To circumvent this difficulty, muscarinic receptor deficient mice have been generated and  
their respective functional roles in airway responsiveness has been assessed.   Coinciding 
with previous pharmacological assessments, following challenges with either increasing 
doses of MCh or following vagal stimulation, mAChR3-/- mice demonstrate a complete loss 
of cholinergic mediated bronchoconstriction (APTI responses).  However, similar to results 
described by previous pharmacological studies conducted in other model organisms, the 
mAChR2-/- mice actually demonstrate significantly enhanced bronchoconstrictor responses 
(49). In addition to the in vivo analysis discussed above, ex vivo precision cut lung slices 
(PCLS) from these mice were also utilized to assess the roles of the M1, M2, and M3 
mAChRs in peripheral airway constriction. As with the before mentioned in vivo study, 
PCLS from mAChR3-/- mice demonstrated significantly attenuated bronchoconstriction in 
response to muscarine administration.  However, unlike the previous study, loss of the M3 
mAChR did not completely inhibit muscarine mediated airway constriction, as the lung slices 
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from these animals only demonstrated a 60% reduction in airway constriction (142).  Similar 
to the previous in vivo study, the PCLS from mAChR2-/- mice demonstrated rapid 
bronchoconstriction; however, these airways subsequently relaxed while still in the presence 
of muscarine.  Additional assessments of PCLS from M2/M3 mAChR double knockout mice 
demonstrate complete inhibition of airway constriction in response to muscarine (142).  This 
implies that in the peripheral airways, constriction is mediated by the M3 receptor and 
provides additional evidence supporting a role for the M2 receptor in constriction, possibly 
via the inhibition of relaxation.  In addition to the mAChR2-/- and mAChR3-/- mice, in the 
peripheral airways, cumulative administration of muscarine induced significantly increased 
bronchoconstriction responses and significantly reduced levels of transient relaxation in the 
PCLS from mAChR1-/- mice (142).  This suggests that in mice, an M1 mAChR-dependent 
mechanism exists, which is capable of reversing cholinergic mediated bronchoconstriction.        
In addition to parasympathetic innervation, sympathetic nerves also innervate the 
lungs via postganglionic fibers, which release norepinerphrine.  While the extent of airway 
sympathetic innervation is species dependent, several model organisms are known to have 
extensive sympathetic innervation in the lungs, including cats and guinea pigs (122).  In 
humans, sympathetic nerves do not directly innervate the airway smooth muscle; however, 
sympathetic fibers extend to the submucosal mucus glands, blood vessels, and the 
parasympathetic ganglia, and adrenergic receptors are located extensively throughout the 
lung (19, 121).   Adrenergic receptors are GPCRs that can be grouped into two distinct 
families based on their respective airway smooth muscle effects.  The α1 and the α2 
adrenergic receptors are both located on airway smooth muscle, and are associated with Gq 
and Gi proteins, respectively.   In some species and under specific physiological conditions, 
  52
such as postjunctional β-adrenergic receptor (β2AR) antagonism and simultaneous 
sympathetic nerve stimulation, α-adrenergic receptor stimulation can result in broncho-
constriction.  However, in humans, α-adrenergic receptor mediated bronchoconstriction is 
relatively nonexistent.   Even in species where this bronchoconstriction has been observed, in 
the absence of β2AR antagonism, noradrenaline activation of the β2ARs is capable of 
overcoming any α-adrenergic receptor mediated constriction, thus evoking bronchodilation 
(reviewed in (18)).  β2ARs are associated with Gs proteins and stimulation by either 
noradrenaline or a β-agonist results in a rapid bronchodilation response.  Inhaled β2-agonists 
have been the cornerstone of the standard of care for asthma for over 40 years because of the 
rapid improvement in symptoms, as well as, preventing the onset of symptoms following 
exercise and exposure to allergens and/or pollutants.  It is unclear whether β2AR dysfunction 
directly affects the pathophysiology of asthma; however, the β2AR gene is located in a region 
on chromosome 5q23-31 that has been associated with asthma, airway hyper-responsiveness, 
and other allergic airway phenotypes.  Even though several polymorphisms have been 
identified in the β2AR gene, none have been shown to directly affect the asthma phenotype.  
Instead, these polymorphisms may determine the extent to which the β2AR down regulates, 
and therefore modifies, the overall bronchodilator response to both short acting and long 
acting β-agonist asthma therapy (120). 
 Nonadrenergic, noncholinergic (NANC) parasympathetic nerves are the primary 
relaxant nerves innervating the airway smooth muscle.  Activation of these nerves has been 
shown to completely reverse preconstricted tracheal and bronchial smooth muscle 
preparations and completely dilate constricted guinea pig airways in vivo (25, 92).  These 
nerves can be loosely divided into 2 systems, inhibitory NANC (i-NANC) and excitatory 
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NANC (e-NANC), based on the smooth muscle responses following nerve stimulation.  The 
i-NANC system mediates smooth muscle relaxation, while the stimulation of the e-NANC 
system has multiple physiological responses, including smooth muscle constriction.  
However, labeling these nerves as either inhibitory or excitatory only applies to neurally 
mediated smooth muscle function, and may be misleading as the same transmitters can have 
opposite actions in other NANC mediated mechanisms affecting the mucus glands, blood 
vessels, and the epithelium (reviewed by (162)).  While i-NANC mediated smooth muscle 
relaxation has been observed in all mammalian species, e-NANC mediated smooth muscle 
constriction has not been observed in humans.  
The airway smooth muscle relaxation generated by i-NANC activation is thought to 
be mediated via Vasoactive Intestinal Polypeptide (VIP) and Nitric Oxide (NO).  VIP is a 
small diffusible peptide released by NANC nerves in a Ca2+ dependent mechanism following 
stimulation, and has been demonstrated to relax airway smooth muscle when applied 
exogenously.  In vivo, VIP has been shown to colocalize with acetylcholinesterase (AChE), 
thus the combined effects of direct VIP smooth muscle relaxation and the degradation of 
acetylcholine rapidly results in the relief of smooth muscle constriction.  VIP is broken down 
by neutral endopeptidase (NEP) and various mast cell derived factors such as tryptase and 
chymase.  While VIP is a primary i-NANC mediator in the airway of various model 
organisms and is abundant in human airway nerves, i-NANC facilitated relaxation in humans 
is not inhibited by the VIP antagonist α-chymotrypsin and VIP does not cause significant 
bronchodilation when applied exongenously (reviewed in (162)).  However, i-NANC 
relaxation of bronchial smooth muscle in humans is inducible by inhibitors of NO generation.  
Thus, it stands to reason that NO, rather than VIP, is the primary NANC relaxant mediator in 
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the human lung.  NO is synthesized from arginine by a family of enzymes collectively 
described as NOS synthases.  NOS has been identified in airway nerves, and like VIP, NO 
diffuses readily to the smooth muscle and induces relaxation when administered 
exogenously.  The in vivo mechanism of NO release is unknown; however, current literature 
suggests that NO exists in solution within the cytoplasm of the nerve cell and is released 
locally through an unknown mechanism, and is rapidly inactivated in the mucosal 
vasculature by hemoglobin (reviewed in (162)).    Due to their roles in preventing and/or 
relaxing airway smooth muscle, both VIP and NO play central roles in maintaining airway 
caliber and likely contribute to airway pathophysiology.   
In an effort to further assess VIP and NO contributions to airway responsiveness, the 
impact of gene loss and the effects of airway specific overexpression have been assessed in 
various mouse models of airway pathophysiology.  In naïve mice with a targeted deletion of 
the VIP gene, features of airway inflammation were observed, including increased airway 
and BALF eosinophilia, increased levels of proinflammatory cytokines and chemokines, and 
increased AHR following MCh challenge (145).  Following immunologic sensitization and 
challenge with ovalbumin, the VIP deficient mice demonstrated only marginal increases in 
airway and BALF eosinophilia and prolonged AHR; however, these increases were 
significantly higher then those observed for the wild type control animals (145).  VIP exerts 
its influence through interactions with 2 GPCRs, VPAC1 and VPAC2.  Mouse lines featuring 
disrupted VPAC1 and VPAC2 have been generated (54); however, the loss of these receptors 
on AHR has yet to be examined.   
To assess the contribution of nitric oxide to airway inflammation and hyper-
responsiveness, mice were generated with targeted deletions of each of the 3 nitric oxide 
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synthases (NOS-1, NOS-2, and NOS-3)(35, 36, 54).  Targeted deletion of NOS-1, considered 
to be a constitutively expressed neuronal NOS, was associated with a decrease in naïve 
airway responsiveness to MCh administered via jugular stint and an approximately 40% drop 
in expired NO levels compared to wild type animals (36).  This suggests that NO derived 
from NOS-1 is a substantial constituent of the total NO found in expired gas and may be a 
factor in airway constriction.  Targeted deletion of NOS-2, considered to be the inducible 
NOS, did not appear to affect AHR, airway inflammation, and cellular recruitment to the 
airways following sensitization and challenge with ovalbumin (35).  These findings would 
suggest that NOS-2 is not critical for the development of airway inflammation and alterations 
in lung mechanics.  To further assess the role of NOS-2, externally regulatable transgenic 
mice that are capable of overexpressing NOS-2 in the airway (CC10-rtTA-NOS2) were 
generated (62).  These mice are capable, in the presence of doxycycline, of producing 
exhaled NO, which approach equilevant values found in many asthmatic individuals.  NO 
has been characterized as a weak bronchodilator and not surprisingly, NO induction in the 
mouse airway resulted in decreased baseline airway resistance and airway responsiveness to 
methacholine (62).  However, NO has also been suggested to induce and perpetuate airway 
inflammation in asthmatic individuals.  Thus, it was surprising that prolonged NO induction 
(up to 10 weeks) did not influence airway inflammation in these mice (62).  Targeted 
deletion of NOS-3, considered to be a constitutively expressed endothelial NOS, generated 
mice that were significantly more hyperresponsive to MCh following OVA sensitization and 
challenge, when compared to the NOS-1 deficient mice.  However, these animals 
demonstrated attenuated hyperresponsiveness when compared to the wild type animals.  The 
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NOS-3 deficient mice did not demonstrate any alterations in airway inflammation when 
compared with the other NOS deficient mice or wild type animals (62).   
 
The Stress Response and Asthma Exacerbations  
Neurally mediated mechanisms directly influence normal airway tone and underlie 
abnormal pathophysiology.  However, neural mechanisms can also indirectly modulate 
airway exacerbations.  Asthma and other chronic inflammatory diseases, such as atopic 
dermatitis (AD) and rheumatoid arthritis (RA), are especially susceptible to modulation by 
stress and emotion (13, 14, 91, 95, 155).  Indeed, many asthmatics have demonstrated a 
reduction in pulmonary function in response to increased anxiety levels following exposure 
to emotionally charged films (7), listening to stressful interactions (78), and participating in a 
sustained stressful life event (final academic examinations)(95).  Increasing evidence 
suggests that the biological basis for these observations involves alterations of the stress 
response, which can contribute to dysfunctional interactions between the neuroendocrine and 
immune systems (reviewed by (155)).  Many studies have demonstrated that exposure to 
allergens, pathogens, trauma, stress, and toxins results in the release of inflammatory 
mediators, which act either directly or indirectly to modify neuroendocrine function 
(reviewed by (56)).  Central to the neuroendocrine response is the hypothalamic-pituitary-
adrenal axis (HPA axis).  The HPA axis is the primary mediator of neuroendocrine function 
and studies have demonstrated that subpopulations of asthmatic individuals have reduced 
HPA axis function (29).   
 While controversy exists regarding the significance of the stress response to immune 
system stimulation, the generation of mice with defective HPA axis components has allowed 
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significant progress to be made in defining interactions between the HPA axis and 
inflammatory responses. Corticotropin-releasing hormone (CRH) is the major regulator of 
the HPA axis.  CRH is synthesized in the hypothalamus and upon release, is carried through 
the portal blood system to the pituitary gland.  CRH interacts with the CRH type 1 receptor 
and stimulates the synthesis and release of ACTH from the pituitary corticotrophs (reviewed 
in (154)).  Ultimately, ACTH stimulates the synthesis and release of glucocorticoids from the 
adrenals.  Interestingly, basal ACTH levels are normal in CRH deficient mice; however, 
these animals demonstrate a significantly reduced ability to mount an adequate 
glucocorticoid response following physiological or behavioral stress (71, 104).  Stimulation 
of the immune system and the release of proinflammatory cytokines have been shown to 
significantly induce HPA axis activity.  The effect of IL-6 on the HPA axis has been the 
subject of extensive investigation and CRH has been shown to regulate the expression of this 
cytokine during inflammation (153).  Using the CRH-/- mice in a turpentine-induced 
inflammation model, CRH was shown to be essential for increased ACTH levels, but not for 
elevated adrenal corticosterone levels (153).  This study also demonstrated increased levels 
of plasma IL-6 associated with CRH deficiency and the complete inhibition of the HPA axis 
response to inflammatory stress in CRH-/-/IL-6-/- mice (153).  CRH deficiency has also been 
shown to increase airway inflammation in response to OVA sensitization and challenge 
(136).  The CRH-/- mice demonstrated significantly increased airway eosinophilia (~80% -
110% increase over wild type), increased goblet cell hypertrophy (~70% increase over wild 
type), and increased levels of select proinflammatory cytokines (IL-4, IL-5, and IL-13).  The 
CRH deficient mice also demonstrated significantly increased airway responsiveness, as 
assessed via the forced oscillation technique.  While no differences were observed between 
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naïve wild type and mutant animals, the OVA challenged CRH-/- mice demonstrated 
significant increases in total lung resistance, elastance, and tissue damping over those 
increases observed in the OVA challenged wild type mice (136).  Interestingly, not all 
indices of allergic airway inflammation were increased in the CRH deficient animals.  For 
example, while IgE levels were increased in the serum from OVA challenged mice, no 
difference was observed between the wild type and CRH-/- mice (136).  Despite these 
exceptions, this study suggests that CRH and the HPA axis have a significant role in 
mediating allergen induced airway inflammation in mouse models of asthma. 
 
Summary 
 The overall aim of this dissertation was to assess the role of various GPCRs and their 
associated ligands in regulating ASM constriction and inflammation.  The first aim of this 
work focuses on assessing the mechanism by which TXA2 mediates ASM constriction in the 
mouse.  Although it is possible that TXA2 can mediate its effects by engaging Tp receptors 
directly on ASM, the mechanism by which Tp receptor activation leads to bronchoconstriction 
is not well defined. Here we address this question directly using both genetic and 
pharmacological approaches, in conjunction with both in vivo and ex vivo studies of mouse 
airways. The second research aim utilizes a genetic approach to further define the mechanism 
underlying TXA2 meditated airway constriction.  To address this aim, we generated mice 
carrying a Tp receptor locus that is sensitive to disruption by cre recombinase. These mice 
were subsequently crossed with either nestin-cre transgenic mice, which express cre 
recombinase throughout the nervous system, or SM22-cre transgenic mice, which express cre 
recombinase in smooth muscle. The in vivo airway mechanics of the resultant tissue specific 
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Tp receptor deficient mice were then characterized.  The third research aim addresses the role 
of NPSR1 (GPRA) in airway constriction and inflammation.  NPSR1 is a newly deorphanized 
GPCR found to be associated with asthma and atopy in human populations.  Here we describe 
the generation of NPSR1 deficient mice and assess their airway physiology and airway 
inflammatory responses.   
 
Organization of the dissertation   
Chapter II of this dissertation introduces a model of thromboxane A2 mediated ASM 
constriction in both the naïve and inflamed lung, which is dependent upon the m3 mAChR. 
Chapter III further defines the mechanism behind this model utilizing a panel of conditional 
Tp receptor deficient mouse lines, which lack functional Tp receptors either throughout the 
nervous system or on smooth muscle cells.  Chapter IV describes a detailed assessment of 
airway reactivity and inflammation development in mice deficient in the newly deorphanized 
GPCR, NPSR1 (GPRA).  Together, the work described herein demonstrates the diverse roles 
of GPCRs in the neuropathophysiology of asthma. 
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Abstract 
Thromboxane A2 (TXA2) is a potent lipid mediator released by platelets and 
inflammatory cells and is capable of inducing vasoconstriction and bronchoconstriction.  In 
the airways, it has been postulated that TXA2 causes airway constriction by direct activation 
of thromboxane prostanoid (TP) receptors on airway smooth muscle cells.  Here we 
demonstrate that although TXA2 can mediate a dramatic increase in airway smooth muscle 
constriction and lung resistance, this response is largely dependent on vagal innervation of 
the airways and is highly sensitive to muscarinic acetylcholine receptor (mAChR) 
antagonists.  Further analyses employing pharmacologic and genetic strategies demonstrate 
that TP-dependent changes in lung resistance and airway smooth muscle tension require 
expression of the M3 mAChR subtype.  These results raise the possibility that some of the 
beneficial actions of anticholinergic agents used in the treatment of asthma and COPD result 
from limiting physiological changes mediated through the TP receptor.  Furthermore, these 
findings demonstrate a unique pathway for TP regulation of homeostatic mechanisms in the 
airway and suggest a paradigm for the role of TXA2 in other organ systems. 
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Introduction 
Thromboxane (TXA2) was originally identified as the active agent in extracts of human 
platelets and was subsequently shown to be capable of initiating the contraction of both 
vascular and airway smooth muscle (ASM) (21).  TXA2 synthesis is initiated by the 
oxidation of arachidionic acid (AA) by either prostaglandin G/H synthase-1 (or 
cyclooxygenase-1) (COX-1) or prostaglandin G/H synthase-2 (COX-2) (21). The PGH2 
produced by the cyclooxygenases is metabolized to TXA2 by thromboxane synthase, an 
enzyme expressed by many cell types.  In the lung, for example, TXA2 is produced by a 
number of cells, including the epithelia, smooth muscle and resident macrophages (39, 56).  
In aqueous solutions, TXA2 is rapidly hydrolyzed to TXB2, a stable and inactive metabolite 
(21).  The short half life of TXA2 suggests that it functions in an autocrine/paracrine fashion 
and that its actions are limited to tissues in proximity to the source of its synthesis.  Because 
of the instability of TXA2, most experimental studies of TXA2 biology have utilized stable 
TXA2 mimetics such as U46619 (8, 9, 32).  
The actions of TXA2, as well as those of other prostanoids, are mediated through 
binding to specific heterotrimeric G protein-associated prostanoid receptors.  With the 
cloning of the TP receptor and the generation of a mouse line lacking expression of this gene, 
all of the in vivo actions of TXA2 studied to date have been shown to be dependent on 
expression of this single G protein coupled receptor (30, 40, 45, 52).  Most evidence supports 
the coupling of this receptor to the Gq family of proteins, and many of its physiological 
actions have been attributed to Gq -mediated activation of phospholipase C (PLC) and 
increases in intracellular calcium [Ca2+].  In addition to ASM, many other tissues and cell 
types in the mouse have been reported to express TP receptors, including cells of the immune 
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system and epithelial cells (11, 13, 22, 37, 38, 49, 54, 56).  TP receptor expression on 
neurons has also been implied from pharmacological studies (26, 29). 
Exposure of human tracheal rings to U46619 results in cumulative, concentration-
dependent contractions (3).  In studies examining isolated human bronchial smooth muscle, 
U46619 was shown to be 300 times more potent as a constricting agent than other 
prostanoids. These ex vivo studies were consistent with studies in humans (27) and other 
animals (34) demonstrating that inhalation of U46619 results in rapid bronchoconstriction 
(12).  Furthermore, some studies have even suggested that other constricting prostanoids, 
such as PGF2 and PGD2, may mediate constriction by binding the TP receptor (10, 14).     
Concentrations of TXA2 and other prostanoids in the airway are elevated in a number 
of lung diseases including asthma and chronic obstructive pulmonary disease (COPD) (15, 
41, 42).  In addition to higher concentrations, airway sensitivity to these lipid mediators is 
also increased in disease states (44).  Although TXA2, and possibly other lipid mediators, can 
mediate their effects by engaging the TP receptor on ASM, the mechanism by which TP 
receptor activation leads to bronchoconstriction is not well defined.  Here we address this 
question directly using both genetic and pharmacological approaches in conjunction with 
both in vivo and ex vivo studies of mouse airways.  Similar to observations in other species 
including humans, we show that inhaled TXA2 leads to an increase in lung resistance and that 
TXA2 can also mediate constriction of tracheal rings ex vivo.  Analysis of M3 muscarinic 
acetylcholine receptor subtype (M3 mAChR) knockout mice showed that the in vivo airway 
constrictor responses to TXA2 are primarily dependent on parasympathetic innervation of the 
lungs and the presence of functional M3 mAChRs. 
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Methods 
Experimental Animals 
All studies were conducted in accordance with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use 
Committee guidelines of the University of North Carolina at Chapel Hill.  Mice deficient in 
the TP receptor were generated and genotyped by Southern blot analysis or PCR as 
previously described (52).  The 129 TP-/- mice were obtained by breeding chimeras generated 
from TP+/- 129/Olac embryonic stem (ES) cells directly with 129/SvEv females. 
Heterozygous animals were crossed for two consecutive generations to 129/SvEv animals to 
reduce the contribution of the 129/Olac substrain. The generation of mAChR3-/- mice has 
been described previously (58).  The mAChR3-/- and corresponding mAChR+/+ control mice 
are maintained on a 129SvEv (50%) X CF1 (50%) mixed genetic background.  All 
experiments were carried out using 8-12 week old mice.   
 
Measurement of Airway Reactivity in Intubated Mice 
 Mice were anesthetized with 70-90 mg/kg pentobarbital sodium (American 
Pharmaceutical Partners, Los Angeles, CA), tracheostomized, and mechanically ventilated at 
a rate of 300 breaths/min, tidal volume of 6 cc/kg, and positive end-expiratory pressure of 3-
4 cm H2O with a computer controlled small-animal ventilator (Scireq, Montreal, Canada).  
Once ventilated, mice were paralyzed with 0.8 mg/kg pancuronium bromide.  Dynamic lung 
resistance (RL) and dynamic compliance (Cdyn) were determined by transducing airway 
pressure and airflow using a precisely controlled piston during a single inspiration and 
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expiration with an amplitude of 150 µl and a period of one second (SnapShot).  The single 
compartment equation of motion (Eq1) allows determination of RL and Cdyn (25).  
 
P(t) = R X ϋ(t) + (1/C) X V(t) + P0  (Equation 1) 
 
Where P(t) = pressure at time t, R= resistance, ϋ(t) = flow at time t, C = compliance, V(t) = 
volume at time t and P0 = resting pressure (PEEP) 
 
Five separate baseline measurements of parameters were taken before exposure to U46619.  
Following baseline assessments, aerosols of (15S)-hydroxy-9,11-epoxymethanoprosta-
5Z,13E-dienoic acid (U46619)(Caymen Chemical, Ann Arbor, MI), at doses indicated 
(generally 10-6 M - 10-3 M), were delivered via nebulizer through a side port in the ventilator 
circuit for 30 seconds at a rate of 200 breaths per minute.  As a response to U46619 was 
observed only following 10-4 M and 10-3 M doses, these concentrations were used in lieu of 
the full range of doses in some experiments.  Following U46619 exposure, RL was measured 
every 10 seconds for 3 minutes.  To determine the contribution of mAChRs to the U46619 
response, mice received either an intraperitoneal injection of atropine sulfate (10 
µM/kg)(American Pharmaceutical Partners, Los Angeles, CA) or an i.v. injection of 
hexahydro-sila-difenidol p-fluorohydrocholride (4DAMP) (4ng/g)(Sigma Chemical, St. 
Louis, MO).  Similar to other studies measuring airway resistance using these techniques (4, 
23, 53), data are presented as percent baseline RL. 
 A surgical vagotomy was conducted to assess the contribution of intact 
parasympathetic innervation.  While anesthetized, the vagal nerves on each side of the 
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esophagus were identified under a dissecting microscope and dissected free of the fascia and 
carotid artery.  A silk suture was passed under each vagus to allow easy identification and 
severing of the nerve in the ventilated animals.  Mice were then tracheostomized and placed 
on a ventilator (Flexivent).  After treatment with the paralytic agent, five snapshots were 
recorded.  In the experimental animals, after establishment of basal lung mechanics, both 
vagal nerves were severed.  Post-vagotomy baseline RL and Cdyn was then reassessed and the 
mice were challenged with U46619. 
 
Measurement of Tension Development in Tracheal Rings 
Mice were euthanized by inhalation of CO2.   The tracheas were then rapidly excised in 
3- to 4- mm segments, cleaned of superficial fat and connective tissue, and placed in a Krebs-
Henseleit solution (53). These segments were mounted between two triangular stainless steel 
hooks, put into double jacketed glass organ baths containing Krebs-Henseleit solution 
(maintained at a pH of 7.40-7.45), and continuously gassed with carbogen (5% O2 and 5% 
CO2).  The upper support for the tracheal segment was attached, via silk thread, to a FT03 
isometric transducer (Astro-Med, West Warwick, RI) and force generation was recorded with 
a MP 100WS system (BIOPAC Systems). The rings were equilibrated in the respective 
buffered solutions for 30 min at a predetermined resting tension based on experimental 
calibration (approximately 0.5 g) (18, 47, 51).  Rings were then pre-constricted with MCh 
(10-8 M), allowed to equilibrate for 10 minutes, washed 3 to 4 times, and re-equilibrated to 
0.5 grams.  A dose response curve was then generated with either MCh (10-8 M to 10-3 M) or 
U46619 (10-10 M to 10-3 M)(50).   
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To assess the contribution of muscarinic receptors, atropine (10-6 M) was added directly 
to the buffers of selected rings 15 min prior to experimental challenges.   The response to 
U46619 (50 nM to 500 nM) was examined, as well as, the response to a single dose of MCh 
(100 µM) delivered immediately after the final dose of U46619.  The response to this 
application of MCh is shown in the figures.  The rings were then washed 3 to 4 times and a 
final dose of MCh (100 µM) was added to ensure tissue viability (data not shown).  To assess 
the contribution of the M3 mAChR, rings from mAChR3-/- and mAChR3+/+ mice were pre-
constricted with serotonin (5-HT) (20 mM), allowed to equilibrate for 10 minutes, washed 3 
to 4 times, and re-equilibrated to 0.5 grams.  The response to U46619 (50 nM and 100 nM) 
was examined, as well as, the response to a single dose of 5-HT (20 mM) delivered 
immediately after the final dose of U46619.  The response to this application of 5-HT is 
shown in the figures.   
All experiments and dissections were conducted in the presence of indomethacin (10-6 
M) (Sigma-Aldrich, St. Louis, MO) to prevent endogenous prostaglandin release.  Similar to 
other studies using these techniques (36, 53, 57), data are presented as mg developed 
tension/mg tissue weight. 
 
OVA Sensitization and Airway Challenge 
Groups of mice were sensitized by i.p. injection of 20 ug of OVA (Grade V; Sigma) 
emulsified in 2.25 mg of aluminum hydroxide (Sigma) in a total volume of 200 ul, on days 1 
and 14.  Mice were challenged (45 min) via the airways with OVA (1% in saline) for 3 days 
(days 21 – 23) using a jet nebulizer (TSI Jet Neb).  Control mouse groups received the 2 
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OVA immunizations but were challenged with aerosolized saline.  Airway mechanics were 
assessed 24 hours after the final aerosol OVA or saline challenge (day 24).   
Following airway assessments, mice were euthanized and approximately 1 ml of blood 
was collected by heart stick.  Blood was allowed to coagulate and the serum was collected.  
Total IgE levels were determined by ELISA (ICN Biomedicals, OH).  BALF was performed 
5 times with 1.0 ml of sterile Hank’s Buffered Saline Solution each time.  Cells present in the 
BALF were determined using a hemacytometer.  The recovered BALF fluid was centrifuged 
to remove cells and the IL-13 levels in the supernatant was determined using ELISA (R&D 
Systems, MN).  
 
Statistical Analysis  
Data are presented as the means +/- standard error of the mean (SEM).  A Random 
Effects Model followed by Tukey’s Multiple Comaprison Test was utilized to assess dose 
response data.  Analysis Of Variance (ANOVA) followed by Tukey’s Multiple Comaprison 
Test was performed on complex data sets.  Statistical significance for single data points was 
assessed by the Student’s two-tailed t-test. A p-value of less than 0.05 was considered 
statistically significant. 
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Results 
TXA2 increases airway constriction in a TP receptor-dependent manner. 
TXA2 has been shown to cause bronchoconstriction in a number of species.  Because of 
the short half-life of TXA2, experimental investigation into TXA2/TP receptor–dependent 
effects typically employs the synthetic agonist U46619.  Preliminary experiments verified 
that under our experimental conditions and with doses of U46619 generally used in in vivo 
experiments, all of the actions of this mimetic were dependent on the expression of the TP 
receptor. U46619 at concentrations up to 1 mM failed to elicit an increase in RL from mice in 
which the gene encoding the TP receptor was disrupted by homologous recombination (TP-/-) 
(Figure 2.1A). In contrast, RL in wild type mice increased in response to 100 µM and 1 mM 
U46619 (Figure 2.1A). Conversely, methacholine (MCh) challenge resulted in similar 
increases in RL in wild type and TP-/- mice (Figure 2.1B).  We next examined the ability of 
U46619 to constrict mouse trachea. A very steep dose response was observed: U46619 
elicited no significant increase in tension at doses below 10 nM while maximal responses 
were achieved with 100 nM of this agonist (data not shown).  Consistent with our in vivo 
data, ex vivo tension generation in tracheal ring preparations was similar in rings from wild 
type and TP-/- mice stimulated with MCh, whereas U46619 caused significant tension 
generation in rings from wild type mice but not in rings isolated from TP-/- mice (Figure 
2.1C).    
 
Vagotomy significantly attenuates U46619-induced increases in lung resistance (RL)  
The simplest explanation for the observed changes in RL and ex vivo tension generation 
is that binding of U46619 to TP receptors expressed by ASM directly activates Gq coupled 
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pathways leading to increases in [Ca2+]i, and that this constriction is independent of the 
activity of the parasympathetic innervation of the airways.  To test this model, we examined 
the ability of U46619 to elicit an increase in RL in animals in which the vagus nerves were 
surgically severed just proximal to the nodose ganglion.  Sham operated animals, treated 
identically to the experimental animals except for the final severing of the nerve, served as 
controls.  Baseline RL was assessed for 5 minutes before and 5 minutes after vagotomy.  
Baseline RL was higher in the mice in which the surgeries had been preformed compared to 
values generally observed for mice on the 129SvEv background, likely reflecting local 
mediator release during the surgical procedure.  As expected, the lung resistance of the sham 
operated animals increased in response to U46619.  However, the magnitude of the percent 
change in RL was smaller than that previously measured in wild type 129 animals.  This 
likely reflects the higher baseline RL in the surgically manipulated animals.  A slight but 
significant drop in the baseline RL (Figure 2.2A) and an increase in airway compliance (data 
not shown) were observed after vagotomy.  This change in baseline resistance was expected, 
as similar changes have been observed in other species after vagotomy (6, 7, 33).  The drop 
in RL reflects the loss of basal parasympathetic tone in the airways.   Following establishment 
of post-vagotomy baseline RL, mice were challenged with U46619 (10-4 M and 10-3 M).  
Although U46619 still elicited an increase in RL in the vagotomized animals, the response 
was significantly attenuated compared to that observed in the sham-operated animals 
(p<0.05)(Figure 2.2B).  These data suggest that in vivo, TXA2 functions in part via an 
indirect neurally-mediated mechanism to induce ASM reactivity.  This neurally-mediated 
mechanism functions in a concerted manner with other mechanism(s) that are not dependent 
on vagal innervation of the airways. 
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 Atropine attenuates U46619 induced ASM constriction  
Previous studies investigating the ability of TXA2/U46619 to meditate direct actions on 
smooth muscle cells utilized ex vivo preparations of either tracheal rings or strips of ASM 
prepared from tracheae or bronchi.  In our studies, tracheal rings were isolated from wild 
type and TP-/- mice and stimulated with increasing doses of U46619 (Figure 2.3A).  Rings 
from untreated TP-/- mice were included in the study to control for non-receptor mediated 
actions of U46619 (data not shown).  As expected, U46619 increased tension in the rings 
from wild type mice. No response was observed in the TP-/- animals.  To determine whether 
the response observed with the wild type preparations was dependent on muscarinic 
cholinergic pathways, we next examined the ability of atropine (10-6 M), a nonselective 
mAChR antagonist, to block this response.  At all stimulating concentrations of U46619, 
pretreatment of rings with atropine significantly attenuated tension generation.  However, 
U46619 at doses above 100 nM provoked a significant change in tension in the atropine 
treated rings over baseline (p<0.005)(Figure 2.3A).  As expected, in the presence of atropine, 
addition of MCh to rings contracted with 500 nM U46619 did not evoke a further increase in 
tension (Figure 2.3A).  To ensure that the atropine-pretreated tracheal rings were still capable 
of MCh-induced contraction, the rings were washed multiple times to remove the atropine.  
MCh was subsequently added back to the ring buffer.  In this case, MCh increased tension in 
all groups of mice, irrespective of previous treatment protocol or genotype (data not shown).  
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Atropine inhibits U46619 induced increases in lung resistance. 
We next evaluated the ability of atropine to block U46619-mediated increases in lung 
resistance.  TP-/- and wild type mice were pretreated with either atropine (10 µM/kg) or 
saline.  Untreated TP-/- mice were included in the study to control for TP receptor-
independent effects of U46619.  Mice were intubated, baseline RL was established, and the 
mice were then exposed to vehicle followed by aerosols of U46619 (10-4 M and 10-3 M).  As 
expected, a significant increase in RL was observed in the saline-pretreated wild type mice 
exposed to U46619 (Figure 2.3B). The U46619 response in the atropine-pretreated mice was 
significantly attenuated compared to the saline pretreated animals (Figure 2.3B).  As 
previously observed, TP-/- mice failed to respond to U46619 (Figure 2.3B).   
 
The M3 mAChR receptor-preferring antagonist 4DAMP significantly attenuates U46619-
induced increases in lung resistance. 
 ASM expresses the Gq/11 coupled M3 mAChR and both pharmacological studies and 
studies with mice lacking this receptor indicate that airway constriction in response to 
cholinergic agents is mediated primarily through this receptor (19, 43, 46, 48).  The 
muscarinic antagonist 4DAMP preferentially binds to the M3 mAChR receptor (5); however, 
it also displays high affinity for M1, M4, and M5 mAChRs (5).  Therefore, we determined the 
lowest dose of 4DAMP that completely blocks MCh-induced changes in airway resistance in 
the mouse.  This dose of 4DAMP (4 ng/g; data not shown), when delivered by i.v. injection 
prior to challenge with U46619, significantly inhibited U46619-induced increases in RL, with 
values never significantly exceeding those recorded for the TP-/- mice (Figure 2.4).  
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Mice lacking the M3 mAChR demonstrate a significant decrease in U46619-induced airway 
smooth muscle constriction and lung resistance. 
 To further demonstrate the role of muscarinic cholinergic pathways in TXA2-
mediated changes in airway constriction, we examined the response to U46619 in mice 
lacking the M3 mAChR (mAChR3-/-).  Tracheal rings from mAChR3-/- and age/strain-
matched control mice were exposed to constricting doses of U46619.  A significant increase 
in tension was observed in the wild type control animals following exposure to 50 nM and 
100 nM of agonist.  Consistent with the ability of atropine to modulate contraction of the 
tracheal rings, response of the mAChR3-/- tracheas was dramatically attenuated at both 
concentrations of U46619 examined.  However, a small but significant increase in 
constriction was still observed in mAChR3-/- tracheal rings in response to U46619 (Figure 
2.5A).  To verify that the altered response of the mAChR3-/- rings did not reflect a 
fundamental defect in smooth muscle function as a consequence of loss of this receptor and 
to verify that the preparations used in this study were viable, we examined the response of 
these same tracheas to serotonin.   A robust increase in tension was observed following 
treatment of both wild type and mAChR3-/-  trachea with this constricting agent. 
We next examined the ability of thromboxane to increase lung resistance in mice 
lacking the M3 mAChR. As seen in Figure 2.5B, loss of the M3 mAChR significantly 
attenuates the U46619-induced increases in RL.  Greater than 80% of the response to U46619 
(10-3 M) was lost in the mAChR3-/- mice.  However, consistent with our findings in 
experiments examining the effects of atropine, mAChR3-/- mice showed a small but 
significant increase in RL in response to U46619 (Figure 2.5B).  These data suggest a 
predominant role for the M3 mAChR in TXA2-mediated airway constriction. 
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 TP receptor-mediated changes in RL are enhanced in the allergic inflamed airway, but 
remain sensitive to atropine.  
Allergic airway inflammation was induced in wild type and TP-/- mice.  All mice were 
immunized via i.p. injection with ovalbumin (OVA)/alum.  To induce allergic lung disease, 
mice were challenged with aerosols of OVA.  Control animals were exposed to aerosols of 
saline.  Twenty-four hours after the final exposure to antigen or saline, mice were intubated 
and exposed to increasing doses of U46619.  As depicted in Figure 2.6, the response to both 
10-4 M and 10-3 M U46619 was substantially increased in OVA-challenged wild type mice 
compared to saline exposed control animals.  Thus, as observed in humans, the 
bronchoconstricting actions of TXA2 are dramatically enhanced in the inflamed airway (1).  
No significant change in RL in response to U46619 was observed in TP-/- mice, confirming 
that even in the inflamed airway the response to U46619 remains dependent on TP receptor 
expression (Figure 2.6).  We next determined whether, similar to the response in naïve mice, 
the response of mice with allergic lung disease to U46619 was sensitive to atropine.  
Alternatively, we considered the possibility that the M3 receptor-independent TP response is 
amplified in the inflamed lung.  To distinguish between these two possibilities, a group of 
OVA challenged mice and their corresponding saline challenged controls received a single 
i.p. treatment of atropine just prior to intubation and measurement of airway mechanics.  As 
seen in Figure 2.6, the response of the mice with allergic lung disease to U46619 was 
dramatically reduced.  The response remaining in these animals was not significantly greater 
than the response to U46619 measured in atropine treated naïve animals.  Thus, the 
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mechanism by which U46619 mediates the increased responsiveness in the diseased animal 
is similarly dependent on an intact muscarinic cholinergic pathway(s). 
At the end of the measurements of lung mechanics, as described above, the induction of 
allergic airway disease was verified by determining serum IgE levels, cellularity of 
bronchoalveolar lavage (BALF), and histopathology of the lungs.  Increases of similar 
magnitude were observed in total BALF cell counts (3.3 x 106 total cells in OVA treated 
animals vs 1 x 105  in saline treated animals) and airway eosinophilia (approximately 80% of 
cells present were eosinophils) between the OVA-challenged TP-/- and wild type mice (data 
not shown). Likewise, a similar increase in IgE levels (2500 ng/ml in OVA vs 225 ng/ml in 
saline) and IL-13 levels (550 pg/lung after OVA challenge vs undetectable in saline treated) 
were observed between the OVA-challenged TP-/- and wild type mice (data not shown). 
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Figure 2.1.  Changes in airway physiology of wild type and TP-/- mice in response to the 
TXA2 analog U46619 and MCh.  A) Change in lung resistance (RL) of TP+/+ and TP-/- mice 
in response to U46619.  Following baseline measurements, the airways were exposed to 
aerosolized vehicle followed by increasing doses of aerosolized U46619 (10-6 M to 10-3 M).  
The percent change in RL from baseline increased significantly in the wild type mice exposed 
to 10-4 M and 10-3 M U46619 as compared with no increase in RL in TP-/- mice.  TP+/+ mice, 
n=34; TP-/- mice, n=13 (**p<0.005).  B) TP-/- and TP+/+ mice demonstrate similar increases in 
RL following exposure to methacholine (MCh).  TP+/+ and TP-/- mice were subjected to 
aerosolized vehicle and 1 bolus dose of aerosolized MCh (50 mg/ml = 255.1 mM).  The 
percent increase from baseline was similar for both TP+/+ and TP-/- mice.  TP+/+ mice, n=5; 
TP-/- mice, n=5 (*, # p<0.05).  C) Contraction of TP-/- and TP+/+ tracheal rings.  Excised 
tracheal rings from both TP+/+ and TP-/- mice were challenged with a single dose of U46619 
(1 µM) and the change in tension recorded.  This was followed by treatment with MCh (100 
µM). Ring tension was significantly increased following addition of U46619 in rings from 
TP+/+ mice while no increase was observed in rings from TP-/- mice.  Ring tension was 
significantly increased in response to MCh in both groups.  TP+/+ mice, n=3; TP-/- mice, n=3 
(**p<0.007; #, *p<0.05). 
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Figure 2.2 
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Figure 2.2.  Vagotomy significantly attenuates change in airway resistance induced by 
U46619 challenge.  A) Parasympathetic tone in mouse lung.  Mice were anesthetized and the 
vagal nerve dissected free of the fascia and carotid artery. Mice were tracheostomized and 
placed on a ventilator (Flexivent).  After treatment with a paralytic agent, five snapshots were 
recorded.  In one group of animals, after establishment of basal lung mechanics, the vagus 
nerves were severed.  The percent change in RL from the pre-cut baseline decreased 
significantly in vagotomized mice as compared to the surgical controls.  TP+/+ mice, n=10; 
vagotomized TP+/+ mice, n=9 (* p<0.05).  B) The response to U46619 is attenuated in 
vagotomized mice.  Following the baseline assessment described above, vagotomized mice 
and the surgical controls were exposed to vehicle for 20 seconds and airway reactivity was 
assessed every 10 seconds for the next three minutes.  Mice were then exposed to increasing 
doses of the TXA2 analog U46619 and the change in lung mechanics after each dose was 
recorded.  The response of the vagotomized mice was significantly attenuated at the highest 
dose of U46619 (* p<0.05).  Importantly, a significant response to U46619 could still be 
measured in the vagotomized animals.    
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Figure 2.3 
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Figure 2.3. Atropine attenuates U46619 mediated changes in ASM constriction and lung 
resistance.   A) Atropine partially blocks the contractile response to U46619.  Excised 
tracheal rings from TP+/+ mice were incubated in either the presence or absence of atropine 
(10-6 M), challenged with increasing doses of U46619 (50 – 500 nM), and challenged with a 
bolus dose of MCh (100 µM).  Atropine significantly reduced the average tension during all 
doses tested.  TP+/+ mice with atropine, n=17; TP+/+ mice, n=11 (**p<0.005).  B) Atropine 
attenuates U46619 mediated changes in lung resistance (RL).  The change in RL in response 
to U46619 in intubated TP+/+ mice pretreated with atropine (10µM/kg i.p.), TP+/+ mice 
pretreated with saline, and TP-/- mice was determined.  Mice were subjected to aerosolized 
vehicle followed by increasing doses of aerosolized U46619 (from 10-6 to 10-3 M; 10-6 and 
10-5 M data not shown).  Following the U46619 challenge, the response to aerosolized MCh 
(50 mg/ml = 255.1 mM) was measured (data not shown).  A dose-dependent increase in RL 
was observed in the TP+/+ mice in response to U46619 and this response was absent in the 
TP-/- animals.  Pretreatment with atropine dramatically attenuated the response of TP+/+ mice 
to U46619.  As expected, atropine pretreatment inhibited the MCh response (data not 
shown).  Atropine pretreated TP+/+ mice, n=10; saline pretreated TP+/+ mice, n=10; TP-/- 
mice, n=11 (§p<0.05; *p<0.05; **p<0.005).   
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Figure 2.4 
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Figure 2.4. The M3 mAChR-preferring antagonist 4DAMP attenuates U46619 mediated 
lung resistance.   The change in RL in response to U46619 in intubated TP+/+ mice pretreated 
with 4DAMP (4 ng/g; i.v. injection), TP+/+ mice treated with vehicle, and TP-/- mice was 
determined.  A dose-dependent increase in RL was observed in the TP+/+ mice in response to 
U46619 and this response was absent in the TP-/- animals.  Pretreatment with 4DAMP 
inhibited the response of wild type mice to U46619 and no significant increase in RL was 
observed in this group over that measured in TP-/- animals.  4DAMP pretreated TP+/+ mice, 
n=10; Vehicle pretreated TP+/+ mice, n=21; TP-/- mice, n=3 (§p<0.05; #p<0.05; *p<0.005). 
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Figure 2.5 
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Figure 2.5.  ASM constriction and lung resistance following U46619 treatment is 
attenuated in mice lacking the M3 mAChR (mAChR3-/-).  A) Tracheal rings from 
mAChR3-/- mice demonstrated attenuated contractile responses to U46619.  Excised tracheal 
rings from mAChR3+/+ and mAChR3-/- mice were exposed to U46619 (50 nM and 100 nM) 
and changes in tension were recorded.  Ring tension was significantly increased following 
addition of U46619 in rings from mAChR3+/+ mice.  A small, but significant, increase in 
average tension was observed in mAChR3-/- mice at both U46619 doses.  To verify the 
viability of the rings, these manipulations were followed by treatment with a constricting 
dose of serotonin (5-HT) (20 mM).  No difference in 5-HT mediated constriction was 
observed between the mAChR3+/+ and mAChR3-/- tracheal rings. mAChR3+/+ mice, n=7; 
mAChR3-/- mice, n=8 (**p<0.005; #p<0.05; ‡p<0.05).  B)  The change in RL in response to 
U46619 in intubated mAChR3+/+ mice was significantly attenuated.  Mice were subjected to 
a 20-second aerosolization of increasing doses of U46619 (10-4 to 10-3 M).  A dose-
dependent increase in RL was observed in the mAChR3+/+ mice in response to U46619 and 
this response was significantly attenuated in the mAChR3-/- animals.  mAChR3+/+ mice, n=5; 
mAChR3-/- mice, n=7 (*p<0.05; **p<0.005).  
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Figure 2.6 
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Figure 2.6. Atropine inhibits U46619 mediated changes in resistance in the inflamed 
lung.   Atropine inhibits U46619 mediated changes in lung resistance (RL) following 
challenges with 1% Ovalbumin (OVA).  The change in RL in response to U46619 in 
intubated TP+/+ mice, TP+/+ mice pretreated with atropine (10µM/kg i.p.), TP+/+ mice treated 
with saline, and TP-/- mice was determined.  Mice were subjected to a 30 second 
aerosolization of increasing doses of U46619 (10-4 and 10-3 M), followed by 3 minutes of 
response measurements.  A dose-dependent increase in RL was observed in the TP+/+ mice 
and in the OVA challenged TP+/+ mice in response to U46619 and this response was absent 
in the TP-/- animals.  Pretreatment with atropine inhibited the response of the wild type mice 
to U46619.  Furthermore, no significant increase in RL was observed in the atropine 
pretreated group over that measured in TP-/- animals.  TP+/+ mice, n = 11; atropine pretreated 
TP+/+ mice, n=6; saline pretreated TP+/+ mice, n=24; TP-/- mice, n=6 (*p<0.05; #p<0.05; 
7p<0.05; ‡p<0.05).   
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Figure 2.7 
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Figure 2.7.   Possible mechanism for TP dependent alteration in airway resistance.  In 
the naïve healthy airway, basal release of acetylcholine by pre-synaptic cholinergic neurons 
are responsible for the resting tone of the airways.  Increased production of TXA2, the 
primary ligand of the TP receptor, or increased production of PGD2 or PGF2, results in 
increased TP receptor activation.   TP receptors expressed by pre-synaptic cholinergic 
neurons increase the release of acetylcholine, which in turn results in increased activation of 
M3 mAChRs present on smooth muscle cells and contraction of the smooth muscle.  
Alternately, or in addition, the prostanoids might engage post-junctional TP receptors present 
on the airway smooth muscle.  Cooperativity between the activated TP receptor and the M3 
mAChR, stimulated by the low levels of basal acetylcholine, results in contraction of the 
airway smooth muscle.  The interactions between these two receptors may simply reflect an 
additive effect of stimulation of two Gq associated receptors, or a unique relationship 
between TP receptors and M3 mAChRs in airway smooth muscle cells.   
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Discussion 
TXA2 is a potent mediator of human airway constriction.  The expression of the TP 
receptor on ASM, combined with the early demonstration of the ability of TXA2 to mediate 
constriction of vascular smooth muscle, suggested that TXA2-induced increases in airway 
resistance are mediated through direct actions of TXA2 on ASM.  However, results from the 
present study demonstrate that in both the naïve and inflamed airway, the constrictor effect of 
TXA2 is dependent on the activity of muscarinic cholinergic pathways.     
We utilized both pharmacological and genetic approaches to establish the role of the 
cholinergic pathways in TP receptor-mediated changes in airway and lung resistance.  
U46619-mediated increases in RL were largely attenuated when animals were treated with 
the nonselective muscarinic receptor antagonist atropine or the M3 receptor-preferring 
antagonist 4DAMP.  Consistent with these findings, U46619 caused only minimal increases 
in RL in both mAChR3-/- mice (suggesting a primary role for the M3 mAChR subtype) and 
vagotomized mice (suggesting a dependence on parasympathetic innervation).   
 A number of mechanisms that are consistent with our findings can be proposed 
(Figure 2.7).  For example, stimulation of ASM TP receptors may result in an increase in 
intracellular Ca2+.  This increase in Ca2+ is insufficient to mediate significant ASM 
contraction.  However, binding of TXA2 to the TP receptor potentiates the activity of the M3 
mAChR, thereby increasing the sensitivity of the M3 mAChR to its cognate physiologic 
ligand, acetylcholine.  With the loss of vagal tone, the release of acetylcholine diminishes, as 
does the ability of the muscle to respond to TP receptor activation.   A number of possible 
mechanisms by which TXA2 binding to the TP receptor can alter the activity of a co-
expressed Gq coupled receptor can be envisioned, including the formation of heterodimers or 
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simple additive effects of receptor-specific induced changes in intracellular Ca2+ or other 
second messengers.  In support of this mechanism, both TP receptors (16, 24) and muscarinic 
receptors (31, 55, 59, 60) have been shown to form heterodimers with other GPCRs.  Implicit 
in this model is the existence of a basal tone of the ASM and constitutive release of 
acetylcholine in the unprovoked airway. We report here, consistent with findings in other 
species (6, 7, 20, 33), that a basal ASM tone can be measured in mice, as indicated by a 
decrease in lung resistance following vagotomy.   
Our data are also consistent with alternate pathways, which also involve constitutive 
release of acetylcholine from parasympathetic nerves (Figure 2.7).   In this example, the 
release of acetylcholine from the postsynaptic neurons is enhanced by TXA2 binding to 
presynaptic TP receptors on the vagus nerve.  Activation of these TP receptors on the nerve 
or nerve terminals results in a substantial increase in ACh release.  After vagotomy, this 
constitutive release is diminished and thus is no longer potentiated by activation of TP 
receptors on nerve termini.  Consistent with this model, TP receptors are expressed 
throughout the CNS and spinal cord.  However, there is little information concerning the 
expression of TP receptors by either sensory or afferent nerves of the airways.  This model, 
in which TP receptor activation mediates constriction by modulating neural activity, is 
consistent with early studies in dogs (2).  These studies showed that TXA2 potentiated vagal 
nerve neuro-effector transmission in ASM tissue.  Contractions of canine tracheal smooth 
muscle (ex vivo preparations) were induced by electrical field stimulation (EFS) or by 
acetylcholine in the presence or absence of U46619.  Although U46619 had no effect on the 
contractile response of acetylcholine when applied exogenously to smooth muscle, it 
significantly increased the amplitude of the EFS evoked contractions in an atropine sensitive 
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manner (2).  These results suggest that, in canines, U46619 has a prejunctional action 
stimulating increased acetylcholine release from vagal nerve terminals through TP receptors 
(2).  There is some limited evidence that TXA2 can directly stimulate nerves.  Nerve fibers 
isolated from felines, including unmyelinated vagal afferent nerves from the lung and nerves 
originating from skeletal muscle of the hindlimb, were reported to respond to U46619 (28, 
29).   
Both mechanisms described above are consistent with the observation that atropine 
decreased the response of tracheal rings to TXA2 and that rings from mice lacking the M3 
mAChR have a diminished response to TXA2.   Previous tracheal ring studies have 
demonstrated that after removal of vagal signaling, the concentration of acetylcholine at the 
neuroeffector junction is directly proportional to its rate of release, rate of diffusion, and rate 
of enzymatic hydrolysis (20).  Acetylcholine levels are preserved at neuroeffector junctions 
and these stores are capable of maintaining muscarinic tone and effective cholinergic 
signaling for an extended amount of time after eliminating efferent vagal activity (20).  
TXA2 is a potent vaso- and broncho- constricting agent.  We demonstrate here that the 
full action of TXA2 is dependent on intact parasympathetic innervation and the presence of 
M3 mAChRs in both the healthy and inflammed airway.  These findings also raise the 
possibility that the TP receptor interacts with muscarinic cholinergic pathways in other 
biological systems. Anti-cholinergic agents continue to be used in the treatment of severe 
asthma and COPD.  Our work suggests that these drugs, by blocking M3 receptors, may act 
downstream of a number of important bronchoconstricting agents, such as TXA2, that 
mediate their actions through prostanoid receptors. 
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CHAPTER III 
 
Thromboxane Mediates Airway Reactivity and Hyperresponsiveness Through Collaborations 
Between Smooth Muscle TP Receptors and The M3 Muscarinic Acetylcholine Receptor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Thromboxane A2 (TXA2) is a potent lipid mediator released by platelets and 
inflammatory cells and is capable of inducing vasoconstriction and bronchoconstriction.  In 
the airways, recent studies have demonstrated that TXA2 mediated increases in airway 
smooth muscle (ASM) constriction is dependent on vagal innervation and that thromboxane 
prostanoid (TP) receptor mediated changes in airway constriction requires the expression of 
the M3 muscarinic acetylcholine receptor (mAChR).  To further define the mechanism 
underlying TXA2 meditated airway constriction, we generated mice carrying a TP receptor 
locus that is sensitive to disruption by Cre recombinase.  These mice were crossed with 
Nestin-Cretg transgenic mice, which express Cre recombinase throughout both the central and 
peripheral nervous systems.  Here we demonstrate that loss of the TP receptor throughout the 
nervous system does not significantly affect naïve airway reactivity induced by the stable 
TXA2 analog, U46619.  Because we did not observe a robust phenotype in the neurally TP 
receptor deficient animals, the floxed Tp receptor mice were subsequently crossed with 
SM22-Cretg transgenic mice, which express Cre recombinase in smooth muscle cells.  The 
resultant smooth muscle TP receptor deficient animals demonstrate attenuated airway 
responses following aerosol challenges with U46619 and also exhibit attenuated TXA2 
mediated airway hyperreactivity (AHR) to cholinergic stimuli.  Together, these findings 
suggest that TXA2 mediates airway reactivity and AHR through collaborations between 
ASM TP receptors and the M3 mAChR or associated signaling pathways. 
 
Keywords 
asthma; Cre recombinase; SM22; Nestin; thromboxane; bronchoconstriction 
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Introduction 
 
Since its discovery and description as the active extract from human platelets (21), 
thromboxane A2 (TXA2) has been the focus of intense research describing the interactions of 
this prostanoid with components of the cardiovascular system.  Production of TXA2 results in 
the promotion of platelet aggregation, increased cholesterol loading, and vascular smooth 
muscle proliferation (39).  However, TXA2 is also capable of inducing potent smooth muscle 
constriction, which can influence diverse physiological processes including vasoconstriction, 
bronchoconstriction, uterine contractions, and intestinal contractions.  Similar to other 
prostanoids, TXA2 synthesis is initiated by the oxidation of arachidionic acid (AA) by either 
cyclooxygenase-1 (COX-1) or cyclooxygenase-2 (COX-2) into prostaglandin H2 (PGH2).  
The thromboxane synthase enzyme (TXAS) catalyzes the isomerization of PGH2 to generate 
TXA2, which has a very short half-life in aqueous solution and is rapidly hydrolyzed to the 
stable inactive metabolite thromboxane B2 (TXB2).  Because of this instability, most 
experimental studies of TXA2 biology have utilized stable TXA2 mimetics such as U46619 
(10, 11, 36).  TXA2 exerts its biological functions through interactions with the 
heterotrimeric G-protein coupled thromboxane prostanoid (TP) receptor (33, 44, 53, 57).  All 
of the known physiologic functions of TXA2 are dependent upon the expression of this 
receptor, which associates with the Gq family of proteins and asserts most of its 
physiological actions through the activation of phospholipase C (PLC) and increases in 
intracellular calcium concentrations ([Ca2+]i). 
Pharmacological assessments with selective TXA2 antagonists and conventional TP 
receptor deficient mouse lines have been crucial in implicating TXA2 in a number of 
pathophysiological conditions including cardiovascular disease (45), intrauterine growth 
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retardation (48), various kidney diseases (12, 14, 18), and angiogenesis (5).  In addition to 
these disorders, pharmacological and genetic approaches have been essential in establishing 
TXA2 as a potent mediator of human and mouse airway constriction, where it has been 
shown to be capable of influencing a variety of mechanisms associated with lung diseases 
such as asthma and chronic obstructive pulmonary disease (COPD)(2, 3, 15, 54).  However, 
the intrinsic limitations of pharmacological assessments (potency, specificity, and dosage) 
have hampered efforts to explore many of the underlying mechanisms affecting these 
pathophysiological processes.  Likewise, conventional TP receptor deficient mice, which 
lack functional TP receptors in all cell types, lack the resolution to discern which TP 
receptors are responsible for specific physiological outcomes.  This is especially troublesome 
in tissues where multiple cell types express TP receptors. 
Considerable evidence has suggested that TXA2 mediates airway smooth muscle 
(ASM) constriction through neural mechanisms affecting acetylcholine release (30, 51, 55).  
Indeed, the TP receptor has been found expressed on neurons and in discrete regions of the 
brain, where TXA2 has been implicated in the proliferation and survival of oligodendrocytes 
(6, 37). Though no direct evidence has demonstrated that these receptors are present on 
peripheral or sensory nerves, peripheral neuron expression of TP receptors has been implied 
from pharmacological studies (29).  Nerve fibers isolated from felines, including 
unmyelinated vagal afferent nerves from the lung, have been reported to respond to U46619 
stimulation (31, 32).   Likewise, U46619 has also been reported to potentiate vagal nerve 
neuro-effector transmission in ASM tissue (2).  Contractions of canine smooth muscle 
preparations were induced by either electrical field stimulation (EFS) or by ACh in the 
presence or absence of U46619. The TXA2 analog did not affect the contractile response of 
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ACh when applied exogenously to smooth muscle; however, it significantly increased the 
amplitude of the EFS-evoked contractions in an atropine sensitive manner (2). These results 
suggest that, at least in canines, TXA2 has a pre-junctional role in stimulating ACh release 
from vagal nerve terminals in a TP receptor dependent mechanism.  
Supporting these data, recent studies have demonstrated in both the naïve and inflamed 
airway, that the constrictor effect of TXA2 is dependent on the activity of muscarinic receptor 
mediated cholinergic pathways (3).  U46619-mediated increases in lung resistance were 
largely attenuated when animals were treated with the nonselective muscarinic receptor 
antagonist atropine or the M3 muscarinic acetylcholine receptor (mAChR)-preferring 
antagonist 4DAMP.  Consistent with these findings, U46619 was shown to induce only 
minimal increases in lung resistance in both mAChR3-/- mice (suggesting a primary role for 
the M3 mAChR subtype) and vagotomized mice (suggesting a dependence on 
parasympathetic innervation) (3).  A possible model suggested by these findings describes a 
situation whereby the release of acetylcholine from the postsynaptic neurons is enhanced by 
TXA2 binding to presynaptic TP receptors on the vagus nerve.  Activation of these TP 
receptors on the nerve or nerve terminals results in a substantial increase in ACh release and 
the subsequent increase in M3 mAChR mediated ASM constriction.  
Bronchoconstriction is a dynamic process that involves ASM and parasympathetic 
innervation, and can also be influenced by bronchial epithelial cells and leukocytes.  Each of 
these cell types has been suggested to express TP receptors (8, 9, 29, 32, 38, 59), thus the 
classical pharmacological and genetic techniques are inadequate to further define the in vivo 
mechanism underlying TXA2 induced ASM constriction. Here we directly assess the 
contribution of neurally expressed TP receptors in mediating airway reactivity, by generating 
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mice carrying a Tp locus that is sensitive to disruption by Cre recombinase.  The floxed Tp 
mice were crossed with a mouse line in which Cre expression is under the control of the 
nerve cell specific Nestin promoter.  We show that loss of neurally expressed TP receptors 
does not appear to dramatically affect increases in airway reactivity in response to U46619 in 
these animals.  In addition to neural expression, TP receptors are also abundantly expressed 
on ASM cells.  To evaluate the role of these receptors, mice carrying the floxed Tp locus 
were crossed with a mouse line in which Cre expression is under the control of the smooth 
muscle specific SM22 promoter.  Here we demonstrate that the in vivo increases in airway 
reactivity in response to U46619 challenge are attenuated in the smooth muscle specific TP 
receptor deficient mice.  We also demonstrate that the in vivo generation of U46619 mediated 
AHR to cholinergic stimuli is also attenuated in mice lacking smooth muscle TP receptors.  
Together, these findings suggest that TXA2 induced ASM constriction and AHR are 
predominately mediated by TP receptors expressed by the smooth muscle.  
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Methods 
Generation of mice carrying a Tp locus sensitive to Cre mediated disruption 
 Segments of the Tp receptor gene were amplified by PCR.  The resultant PCR 
products were utilized to create a plasmid capable of undergoing homologous recombination 
with the endogenous locus and in doing so, introduce loxP sites flanking the major coding 
exon of the TP receptor (Figure 3.1).  Three fragments of the Tp receptor gene were 
amplified using the following primer sets:  5’-ATAAGCTTGCGGCCGCAGTTTCCCTGGT 
GGTACGTG-3’ and 5’-ATATCGATTAGCCCTAGCTGTCCTGGAA-3’ (to amplify a 
3073 bp region of homology in intron 1), 5’-GCTGCCTCAAAGAAAGGGTA-3’ and 5’-
GTGCGG CCGCTCCTAAAGCCCCAAAGACCT-3’ (to amplify a 1032 bp region 
containing exon 2), and 5’-GTGGATCCCTGCAGGATGTAACAGGAAAGA-3’ and 5’-
GTGGTACCAGAACCCATCCCAGTTCTGA-3’ (to amplify a 4424 bp region of homology 
in intron 2).  These fragments were sub-cloned into the pCR 2.1 vector (Invitrogen) and 
sequenced to verify that the PCR amplification did not introduce mutations into essential 
sequences. The fragment corresponding to intron 2 was directly cloned into the pXenaLF2 
vector, 3’ to the neomycin cassette and 5’ to the pgk-tk cassette (Figure 3.1). The pXenaLF2 
vector contains the selectable marker gene for neomycin resistance (pgk-neo) flanked on both 
5’ and 3’ sides by a loxP and frt site.  The fragments corresponding to intron 1 and exon 2 of 
the Tp receptor were subcloned 5’ and 3’ of the loxP cassette, respectively, in the pNebLox 
vector.  This generated a fragment of Tp receptor DNA with a loxP site placed in intron 1. 
This newly generated 5’arm-loxP-exon 2 cassette was subsequently removed from pNebLox 
and cloned into the pXenaLF2 vector, 5’ to its loxP cassette (Figure 3.1).   
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The targeting plasmid was linearized with PvuI and introduced into embryonic stem 
(ES) cells derived from 129/SvEv mice and transformants were isolated using standard 
methodologies (40).  A DNA probe corresponding to the region immediately downstream of 
the targeted region (3’ probe) was generated as previously described (57) and a probe 
corresponding to exon 2 of the Tp receptor (internal probe) was generated using the 
following primer sets: 5’-GCTGCCTCAAAGAAAGGGTA-3’ and 5’-GTGCGGCCGCTCC 
TAAAGCCCCAAAGACCT-3’.  These probes were used to identify targeted ES cells by 
Southern blot and were used to confirm the incorporation of loxP sites in successfully 
targeted ES cells.  These probes were also used to genotype the resultant mice.  ES cells in 
which the plasmid integrated by homologous recombination and contained the loxP-exon2-
loxP-flp-neo-flp cassette were used to generate chimeric animals, which in turn were bred to 
generate animals heterozygous for the floxed allele.  The neomycin gene was then removed 
by breeding the heterozygous mice with C57BL/6J mice that express of flp recombinase in 
the germline (B6;SJL-Tg(ACTFLPe)9205Dym/J, Jackson Laboratories).  Following 
digestion with BamHI, the exon 2 probe discussed above was utilized to confirm the removal 
of the neomycin cassette.   
Mice expressing Cre recombinase under the control of the SM22 promoter are 
commercially available (STOCK Tg(Tagln-cre)1Her/J, Jackson Laboratory) and maintained 
on a mixed genetic background of 129S5/SvEvBrd, C57BL/6, and SJL.  These animals have 
been shown to express Cre recombinase throughout the smooth muscle from all tissues 
examined, including the lungs (7, 26, 35).  C57BL/6J mice expressing Cre recombinase 
under the control of the Nestin promoter are also commercially available (B6.Cg-Tg(Nes-
cre)1Kln/J, Jackson Laboratory).  These mice express Cre early in embryonic development in 
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cell lineages that give rise to all neurons including sensory neurons, neurons of the CNS, and 
parasympathetic and sympathetic pathways (34).  The introduction of these transgenes onto 
the 129/SvEv Tp-/- background was initiated.   A DNA probe corresponding to the region 
immediately 5’ of the targeted region was generated by PCR (5’-AACCTGAGTCTGTGG 
GGTTG-3’ and 5’-ACAAGCATCAAGGAGGGATG-3’) and was used, in conjunction with 
a BamHI digest, to assess Tp exon 2 removal by Cre/lox in selected tissues. All animal 
studies were conducted in accordance with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals as well as the Institutional Animal Care and Use 
Committee (IACUC) guidelines of the University of North Carolina at Chapel Hill.   
 
Measurement of Airway Reactivity in Intubated Mice 
 Mice were anesthetized with 70-90 mg/kg pentobarbital sodium (American 
Pharmaceutical Partners, Los Angeles, CA), tracheostomized, and mechanically ventilated at 
a rate of 300 breaths/min, tidal volume of 6 cc/kg, and positive end-expiratory pressure of 3-
4 cm H2O with a computer controlled small-animal ventilator (Scireq, Montreal, Canada).  
Once ventilated, mice were paralyzed with 0.8 mg/kg pancuronium bromide.  Following 
baseline assessments, mice were exposed to aerosol challenges by directing the inspiratory 
line through the aerosolization chamber of an ultrasonic nebulizer connected through a 
sideport in the ventilator circuit.  Animals were ventilated at a rate of 200 breaths/min for 30 
seconds with a tidal volume of 0.15 mls.  Immediately following the aerosol challenge, the 
nebulizer was isolated from the inspiratory circuit and the original mechanical ventilation 
was resumed.  Forced Oscillatory Mechanics (FOM) were determined every 10 seconds for 
the following 3 minutes, as previously described (62).  Briefly, following passive expiration, 
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a broadband (1-19.625 Hz) volume perturbation was applied to the lungs while the pressure 
required to generate the perturbations was assessed (20, 58, 62).  The resultant pressure and 
flow data were fit into a constant phase model as previously described (22, 62).  Similar to 
other studies assessing forced oscillatory mechanics, we confined our analysis to Raw (Rn; 
Newtonian resistance), which assesses the flow resistance of the conducting airways and G 
(tissue damping), which reflects tissue resistance (58, 62). To assess thromboxane mediated 
airway reactivity, mice were exposed to aerosol challenges of the stable thromboxane analog 
U46619 (Caymen Chemical, Ann Arbor, MI) as previously described (3).  Briefly, mice were 
exposed to a 30-second aerosol dose response challenge of 10-5 M, 10-4 M, and 10-3 M.  
Following each aerosol challenge, airway responses were assessed for 3 minutes as 
previously described (3). 
 
TXA2 mediated airway hyperresponsiveness to cholinergic stimuli   
 Because thromboxane has also been suggested to induce airway hyperresponsiveness, 
we also assessed the increases in airway mechanics to methacholine, an acetylcholine analog, 
following pretreatment with a mildly provoking dose of U46619.  Airways were exposed to a 
30-second aerosol dose of U46619 (10-4 M), MCh (6 mg/ml)(Sigma Chemical, St. Louis, 
MO), or saline and changes in airway mechanics were assessed for 3 minutes.  Following this 
exposure, mice were challenged with a 30-second aerosol dose of U46619 (10-4 M), MCh (6 
mg/ml), Serotonin (5 mg/ml)(Sigma Chemical, St. Louis, MO), Adenosine (6 mg/ml)(Sigma 
Chemical, St. Louis, MO), PGF2α (10-4 M) (Caymen Chemical, Ann Arbor, MI), or PGD2 (10-
4 M) (Caymen Chemical, Ann Arbor, MI).  
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Statistical Analysis  
Data are presented as the means +/- standard error of the mean (SEM).  A Random 
Effects Model followed by the Tukey-Kramer Honestly Significant Difference (HSD) was 
utilized to assess dose response data.  Analysis Of Variance (ANOVA) followed by Tukey-
Kramer HSD for multiple comparisons was performed on complex data sets.  Statistical 
significance for single data points was assessed by the Student’s two-tailed t-test. A p-value 
of less than 0.05 was considered statistically significant. 
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Results 
Generation of mice with tissue specific loss of the TP receptor 
 The development of mouse lines in which loss of gene expression is restricted to 
specific populations of cells requires the placement of loxP sites around a critical exon of the 
gene under study.  To obtain a Cre recombinase-mediated deletion of the TP receptor, a 
targeting vector was designed which would introduce a Neo cassette flanked by loxP-frt sites 
downstream from exon 2.  A third loxP site was introduced into the first intron of the murine 
Tp receptor gene, thereby flanking exon 2, with loxP sites (Figure 3.1A).  Exon 2 contains 
the ATG start codon and encodes 6 of the 7 transmembrane domains of the TP receptor.  
Following electroporation of the targeting plasmid, Southern blot analysis of the ES cell 
clones was used to identify those carrying a floxed Tp allele.  For the initial screen, ES clones 
were digested with BamHI and probed with a 3’ probe that lies outside of the targeting 
plasmid.  Digestion of the DNA from eight neomycin resistant clones produced the 7.4 kb 
fragment that is indicative of successful integration of the targeting plasmid via homologous 
recombination (Figure 3.1B).  These clones were then probed with an internal, exon 2 
specific probe to identify those producing a 6.5 kb fragment, which suggests that the floxed 
Tp exon 2 and loxP-frt-neo-loxP-frt cassette were successfully integrated (Figure 3.1C).  The 
targeted ES cell clones were further analyzed to identify those in which the crossover event 
during homologous recombination resulted in the introduction of the 5’ loxP site in addition 
to the neomycin gene at the Tp locus.  DNA was digested with BamHI and EcoRI and 
analyzed by Southern blot using the exon 2 probe, which recognizes a 7.4 kb wild type allele 
and a 5.5 kb fragment in those clones in which the crossover event failed to introduce the 5' 
loxP site.  The probe is expected to hybridize to a 3.3 kb fragment both in ES cells in which 
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the targeting plasmid integrated randomly and in those clones which underwent homologous 
recombination with the desired crossover event.  Clone number 7, was the only ES cell clone 
identified as clearly carrying a floxed Tp receptor exon 2 allele (Figure 3.1D).  Subsequently, 
mouse lines were generated from this ES cell line. 
 The Nestintg transgene was obtained on a C57BL/6 genetic background, while the 
SM22 transgene was on a mixed genetic background (129S5/SvEvBrd, C57BL/6, and SJL).  
Additionally, removal of the neo gene from the Tp locus of the 129 ES cell derived mice 
required crossing the mice with the germline-flp transgenic line, which is on a C57BL/6 
genetic background.  Thus, as the various lines required for this study were not on a uniform 
background, it was essential that littermates (which on average are expected to have an equal 
composition of B6, 129, and SJL alleles) be generated for these studies. 
  Because of the difficulty of obtaining sufficient numbers of experimental animals by 
simply intercrossing the TploxTp/+ and the Cretg-transgene positive TploxTp/+ mice (only 1 in 8 
mice would be expected to be useful), we first crossed the transgenic mice with Tp-/- animals 
on a 129/SvEv genetic background.  The Cretg-transgene positive female Tp+/- mice were 
then crossed to mice homozygous for the TploxTp allele.  Four different genotypes of mice 
were generated from this cross at approximately equal frequencies.  The TploxTp/+ mice should 
behave essentially the same as wild type mice, since the presence of the loxP sites in the 
introns of the TP receptor is not expected to affect gene expression.  The TploxTp/- mice 
generated would be expected to have a slight attenuation of response based on our previous 
studies showing a decrease in the response of heterozygous animals (Supplemental Figure 
E3.1).  The response of these mice should be indistinguishable from that of the Cretg-
transgene positive TploxTp/+ animals, if TP receptor expression is critical in the Cre 
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recombinase expressing tissues, as either the smooth muscle (TploxTp/+ Tgln+ ve) or neural 
(TploxTp/+ nestin+) tissues will essentially be +/- for the Tp.  If this is not the critical tissue type, 
then these mice should behave similar to a wild type mouse.  The Cretg-transgene positive 
TploxTp/- mice are expected to have no expression of Tp in the smooth muscle (TploxTp/- Tgln+ ve) 
or neural (TploxTp/- nestin+) tissues and are heterozygous for Tp in all other tissues.  Thus the 
ideal comparisons should be made between the Cretg-transgene positive TploxTp/- mice and 
their TploxTp/- littermates.  However, we would expect if a particular tissue is critical for a 
response, the following rank order of responses is predicted (from lowest to highest):  Cretg-
transgene positive TploxTp/- < TploxTp/- = Cretg-transgene positive TploxTp/+< TploxTp/+.  Wild type 
129/SvEv and Tp-/- co-isogenic mice were included as controls in all experiments.   
 Southern blot analysis was utilized on select tissues to demonstrate successful, tissue 
specific, disruption of the TP receptor.  Tissues were harvested from TploxTp/+ mice, which 
either carried the Cretg under the control of the SM22 (transgelin; Tgln) promoter (Tgln+) or 
were negative for the Cretg transgene (Tgln-)(Figure 3.2A).  Tissues were harvested that 
demonstrate high concentrations of smooth muscle (trachea, intestine, and uterus).  Control 
tissues were also harvested including cardiac muscle (heart), skeletal muscle, and kidney 
(high TP receptor expression).  DNA was extracted from each of these tissues and digested 
with BamHI for Southern blot analysis with probes specific for Cre (data not shown), exon 2 
(data not shown), and for a region 5’ of exon 2.  All tissues demonstrate the endogenous 11.2 
kb fragment indicative of the wild type allele and a 4.5 kb fragment indicative of the floxed 
Tp allele.  However, an additional 3.3 kb fragment is present in smooth muscle containing 
tissues, which suggests successful disruption of the TP receptor, at least in some cells (Figure 
3.2A).  To further examine TP receptor loss in the ASM, 3 denuded tracheas were pooled 
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together from either TploxTp/+ or TploxTp/- mice, which either carried the SM22- Cretg transgene 
or were transgene negative (Figure 3.2B).   
Tissues were also harvested from TploxTp/+ and TploxTp/-, which carried the Cretg 
transgene under the control of the Nestin promoter.  The brain, intestine, and kidney were 
harvested and Southern blot analysis was performed as described above.  Animals that are 
wild type for the TP receptor (Tp+/+ and the TploxTp/+ mice) demonstrate an 11.2 kb fragment, 
while mice that carry the TP receptor disrupted by insertion of a neomycin cassette (TploxTp/- 
nestin+ and TploxTp/- mice) demonstrate a 4.1 kb fragment (Figure 3.2C).  In non-neuronal 
tissues (kidney and intestine) a 4.5 kb fragment is present that represents the intact floxed Tp 
receptor.  However, in the brain, a 3.3 kb fragment is generated in the Nestin+ mice that is 
indicative of successful neural disruption of the TP receptor by Cre recombinase (Figure 
3.2C).   
 
Neurally deficient TP receptor mice demonstrate increased airway resistance (Raw) and 
tissue damping (G) following stimulation with TXA2  
Previous reports suggest that TXA2 contributes to ASM constriction through the 
potentiation of vagal nerve neuro-effector transmission (2).  Inflammatory mediators such as 
TXA2 could affect neural activity at a variety of levels, including the primary afferent 
sensory nerve, autonomic ganglia, and autonomic neuroeffector junction.  If this hypothesis 
were true, we would expect that U46619 induced increases in Raw and G would be severely 
attenuated in mice with reduced neural expression of TP receptors.  U46619 induced a 
significant, dose dependent increase in both Raw and G in wild type mice (Tp+/+), while TP 
receptor deficient animals (Tp-/-) were unresponsive (Supplemental Figure E3.1A and B).   
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No significant differences in Raw or G were observed between any of the experimental mice, 
regardless of genotype or Cre expression (Figure 3.3A and B). While no significant 
differences in baseline measurements were observed between any of the mouse groups (data 
not shown), all animals carrying the floxed Tp allele demonstrated significant increases in 
both Raw and G in response to U46619 compared with the 129/SvEv coisogenic Tp-/- mice.  
However, the N1 generation floxed Tp mice demonstrated reduced increases in Raw and 
significantly attenuated increases in G compared with the 129/SvEv Tp+/+ animals (Figure 3A 
and B; Supplemental Figure E3.1A and B).   
 
Airway resistance (Raw) and tissue damping (G) are attenuated in naïve smooth muscle TP 
receptor deficient mice after exposure to TXA2 
 Neural disruption of the TP receptor failed to significantly attenuate airway reactivity 
to U46619, suggesting that TXA2 mediated airway constriction may be mediated by other 
cell types known to express the TP receptor.  TXA2 receptor expression by smooth muscle 
cells is well documented, as is the ability of TP receptor activation to mediate increases in 
[Ca++]i in cultured human primary ASM cells (50).  Here, we sought to examine the 
possibility that TXA2 mediated increases in airway reactivity could be mediated by TP 
receptors located directly on ASM cells.  If this hypothesis were true, we would expect that 
U46619 induced increases in Raw and G would be severely attenuated in mice with reduced 
expression of TP receptors on smooth muscle.  As mentioned above, U46619 induced a 
significant, dose dependent increase in both Raw and G in wild type mice (Tp+/+), while TP 
receptor deficient animals (Tp-/-) were unresponsive (Supplemental Figure E3.1A and B).   
Like the Tp-/- animals, the TploxTp/- Tgln+ ve smooth muscle receptor deficient mice also 
demonstrated significantly attenuated Raw and G responses compared to the TploxTp/+ wild 
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type mice.  The heterozygous TploxTp/- animals demonstrated an intermediate phenotype.  
These mice demonstrated significantly enhanced Raw and increased G compared with the 
TploxTp/- Tgln+ ve smooth muscle receptor deficient mice and significantly attenuated Raw and 
reduced G compared with the TploxTp/+ wild type animals (Figure 3.4A and B).  The TploxTp/+ 
Tgln+ ve smooth muscle heterozygous animals demonstrated significantly increased Raw that 
was reduced, but not significantly, compared to levels observed for the TploxTp/+ wild type 
mice.  (Figure 3.4A).  These animals demonstrated an intermediate G phenotype, which was 
neither significantly increased compared to the TploxTp/- Tgln+ ve smooth muscle receptor 
deficient mice nor significantly decreased compared to the TploxTp/+ wild type animals 
(Figures 3.4B). 
 
Exposure to TXA2 increases airway sensitivity to cholinergic stimuli  
The ability of U46619 to induce AHR to muscarinic receptor agonists has been 
characterized in a variety of model organisms (23, 52, 56).  However, while this phenomenon 
has been identified in canine, guinea pig, and human studies, the mechanism behind this 
increased sensitivity is not well defined.  Therefore, we sought to assess and characterize this 
TXA2 mediated AHR in mice.  Both Tp+/+ and Tp-/- mice were exposed to a mildly provoking 
dose of U46619 (10-4 M), which induces a moderate but significant increase in Raw in the 
Tp+/+ animals, while being relatively non-provoking by assessments with both the G 
parameter and in the single compartment model (RL)(Supplemental Figure E3.2A; 
Supplemental Figure E3.3A and B).   The initial treatment with U46619 (Challenge 1) was 
followed, 3 minutes later, by exposure to a weakly provoking dose of methacholine (6 
mg/ml).  This dose of MCh typically induces an increase of approximately 15% to 25% of 
baseline Raw and G (Supplemental Figure E3.3A and B).  Following the initial challenge 
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(Challenge 1) with U46619 or PBS, all of the mice demonstrated increases in Raw following 
subsequent exposures to MCh (Figure 3.5A).  However, no additional increase in MCh 
responsiveness was observed in mice pretreated with MCh (Figure 3.5A).  In contrast to the 
Raw results, the G results demonstrated that pretreatment with the 10-4 M dose of U46619 
induces a robust MCh response.  This response is significantly greater than that observed in 
the PBS pretreated Tp+/+ mice, the U46619 pretreated Tp-/- mice, and the MCh pretreated 
Tp+/+ mice.  This increase is highly noticeable when utilizing the equation of motion to 
describe the single compartment model of the lung and assessing lung resistance 
(RL)(Supplemental Figure E3.1A).  While the most dramatic effects were observed for MCh 
responses following U46619 pretreatment, exposure to 10-4 M U46619 also increased both 
Raw and G in response to subsequent challenges with U46619 (Supplemental Figure E3.3C 
and D).  No significant increases were observed in Raw or G following pretreatment with 
U46619 for serotonin (5-HT), adenosine, prostaglandin D2 (PGD2), or prostaglandin F2α 
(PGF2) (Figure 3.5C and D). 
 
Synergy between the TXA2 and cholinergic pathways are mediated, at least in part, by 
smooth muscle TP receptors 
As discussed above, we have demonstrated, in vivo, that mild or nonprovoking doses 
of TXA2 can augment the response of airways to methacholine in mice.  This potentiation 
appears to be due to a unique interaction between TP receptors and muscarinic receptors, as 
none of the other agonists were capable of inducing the robust increases observed in response 
to MCh when administered following U46619 pretreatment.  Because we identified a 
primary role for smooth muscle TP receptors in mediating U46619 induced airway reactivity 
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in the naïve model described above, we next wanted to assess whether induction of AHR is 
dependent on smooth muscle expression of TP receptors.  As discussed above, we assessed 
the ability of U46619 to enhance the response to low doses of MCh in the smooth muscle TP 
receptor deficient mice (Figure 3.6).  MCh provoked an increase in Raw in the wildtype 
TploxTp/+ mice, while only a minimal increase was detected in the smooth muscle TP receptor 
deficient TploxTp/- Tgln+ ve animals (Figure 3.6A).  The TploxTp/+ Tgln+ ve smooth muscle 
heterozygous animals demonstrated an increase in Raw following MCh challenge that was 
indistinguishable from the TploxTp/+ wild type mice, while only trivial increases in Raw were 
observed for the TploxTp/- heterozygous animals (Figure 3.6A).  As observed previously, 10-4 
M U46619 did not induce a significant increase in G (data not shown).  Following 
subsequent challenge with MCh, significant increases were observed in the TploxTp/+ wild 
type mice and TploxTp/+ Tgln+ ve smooth muscle heterozygous animals, while the TploxTp/- 
heterozygous mice produced an intermediate response that was neither significantly 
increased over the TploxTp/- Tgln+ ve smooth muscle receptor deficient mice nor reduced versus 
the TploxTp/+ wild type and TploxTp/+ Tgln+ ve smooth muscle heterozygous animals (Figure 
3.6B).  Only a moderate increase in G was observed in the TploxTp/- Tgln+ ve smooth muscle 
deficient mouse line, which was significantly reduced compared with the TploxTp/+ wild type 
and TploxTp/+ Tgln+ ve smooth muscle heterozygous animals (Figure 3.6B). 
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Figure 3.1.  Schematic depicting the generation of a floxed Tp allele in ES cells.  A) The 
organization of the endogenous locus, the targeting plasmid, and the Tp allele generated after 
homologous recombination of the plasmid with the wild type Tp allele are shown.   The 
fragments of DNA required for assembly of the targeting plasmid are prepared from genomic 
DNA isolated from 129 derived ES cells and primers designed using the sequence for the Tp 
gene available in the Celera mouse genome. The fragments are cloned into the vector 
pXenaLF2, which was constructed specifically for the rapid assembly of plasmids capable of 
generating floxed alleles.   The loxP sites are denoted with triangles, the frt sites by 
diamonds, and the neo gene is represented by the shaded arrow.  Relevant restriction sites are 
abbreviated as follows:  B, BamHI; A, ApaI; E, EcoRI.  Greyed boxes represent coding Tp 
receptor exons. B-D) Southern blot analysis of the ES cell clones to identify those carrying a 
floxed Tp allele.  DNA was prepared from neomycin resistant clones obtained after 
electroporation of the targeting plasmid into ES cells.  A 3' probe not included in the 
targeting plasmid was used as a first screen to identify those ES cell clones in which the 
plasmid was integrated by homologous recombination.  Eight such clones were identified and 
further analyzed using a Tp exon 2 specific probe.  Some of the targeted ES cell clones were 
further analyzed to identify those in which the crossover event during homologous 
recombination resulted in introduction of the 5' lox site in addition to the neomycin gene at 
the Tp locus.  To do this, DNA was digested with BamHI and EcoRI and analyzed by 
Southern blot using the exon 2 probe.  This probe recognizes a 7.4 kb wild type allele and a 
5.5 kb fragment in those clones in which the crossover event failed to introduce the 5'loxP 
site.  The probe is expected to hybridize to a 3.3 kb fragment both in ES cells in which the 
targeting plasmid integrated randomly and in those clones which underwent homologous 
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recombination with the desired crossover event.  Clone number seven clearly represents such 
an ES cell clone.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 138
Figure 3.2 
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Figure 3.2.  Southern Blot characterization of floxed Tp mice.  A) Southern blot analysis 
of organs and tissues from TP receptor wild type mice carrying the floxed Tp allele (loxTp/+) 
either with (Tgln+) or without  (Tgln-) the Cretg transgene under the control of the SM22 
(transgelin; Tgln) promoter.  Smooth muscle containing tissues (Intestine and Uterus) 
demonstrate smooth muscle specific disruption of the TP receptor.  B) Southern blot analysis 
of tracheas harvested and pooled from TP receptor wild type (loxTp/+) or TP receptor 
deficient (loxTp/-) mice carrying the floxed Tp allele either with (Tgln/+) or without  (Tgln/-) 
the Cretg transgene under the control of the SM22 promoter.  Airway smooth muscle specific 
disruption of the TP receptor was observed in the tgln/+ preparations.  C) Southern blot 
analysis of organs and tissues from TP receptor wild type (loxTp/+) or TP receptor deficient 
(loxTp/-) mice carrying the floxed Tp allele either with (Nestin+) or without (Nestin-) the 
Cretg transgene under the control of the Nestin promoter.  Neural specific disruption of the 
TP receptor was observed in brain preparations. 
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Figure 3.3 
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Figure 3.3. Neural specific deletion of TP receptors does not significantly affect airway 
resistance and tissue damping induced by U46619 aerosol challenge.  No significant 
differences in A) airway resistance (Raw) or B) tissue damping (G) were detected for any of 
the mice carrying the floxed Tp allele.  All mice demonstrated significantly increased Raw 
and G, compared to 129/SvEv co-isogenic Tp-/- animals (Supplemental Figure 1).  TploxTP/-, n 
= 9; TploxTp/+, n = 15; TploxTp/- nestin+, n = 6; TploxTp/+ nestin+, n = 9. 
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Figure 3.4 
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Figure 3.4.  Smooth muscle specific deletion of TP receptors significantly attenuates 
airway resistance and tissue damping induced by U46619 aerosol challenge.  A) Airway 
resistance (Raw) and B) tissue damping (G) are significantly reduced in TP receptor deficient 
mice carrying the floxed Tp allele and the Cretg transgene under the control of the SM22 
promoter (loxTp/- Tgln+ ve).  The wild type mice carrying the floxed Tp allele (loxTp/+) 
demonstrated a significant increase in the U46619 response.  The heterozygous wild type 
mice carrying the floxed Tp allele and the Cretg transgene (loxTp/+ Tgln+ ve) (thus 
heterozygous for the TP receptor on the smooth muscle) and TP receptor deficient mice 
carrying the floxed Tp allele but no Cretg transgene (loxTp/-)(thus heterozygous in all tissues) 
demonstrated intermediate phenotypes in response to U46619 challenge. However, the 
loxTp/+ Tgln+ ve animals demonstrated a significant increase in Raw compared to the loxTp/- 
mice, but was slightly reduced versus the loxTp/+ animals. TploxTp/-, n = 12; TploxTp/+, n = 12; 
TploxTp/- Tgln+ ve, n = 10; TploxTp/+ Tgln+ ve, n = 17 (*p < 0.05; Ψp < 0.05; Φp < 0.05). 
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Figure 3.5  
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Figure 3.5.  Increased sensitivity of airways to cholinergic stimuli after exposure to 
nonprovoking doses of TXA2.  Airways were exposed to low levels of U46619 (10-4 M) 
followed by subsequent cholinergic stimulation with low levels of MCh (6 mg/ml).  Two 
groups of 129/SvEv wild type mice and a group of 129/SvEv co-isogenic Tp-/- mice were 
intubated and baseline lung mechanics established.  A cohort of wild type and Tp-/- mice 
were then exposed to an aerosol produced from a 1x10–4 M solution of U46619. The second 
group of wild type mice was only treated with vehicle, and a third group of wild type animals 
were treated with an aerosol produced from a 6 mg/ml solution of methacholine (MCh). 
Within 3 minutes of vehicle, U46619, or MCh treatment, all groups of mice were exposed to 
an aerosol produced from a 6 mg/ml solution of MCh, which has been demonstrated to be 
only mildly provoking.  Data are shown as the % change in Raw or G observed between 
challenge 1 and challenge 2.  A) The initial challenge (Challenge 1) of U46619 and MCh 
provoked slight increases in Raw in the Tp+/+ mice (Supplemental Figure 3).  The second 
challenge of MCh did not induce further increases in airway resistance in mice pretreated 
with MCh.  However, all of the other groups demonstrated small increases in Raw following 
subsequent aerosol exposure to 6 mg/ml of methacholine.  Tp+/+ (PBS to MCh), n = 7; Tp+/+ 
(MCh to MCh), n = 4; Tp+/+ (U46619 to MCh), n = 12; Tp-/- (U46619 to MCh), n = 4 (*p < 
0.05).  B) The initial challenge (Challenge 1) of both U46619 and MCh were nonprovoking, 
as determined by the G parameter (data not shown).  The subsequent challenge with the 6 
mg/ml dose of MCh produces only a modest increase in the vehicle challenged mice and 
MCh pretreated animals.  In contrast, a robust response to this dose of MCh was observed in 
wild type mice pretreated with the nonprovoking dose of U46619. The dependence of this 
response on the specific interaction of U46619 with the TP receptor was further 
 146
demonstrated by the fact that only a modest response to this dose of methacholine could be 
measured in the Tp-/- mice.  Tp+/+ (PBS to MCh), n = 7; Tp+/+, n = 12; Tp-/-, n = 4 (*p < 0.05; 
**p < 0.01; §p < 0.01).  C - D) In addition to assessing the response to MCh, the effects of 
exposing mice to a mildly provoking dose of U46619 (10-4 M) followed by exposure to 
serotonin (5-HT) (5 mg/ml), adenosine (6 mg/ml), prostaglandin D2 (PGD2)(10-4 M), and 
prostaglandin PGF2α (PGF2)(10-4 M) were also assessed.  No increases in AHR were 
observed for any of these mediators.  PBS/5-HT, n = 4; U46619/5-HT, n = 4; PBS/adenosine, 
n = 3; U46619/adenosine, n = 3; PBS/PGD2, n = 7; U46619/PGD2, n = 3; PBS/PGF2, n = 
12; U46619/PGF2, n = 3. 
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 Figure 3.6 
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Figure 3.6.  Synergy between the thromboxane and cholinergic pathways are mediated, 
at least in part, by smooth muscle TP receptors. Smooth muscle TP receptor deficient 
mice were exposed to low levels of U46619 (10-4 M) followed by subsequent cholinergic 
stimulation with low levels of MCh (6 mg/ml).  A) U46619 induced a modest increase the 
MCh Raw response in TploxTp/+ (wild type) and TploxTp/+ Tgln+ ve (smooth muscle heterozygous) 
mice.  Only small increases were observed in the TploxTp/- (heterozygous) or the TploxTp/- Tgln+ 
ve (smooth muscle Tp receptor deficient mice).  B) U46619 induced a significant increase the 
MCh G response in TploxTp/+ and TploxTp/+ Tgln+ ve mice.  The TploxTp/- mice demonstrated an 
intermediate phenotype, which was not significantly different from any of the other groups of 
animals.  No significant increase was observed in the TploxTp/- Tgln+ ve.  Data are shown as the 
% change in Raw or G observed between the initial challenge of U46619 (10-4M) and the 
subsequent challenge with MCh (6 mg/ml)(*p < 0.05; Ψp < 0.05). 
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Figure 3.7 
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Figure 3.7.  Schematic depicting possible models of TP receptor and M3 mAChR 
mediated airway smooth muscle constriction.  A) Interactive Pathways Model:  TP 
receptor stimulation fails to increase intracellular Ca++ to levels sufficient to mediate smooth 
muscle constriction.  Acetylcholine acts on M3 mAChRs to maintain cholinergic tone.  
However, binding of TXA2 to its receptor potentates the activity of the M3 mAChR, thereby 
increasing the sensitivity of this receptor to basal release of acetylcholine and leading to 
increased intracellular Ca++ and smooth muscle constriction.  B) Dimer Formation Model:  
I) and II) Agonist binding to a GPCR monomer drives heterodimer formation or III) the 
agonist could bind to a preexisting dimer.  Loading the GPCR with agonist induces a 
conformational shift that allows the accommodation of the heterotrimeric G protein binding. 
GPCR activation results in the dissociation of the G protein subunits ultimately resulting in 
increased intracellular Ca++ and increased smooth muscle constriction. C) G Protein 
Redistribution Model:  A Gα or βγ driven competition may exist between the TP receptor 
and the M3 mAChR.  Upon TP receptor activation, the disassociation of these subunits and 
the subsequent reassociation to the mAChR, or even other TP receptors, is capable of shifting 
the M3 mAChR to a higher affinity state and thereby enhancing M3 mAChR mediated 
signaling events. 
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Thromboxane Mediates Airway Reactivity and Hyperresponsiveness Through Collaborations 
Between Smooth Muscle Tp Receptors and The M3 Muscarinic Acetylcholine Receptor 
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Supplemental Figure E3.1 
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Supplemental Figure E3.1.  Mice heterozygous for the TP receptor (Tp+/-) demonstrate 
an intermediate response to a U46619 dose response challenge.  Increases in both A) 
airway reactivity (Raw) and B) tissue damping (G) were observed in the TP receptor wildtype 
mice (Tp+/+), while no increases were observed for the TP receptor deficient mice (Tp-/-).  
Mice that were heterozygous for the TP receptor (Tp+/-) demonstrated intermediate 
phenotypes, which were neither significantly increased compared to the Tp-/- mice (with the 
exception of the 10-4 M U46619 dose under the Raw parameter) nor significantly reduced 
versus the Tp+/+ animals. Tp-/-, n = 12; Tp+/-, n = 6; Tp+/+, n = 18 (*p < 0.05; §p < 0.01). 
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Supplemental Figure E3.2 
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Supplemental Figure E3.2.  Increased sensitivity of airways to cholinergic stimuli after 
exposure to nonprovoking doses of TXA2. A) We examined the impact of exposure of 
airways to low levels of the TXA2 mimetic U46619 to subsequent cholinergic stimulation 
using the single compartment model of the lung.  Two groups of wild type mice and a group 
of 129/SvEv co-isogenic Tp-/- mice were intubated and baseline lung mechanics established 
and designed as 100% RL.  A cohort of wild type and Tp-/- mice were then exposed to vehicle 
followed by an aerosol produced from a 1x10-5 M solution of U46619. The second group of 
wild type mice was only exposed to vehicle.  As previously shown, this low level of U46619 
does not result in a measurable increase in RL in wild type mice.  Within 3 minutes of either 
vehicle or U46619 treatment, all groups of mice were exposed to a nonprovoking dose of 
MCh.  As expected, the vehicle treated wild type mice showed no increase in RL in response 
to aerosols of 6mg/ml of MCh.  In contrast, a robust response to this dose of MCh was 
observed in wild type mice pretreated with U46619. The dependence of this response on the 
specific interaction of U46619 with the TP receptor was further demonstrated by the fact that 
no response to this dose of MCh could be measured in the Tp-/- mice. Tp-/- with U46619, n = 
7; Tp+/+ no U46619, n = 5; Tp+/+ with U46619, n = 5 (§p < 0.01).   B) We also examined the 
impact of exposure of airways to low levels of cholinergic stimulation with subsequent Tp 
receptor stimulation.  A cohort of wild type and Tp-/- mice were exposed to vehicle followed 
by an aerosol produced from 6mg/ml MCh. The second group of wild type mice was only 
treated with vehicle.  This low level of MCh produces a small increase in RL in wild type 
mice; however this increase is not significant (p = 0.09).  Within 3 minutes of vehicle or 
MCh treatment, all groups of mice were exposed to a nonprovoking dose of U46619.  None 
of the animals demonstrated increases in RL in response to aerosols of 10-5M U46619. 
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Supplemental Figure E3.3 
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Supplemental Figure E3.3. Increased sensitivity of airways to cholinergic stimuli after 
exposure to nonprovoking doses of TXA2.  Airways were exposed to low levels of U46619 
(10-4 M) followed by subsequent cholinergic stimulation with low levels of MCh (6 mg/ml).  
Two groups of 129/SvEv wild type mice and a group of 129/SvEv co-isogenic Tp-/- mice 
were intubated and baseline lung mechanics established.  A cohort of wild type and Tp-/- 
mice were then exposed to vehicle followed by an aerosol produced from a 1x10–4 M solution 
of U46619. The second group of wild type mice was only treated with vehicle, and a third 
group of wild type animals were treated with an aerosol produced from a 6 mg/ml solution of 
methacholine (MCh). Within 3 minutes of vehicle, U46619, or MCh treatment, all groups of 
mice were exposed to an aerosol produced from a 6 mg/ml solution of MCh, which has been 
demonstrated to be only mildly provoking.  A) All three groups of mice demonstrated 
increases in airway Raw in response to subsequent aerosol exposure to 6 mg/ml of 
methacholine.  However, mice pretreated with U46619 demonstrated the greatest increase.  
Tp+/+ (PBS to MCh), n = 7; Tp+/+, n = 12; Tp-/-, n = 4 (*p < 0.05).  B) U46619 did not provoke 
an increase in tissue damping (G) in the wild type animals.  The 6 mg/ml dose of MCh 
produces only a modest increase in the vehicle challenged animals.  In contrast, a robust 
response to this dose of methacholine was observed in wild type mice pretreated with 
U46619. The dependence of this response on the specific interaction of U46619 with the TP 
receptor was further demonstrated by the fact that only a modest response to this dose of 
methacholine could be measured in the Tp-/- mice.  Tp+/+ (PBS to MCh), n = 7; Tp+/+, n = 12; 
Tp-/-, n = 4 (§p < 0.01).  C – D) The impact of low level TP receptor stimulation was assessed 
following airway exposure to low levels of cholinergic stimulation or TP receptor 
stimulation.  Mice were exposed to mildly provoking doses of either MCh (6 mg/ml), 
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U46619 (10-4 M), or PBS for 30 seconds, followed by assessments of airway resistance 
(Raw) and tissue damping (G).  Immediately following these initial challenges (Challenge 1), 
mice were exposed to a second mildly provoking dose of either MCh (6 mg/ml) or U46619 
(10-4 M)(Challenge 2).  Data are shown as the % change in Raw or G observed between 
challenge 1 and challenge 2.  PBS/MCh, n = 7; U46619/MCh, n = 12; MCh/MCh, n = 4; 
PBS/U46619, n = 15; U46619/U46619, n = 3; MCh/U46619, n = 3 (*p < 0.05; #p < 0.05; 
**p < 0.01).  E and F) Smooth muscle TP receptor deficient mice were exposed to low 
levels of U46619 (10-4 M) followed by subsequent cholinergic stimulation with low levels of 
MCh (6 mg/ml).  Data are shown as the % change in Raw or G observed between the U46619 
challenge and the MCh challenge.  E) U46619 induced a small, but insignificant increase the 
MCh Raw response in TploxTp/+ (wild type) mice compared with the Tp-/- animals and the 
animals exposed to PBS prior to the second challenge with MCh.  F) U46619 induced a 
significant increase the MCh G response in TploxTp/+ mice.  No significant increase was 
observed in the Tp-/- mice pretreated with U46619 or from Tp+/+ mice receiving PBS prior to 
the MCh challenge (*p < 0.05; Ψp < 0.01; §p < 0.01). 
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Discussion 
 Extensive characterization of TXA2 mediated airway reactivity has suggested that this 
potent lipid mediator indirectly induces ASM constriction by potentiating the neuro-effector 
transmission of cholinergic stimuli.  The basis for this hypothesis stems from microelectrode 
and tension recording assessments of smooth muscle cells and nerve preparations isolated 
from the canine trachea.  Under these ex vivo conditions, sub-threshold levels of TXA2 (10-10-
10-7 M, depending on study) do not affect the membrane potential, input membrane 
resistance, or the sensitivity to acetylcholine of canine trachea smooth muscle cells; however, 
this concentration is sufficient to significantly increase the amplitude of contractions evoked 
by electrical field stimulation (EFS)(2, 28).  This amplification has been shown to be 
sensitive to atropine, tetrodotoxin, and selective TXA2 antagonists.  Expanding upon these 
findings, the ability of TXA2 to augment the in situ central airway contraction of the canine 
trachea following efferent nerve stimulation was also assessed (41).  These studies monitored 
airway responses to intravenous drug administration and vagal stimulation by in situ 
isometric measurements of tracheal smooth muscle tension.  These data demonstrate that 
U46619 substantially augments the tracheal contraction induced by vagal stimulation.  
However, when acetylcholine was given instead of vagal stimulation, U46619 did not 
enhance the tracheal contractions (41).  It was therefore reasoned that U46619 potentiation is 
caused by a pre-junctional action rather than by nonspecific pre-contraction of ASM with 
another agonist.  Based on previous work demonstrating that U46619 did not enhance 
afferent vagal stimulation of canine ASM (47) and the observation that canine airways lack 
non-adrenergic innervation (24), the authors presumed that TXA2 augmentation depended on 
efferent pre-junctional vagal mechanisms (41). 
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 In addition to data generated with canine tracheal preparations, data that supports the 
enhancement of neural signaling via TXA2 has also been generated by assessments of canine 
bronchial preparations.  As with tracheal preparations, U46619 has also been demonstrated to 
constrict bronchial smooth muscle.  To further characterize this constriction, microelectrode 
studies demonstrated that sub-threshold doses of U46619 (10-9 M) greatly potentiated the 
amplitude (252%) and the duration (over 2-fold) of the EFS excitatory junction potential 
(EJP) without significantly altering the membrane potential or tonic contractions of the ASM 
(1, 29).  This pre-junctional effect was shown to be sensitive to TXA2 receptor antagonists 
and therefore suggests that U46619 is capable of pre-junctionally stimulating nerves, via the 
Tp receptor, to enhance the release of ACh (29).    
 While the Tp receptor has not been definitively localized on nerves of the PNS, it’s 
presence has been inferred by pharmacological assessments and Tp receptor mRNA has been 
localized to nodose ganglion neurons from rabbits (32, 61).  Early functional in vivo studies 
in cats demonstrated that afferent nerves could be stimulated following the local infusion of 
arachidonic acid (AA) into the hindlimb circulation (49).  This stimulation was abolished 
following pretreatment with cyclooxygenase inhibitors, thus suggesting that a metabolite of 
AA was the culprit behind this stimulation.   These early studies suggested that TXA2 might 
contribute to these responses.  Indeed, TXA2 has been shown to be capable of mediating 
changes in bradycardia through a neurally mediated mechanism.  In these studies, U46619 
was directly applied to the epicardial surface of the heart with no effect on cardiac function in 
either cats or rabbits (46, 60).  However, in both species, intravenous injections of U46619 
was shown to evoke a viscerosomatic reflex that was capable of inhibiting somatomotor 
activity, which resulted in a decreased heart rate in rabbits and inhibition of the knee-jerk 
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response in cats (46, 60).  In both studies, these responses were eliminated after bilateral 
cervical vagotomy.   In the airway, additional in vivo studies have demonstrated that U46619 
is capable of stimulating vagal afferent C-fibres, slowly adapting pulmonary receptors 
(SARs), and rapidly adapting pulmonary receptors (RARs)(31) and thus implies that in the 
lung, TXA2 may be able to modify airway responses through vagally derived afferent nerves.  
 Based on the extensive data suggesting that TXA2 mediated ASM constriction is 
neurally mediated, it was surprising that we did not observe a more dramatic phenotype in 
mice lacking neural expression of Tp receptors.  One possible explanation for this 
observation is that Tp receptors may still be intact on peripheral neurons.  While we 
demonstrate the successful disruption of the Tp receptor in the brain (CNS), we do not 
specifically assess nerves of the peripheral nervous system (PNS).  Nestin is an intermediate 
filament protein that is ubiquitously expressed in neuroepithelial precursor cells, which will 
ultimately differentiate into all types of neurons and glia, including nerves of the PNS (63).  
Thus, we made the assumption that Nestin driven Cre recombinase would be an appropriate 
system to disrupt neurally expressed TP receptors in both the CNS and PNS.  However, to 
further resolve this issue, it may be necessary to cross the Tpnestin+ animals generated in this 
study with a reporter mouse, such as the C57BL/6J-Gtrosa26tm2Sor (Rosa26) mice, that carry 
a loxP-disrupted β-galactosidase gene to verify Cre recombinase activity in the PNS.  
Following this strategy, peripheral tissues including the lungs and trachea could be harvested 
and processed for LacZ histochemistry (X-gal staining) and then counterstained 
immunohistochemically for a nerve specific marker, such as PGP9.5.  While inefficient 
Nestin mediated Cre recombinase disruption is one possible scenario to explain the lack of 
phenotype, genetic background issues may also be obscuring the actual impact from neural 
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disruption of the TP receptor in the Tpnestin+ animals and their Tpnestin- littermates.  These mice 
are all N1 generation animals and have a significant C57BL/6 genetic contribution.  In 
general, C57BL/6 mice typically demonstrate significantly reduced airway reactivity.  The 
strong C57BL/6 contribution is evidenced in our data by the reduced Raw responses and 
significantly attenuated G responses in the Nestintg animals compared to the 129/SvEv mice 
(Figure 3.3A and B; Supplemental Figure E3.1A and B).  It may be necessary to continue 
backcrossing these animals onto the 129/SvEv background to further verify the impact of 
neural Tp receptor disruption. 
Because we failed to observe a dramatic decrease in airway reactivity in the neural TP 
receptor deficient animals, we next assessed the ability of smooth muscle TP receptors to 
influence airway mechanics in response to U46619. Extensive data clearly demonstrates that 
TP receptors are expressed on smooth muscle (13, 25, 42) and as discussed above, several 
studies have suggested that these receptors may functionally contribute to ASM constriction.  
To disrupt the smooth muscle TP receptors, we chose to cross the floxed Tp mice with 
transgenic animals expressing Cre-recombinase under the control of the SM22 promoter.  
The SM22-Cre animals have demonstrated highly efficient Cre-mediated recombination in 
smooth muscle cells (19).  Here, we demonstrate that Cre-mediated disruption of the smooth 
muscle TP receptors was successful in uterine, intestinal, and tracheal smooth muscle.  In 
addition to these tissues, the lungs were also harvested and assessed by Southern blot; 
however, we failed to observe the 3.3 kb fragment indicative of successful Cre mediated 
recombination (data not shown).  This was most likely due to the low abundance of ASM 
present in the lungs compared to other cell types.  Previous studies assessing the expression 
pattern of the SM22- Cretg transgene have demonstrated, following breeding of the SM22-
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Cretg mice with the ROSA-26 β-gal reporter animals, that efficient recombination does occur 
in the ASM of the lung (26). It is also important to note that Cre-mediated recombination is 
not 100% efficient, thus some smooth muscle cells will inevitably fail to undergo 
recombination.  
Previously, we predicted that if a particular tissue is critical for the TXA2 response, 
we should observe the following rank order:  Cretg -transgene positive TploxTp/- < TploxTp/- = 
Cretg-transgene positive TploxTp/+< TploxTp/+.  This prediction is similar to what we observed 
for the smooth muscle TP receptor deficient mice.  The TploxTp/- Tgln+ ve mice demonstrate both 
attenuated TXA2 mediated airway reactivity and reduced AHR to cholinergic stimuli.  
Likewise, both TploxTp/- heterozygous and TploxTp/+ Tgln+ ve smooth muscle heterozygous 
animals demonstrated intermediate responses for both Raw and G, while TploxTp/+ wild type 
mice demonstrated significantly increased airway responses to TXA2.  However, the TploxTp/+ 
Tgln+ ve smooth muscle Tp heterozygous mice demonstrated significantly increased Raw in 
response to TXA2 and significantly increased Raw and G in response to MCh in the TXA2 
mediated AHR model, when compared with the TploxTp/- heterozygous animals.  The simplest 
explanation for these data is that TP receptors on other tissues may contribute to TXA2 
mediated AHR.  In addition to smooth muscle and neural TP receptors, high levels of TP 
receptors are also expressed on bronchial epithelial cells and resident leukocytes in the lung 
(43, 59).  Activation of TP receptors on other tissue types may contribute to the increase in 
airway reactivity observed in these animals.  However, if this hypothesis were true, we would 
also expect to see an intermediate increase in AHR in the TploxTp/- Tgln+ ve smooth muscle TP 
receptor deficient animals, whose responses were similar to those observed for the Tp-/- mice.  
While we cannot fully discount the possibility that TP receptors expressed on other tissues 
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may contribute to the TXA2 response, the data presented here strongly suggests that TXA2 
mediates increases in airway reactivity and AHR through direct interactions with smooth 
muscle TP receptors.  
A number of models could be proposed to describe possible mechanisms involved in 
the modulation of smooth muscle TP receptor signaling that are consistent with our previous 
work showing a dependence on both intact vagal innervation and the M3 mAChR for TXA2 
mediated ASM constriction (3)(Figure 3.7).  Because TP receptors and M3 mAChRs are 
both present on smooth muscle, one potential model suggests that stimulation of the TP 
receptor fails to increase intracellular Ca++ to levels sufficient to mediate constriction.  
However, binding of TXA2 to its receptor potentates the activity of the M3 mAChR, thereby 
increasing the sensitivity of this receptor to basal release of acetylcholine (Figure 3.7A).  
While this is the simplest model, other possible models can be envisioned, which reflect a 
possible modulation of M3 mAChR signaling by the TP receptor.  It is well established that 
G-protein coupled receptors (GPCR) function via distinct signal transduction pathways; 
however, it is also accepted that “cross-talk” or synergy can also occur.  This synergism can 
occur through mechanisms such as heterodimerization, cross-reactions among GPCR 
downstream effectors, and G-protein redistribution (27).  While neither heterodimerization 
nor downstream effector cross-signalling have been defined for TP receptors, some 
evidence does suggest the TP receptor is capable of cross-talk with other GPCRs via 
redistribution of G-proteins.  Evidence for this stems from data suggesting synergism 
between platelet PAR1 receptors and TP receptors, as well as, anecdotal evidence 
suggesting a similar synergism between platelet-activating factor (PAF) and Tp receptors 
(16).  The PAR1/TP synergism model describes a dynamic equilibrium between the TP 
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receptor and other GPCRs that couple to the same Gα-subunits as TP (27).  Following this 
model, a Gα driven competition may exist between TP and other GPCRs.  Upon activation, 
the disassociation of the Gα-subunit from these GPCRs, and the subsequent Gα 
reassociation to TP is capable of shifting TP to a higher affinity state and thereby enhancing 
TP receptor mediated signaling events (16, 17).  It is temping to speculate a similar 
synergism may exist between the TP receptor and the M3 mAChR (Figure 3.7C). 
Our data extends the findings that TXA2 contributes to the development of allergic 
airway disease and in particular to changes in airway reactivity through its ability to amplify the 
actions of ACh.  Based on the data generated here for the smooth muscle TP receptor deficient 
mice, it is likely that the primary mechanism by which TXA2 induces airway reactivity and 
enhances subsequent responses to ACh is via the direct activation of ASM Tp receptors.  
Following activation, the TP receptors collaborate through a currently undefined mechanism 
with M3 mAChRs to initiate ASM constriction.  The extent to which TXA2 contributes to the 
asthmatic condition in humans is still undetermined.  However, the improvement in 
subpopulations of asthma patients following TXA2/TP or muscarinic receptor antagonist 
therapies suggests that the mechanisms outlined above may play an important, yet limited, role in 
asthma pathophysiology. 
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 Abstract 
A genetic contribution to asthma susceptibility is well recognized, and linkage studies 
have identified a large number of genes associated with asthma pathogenesis.  Recently, a 
locus encoding a seven transmembrane protein was shown to be associated with asthma in 
founder populations.  The expression of the protein GPRA (G protein-coupled receptor for 
asthma susceptibility) in human airway epithelia and smooth muscle, and its increased 
expression in a mouse model of asthma, suggested that a gain-of-function mutation in this 
gene increased the disease risk.  However, we report here that the development of allergic 
lung disease in GPRA deficient mice is unaltered.  A possible explanation for this finding 
became apparent upon reexamination of the expression of this gene.  In contrast to initial 
studies, our analyses failed to detect expression of GPRA in human lung tissue or in mice 
with allergic lung disease. We identify a single parameter that distinguishes GPRA deficient 
and wild type mice. While the change in airway resistance in response to methacholine was 
identical in control and GPRA deficient mice, the mutant animals showed an attenuated 
response to thromboxane, a cholinergic receptor dependent bronchoconstricting agent.  
Taken together, our studies fail to support a direct contribution of GPRA to asthma 
pathogenesis.  However, our data suggests that GPRA may contribute to the asthmatic 
phenotype by altering the activity of other pathways, such as neurally mediated mechanisms, 
that contribute to disease.  This interpretation is supported by high levels of GPRA 
expression in the brain and its recent identification as the neuropeptide S receptor.   
 
Keywords: 
Neuropeptide S; G protein coupled receptor; allergic lung disease; anaphylaxis 
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 Introduction 
Asthma is a complex genetic disorder with heterogeneous phenotypes and is strongly 
influenced by environmental factors.  A strong genetic predisposition to asthma is well 
recognized.  Over the past decade, linkage analyses for asthma susceptibility loci have 
identified several candidate regions.  A recent addition to the pool of candidate genes 
associated with asthma susceptibility and atopy has been identified using genome-wide 
linkage scans and positional cloning on chromosome 7p15-p14 (19, 20).  Using founder 
populations from Finnish and French-Canadian cohorts, this study identified 2 candidate 
genes within this region.  One, a putative gene with a large open reading frame, was 
designated asthma-associated alternatively spliced gene 1 (AAA1). Expression analyses 
showed some weak hybridization to lung RNA, however the open reading frame for this gene 
is not preserved in mouse.  The second gene identified on the other strand of an overlapping 
region of DNA encodes a 7 transmembrane domain (7TM) protein.  Termed G protein-
coupled receptor for asthma susceptibility (GPRA), an asthma-associated single nucleotide 
polymorphism (SNP) identified in this study alters the primary structure of this gene: the 
polymorphism results in the substitution of an isoleucine for the asparagine located at 
position 107 of the protein in affected individuals.  Excitement regarding this newly 
identified asthma candidate gene was fueled by the demonstration that the GPRA protein was 
expressed at high levels in the lung, particularly in tissues obtained from asthmatic patients.   
Since this initial genetic study, GPRA polymorphisms have been found to be 
associated with asthma and atopy in other populations.  Studies of multiple western European 
populations revealed an association of GPRA haplotypes with asthma and atopy (18, 23).  
Likewise, assessments of a Chinese population revealed an association between a previously 
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 uncharacterized GPRA haplotype and methacholine induced airway hyperresponsiveness, 
thus extending the association findings to a non-Caucasian population (7).  In contrast to 
these original analyses and association studies, a high-resolution fine mapping study 
screening SNPs on chromosome 7p in German and Swedish populations, as well as a 
phylogenetic analysis of GPRA associated SNP haplotypes within a Korean population, 
failed to show GPRA linkage or association with asthma (14, 28).  Additional association 
studies in individuals of northern European descent also failed to show association with the 
GPRA risk haplotypes and atopic dermatitis, a chronic recurring inflammatory skin disease 
that is characterized by high serum IgE levels and the recruitment of Th2 lymphocytes (31, 
34). 
The 7TM receptor encoded in the asthma associated locus and termed GPRA was 
independently identified and characterized as the vasopressin receptor-related receptor 1 
(VRR1) (9).  VRR1 is expressed in the retina and has been mapped between markers 
associated with retinitis pigmentosa subtype 9 (9, 16).  Likewise, GPRA has also been 
described as the receptor for neuropeptide S (NPSR1), a novel neuropeptide that potently 
modulates arousal and could also regulate anxiolytic-like effects.  Both the ligand and the 
receptor were shown to be expressed at extremely high levels in the brain (37).  Biochemical 
studies using cell lines have shown that GPRA/NPSR indeed couples to G proteins.  
Interestingly, these transfection studies in HEK293 cells show that GPRA/NPSR couples to 
both Gq and Gs pathways, induces calcium mobilization, and increases adenylate cyclase 
activity (9).  Which of these pathways dominates in nontransformed cells is not yet clear.  
However, similar studies have also demonstrated that the N107I polymorphism, while not 
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 altering ligand binding affinity, results in a gain-of-function mutation defined by an increase 
in agonist potency (4, 26).  
The GPRA gene encodes a unique and recently deorphanized G-protein coupled 
receptor (GPCR), which was originally identified as GPR154.  Alternative splicing of the 
gene results in variants that differ from one another in the primary amino acid structure of the 
cytoplasmic domain.  Antibodies generated against C terminal peptides of two of the GPRA 
isoforms demonstrated expression of the A isoform in the airways of both asthmatic and 
healthy individuals.  In contrast, expression of the B isoform was detected in airway 
epithelial cells in healthy individuals and predominately in the airway smooth muscle cells in 
asthmatics (20, 35).  Laitinen et al. also reported that GPRA expression could be detected in 
the mouse lung and that the expression increased in a mouse model of asthma.  These data 
suggest that the mouse might provide a useful model for study of the role of GPRA in human 
disease.  Towards this end, we report here the generation of a mouse line deficient in GPRA 
expression as well as the characterization of this mouse in the ovalbumin induced mouse 
model of allergic lung disease.  
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 Methods 
 
Generation of GPRA-deficient mice 
  Segments of the NPSR1/GPRA encoding gene were amplified by PCR and used to 
create a plasmid capable of undergoing homologous recombination with the endogenous 
locus.  Two 5 kb fragments of the Npsr1/Gpra gene were amplified using the following 
primer sets:  5’-GCGGC CGCAAGATGCCCACCCAGTAAGAAATC-3’and 5’-GTCGA 
CCTAGGTAGAGGCATACAGCAGGACAA-3’ and 5’-GGTACCCGGGCCATGGGG 
AACAGAACGGAGAT-3’ and 5’-GCAATTGAGCCCCACCAAGCAAACTGT-3’.  The 
fragments were then cloned 5’ and 3’ of the neomycin gene in the pXena vector.  This 
targeting plasmid is designed to replace a 744 bp region containing the majority of exon 4 
with the neomycin cassette.  Exon 4 includes regions of the gene encoding the 3rd 
transmembrane spanning domain and regions of the i2 intracellular loop.  The plasmid was 
linearized and introduced into embryonic stem cells derived from 129/SvEv mice, and 
transformants were isolated using standard methodologies (24).  A DNA probe 
corresponding to the region immediately 5' of the targeted region generated by PCR (5’-
GCTCATGTGTTTTCTTTCCTTATCT-3’ and 5’-ACCTCCCATGCCCACTCGT-3’) was 
used to identify targeted ES cells by Southern blot.  A second probe, corresponding to DNA 
encoding exon 4, was generated by PCR (5’-CCATCG TTTACCCCATGAAG-3’ and 5’-
CCTGGTACCCCAACAGTAGC-3’) and was used to verify the loss of the region of the 
gene during the homologous recombination event.  ES cells carrying the correctly modified 
locus were used to generate chimeric animals, which in turn were bred to 129/SvEv, 
C57BL/6, or BALB/c mice.  Those carrying the mutant allele were identified by either 
Southern blot analysis using the probes described above or by PCR analysis (common: 5’-
  179
 GTGGGTACATGAGAAGGTTAGGAG-3’; endogenous:  CCTTATCCTCAAACCACGA 
AGTAT-3’; targeted:  AAATGCCTGCTCTTTACTGAAGG) of DNA prepared from tail 
biopsies.  We designate this mutation GPRA∆94-159; however, in the interest of brevity, we 
will refer to mice homozygous for the mutation as GPRA-/-.  All studies were conducted in 
accordance with the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals as well as the Institutional Animal Care and Use Committee guidelines of the 
University of North Carolina at Chapel Hill.   
 
Northern and RT-PCR Analysis of Gpra RNA present in GPRA ∆94-159 homozygous animals. 
 Total RNA was isolated from the brains of GPRA-/- and GPRA+/+ mice by 
phenol/chloroform extraction using RNABee (Tel-test) as instructed by the manufacturer.  
For northern blot analysis, 20 µg of total RNA was electrophoresed on a 1.1% formaldehyde, 
1.2% agarose gel and transferred to an Immobilon-NC nitrocellulose membrane (Millipore 
Corp.).  After transfer, the filters were hybridized with a full-length α[32P]-dCTP random-
labeled Npsr1/Gpra cDNA probe in Quick-Hyb (Stratagene) for 1 hour at 68°C.  The mRNA 
from the GPRA-/- animals was also used to generate cDNA by reverse transcriptase PCR, 
using the primers TGGGAAACTCTGTTGTGCTG (forward) and GAGATGAGCCCTC 
GGTTGTA (reverse).  The resultant cDNA product was cloned into the TA Cloning Vector 
pCR®2.1 (Invitrogen, Carlsbad, CA).  Subsequent sequencing verified the formation of a 
splice variant lacking exons 3 and 4. 
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Measurement of Airway Reactivity in Conscious Mice 
Airway reactivity was assessed by evaluating enhanced pause (Penh) at baseline and after 
increasing doses of methacholine (MCh).  The Penh calculation is based on inspiratory pressure, 
expiratory pressure, and expiratory time, and its use as a measure of airway reactivity has been 
previously validated (11).  Spontaneously breathing, unrestrained, conscious, mice were placed 
in a Biosystem XA whole body plethysmograph (Buxco Electronics, Troy, NY).  Animals were 
placed in individual 80 ml chambers, and each chamber was ventilated by bias airflow at 0.2 
liters/min.  Baseline Penh was assessed for 5 minutes followed by a 2 minute aerosolization of 
vehicle (PBS) and increasing doses of MCh (12, 25 and 50 mg/ml) (Sigma-Aldrich, St. Louis, 
MO).   The response for each aerosol challenge was assessed for 2 minutes.   
 
Measurement of Airway Reactivity in Intubated Mice 
Mice were anesthetized with 70-90 mg/kg pentobarbital sodium (American 
Pharmaceutical Partners, Los Angeles, CA), tracheostomized, and mechanically ventilated at 
a rate of 300 breaths/min, tidal volume of 6 cc/kg, and positive end-expiratory pressure of 3-
4 cm H2O with a computer controlled small-animal ventilator (Scireq, Montreal, Canada).  
Once ventilated, mice were paralyzed with 0.8 mg/kg pancuronium bromide.  Following 
baseline assessments, mice were exposed to aerosol challenges by directing the inspiratory 
line through the aerosolization chamber of an ultrasonic nebulizer connected through a 
sideport in the ventilator circuit.  Animals were ventilated at a rate of 200 breaths/min for 30 
seconds with a tidal volume of 0.15 mls.  Immediately following the aerosol challenge, the 
nebulizer was isolated from the inspiratory circuit and the original mechanical ventilation 
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 was resumed.  Forced Oscillatory Mechanics (FOM) were determined every 10 seconds for 
the following 3 minutes.  Briefly, following passive expiration, a broadband (1-19.625 Hz) 
volume perturbation was applied to the lungs while the pressure required to generate the 
perturbations was assessed.  The resultant pressure and flow data were fit into a constant 
phase model as previously described (12).  Similar to other studies assessing forced 
oscillatory mechanics, we confined our analysis to: Raw (Rn; Newtonian resistance), which 
assesses the flow resistance of the conducting airways; G (tissue damping), which reflects 
tissue resistance; and H (tissue elastance), which reflects the tissue rigidity (33).  
 
 
Induction and Assessment of Allergic Airway Inflammation 
 
To assess ovalbumin (OVA) induced airway inflammation, groups of mice were 
sensitized by i.p. injection of 20 µg of OVA (Grade V; Sigma) emulsified in 2.25 mg of 
aluminum hydroxide (Sigma) in a total volume of 200 µl, on days 1 and 14.  Mice were 
challenged (45 min) via the airways with OVA (1% in saline) for 5 days (days 21 – 25) using 
an ultrasonic nebulizer (DeVillbiss Health Care, Somerset, PA).  Control mouse groups 
received the two OVA immunizations but were challenged with aerosolized saline.  Airway 
reactivity was assessed 24 hours after the final aerosol OVA or saline challenge (day 26).   
Following airway assessments, mice were euthanized, and approximately 1 ml of blood 
was collected by cardiac puncture.  Blood was allowed to coagulate, and the serum was 
collected.  Total IgE levels were determined by ELISA (ICN Biomedicals, OH).  
Bronchoalveolar lavage (BAL) was performed 5 times with 1.0 ml of sterile Hank’s Buffered 
Saline Solution (HBSS) each time.  The number of cells present in the BALF was determined 
using a hemacytometer.  A differential cell count was conducted on a cytospin prepared from 
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 150 µl of BAL fluid and stained with either fast green and neutral red or Diff-Quik solution 
(Sigma).  The remaining BAL fluid was centrifuged to remove cells, and the IL-13 level in 
the supernatant was determined using ELISA (R&D Systems, MN).   
For histopathologic examination, lungs were fixed by inflation (20 cm pressure) and 
immersion in 10% formalin.  To evaluate airway eosinophilia, fixed lung slices were 
subjected to hematoxylin and eosin (H & E) staining.  To assess goblet cell hyperplasia, 
serial sections of the left lobes of the lungs that yield maximum longitudinal visualization of 
the intrapulmonary main axial airway were analyzed following Alcian-blue/periodic acid-
schiff reaction (PAS) staining.  To avoid bias for a certain region, and to consistently view 
the identical region in all slides, a 2-mm length of airway, located midway along the length 
of the main axial airway, was digitally imaged.  Using ImageJ software (NIH, National 
Technical Information Service, Springfield, VA), the area and length of the PAS/AB-stained 
region in the sections were measured and the data expressed as the mean volume density (Vs 
= nl/mm2 basal lamina + SEM of PAS/AB-stained material within the epithelium) as 
previously described (18). 
 
Induction and Assessment of LPS Induced Acute Airway Inflammation 
To assess lipopolysaccharide (LPS) induced airway inflammation, groups of mice were 
anesthetized by isoflurane inhalation, and lipopolysaccharide (LPS)(Sigma) isolated from 
Escherichia coli (sterile serotype 0111:B4) was instilled intratracheally (i.t.) as previously 
described (32).  Control mouse groups received an i.t. dose of saline.  Rectal temperatures 
and baseline Penh were assessed every 4 hours following LPS administration and were 
utilized as surrogate markers of inflammation.  Cohorts of mice were euthanized 18 to 24 
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 hours post LPS exposure, and BALF was collected as described above.  Total cell counts 
were determined and differential staining was conducted as described above. The leukocyte 
composition of the BALF was determined based on morphological criteria. 
 
Passive Airway Anaphylaxis 
Mice were sensitized by intravenous (i.v.) injection with 20 µg of human monoclonal 
anti-dinitrophenyl (DNP) IgE  (Sigma) in 200 µl of sterile PBS.  Twenty-four hours after 
anti-DNP IgE injection, mice were anesthetized, tracheostomized, and mechanically 
ventilated as previously described.  Baseline airway mechanics were assessed for 2 minutes, 
and passive systemic anaphylaxis was induced via i.v. injection of human DNP-albumin 
(Sigma) in 250 µl of sterile PBS.  Immediately following anaphylaxis induction, airway 
resistance (Raw) was assessed for 3 minutes.  Control mice received either an IgE injection 
and no DNP-albumin or DNP-albumin and no IgE.  Age and sex matched mast cell deficient 
mice (KitW-sh/KitW-sh, The Jackson Laboratory) were used to confirm mast cell participation in 
this assay.  
 
NPSR1/GPRA Expression Analysis 
 Total RNA was isolated from various tissues and cells, including the lungs from naïve 
and ovalbumin challenged mice (see OVA protocol above), various human cell lines, and 
primary cells derived from the airways.  Samples of epithelial/fibroblast cells from asthmatic 
and control airways were generated from lung biopsies as previously described (25) and 
generously provided by F. Goulet, Laval University, Quebec, Canada.  Npsr1/Gpra 
expression was analyzed by northern blot, as described above, or by quantitative RT-PCR 
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 (TaqMan) using commercially available primer sets.  Total RNA was purified via a Qiaprep 
RNeasy Kit (Qiagen) and the quality of the RNA was evaluated with an Agilent 2100 
Bioanalyzer.  5-10 µg of RNA was reverse transcribed using the High-Capacity cDNA 
Archive Kit (Applied Biosystems) according to the manufacturer’s instructions.  cDNA was 
amplified with Taqman PCR Universal Master Mix (Applied Biosystems) using the Applied 
Biosystems 7900 HT Fast Real-Time PCR System.  All samples were run in quadruplicate 
and relative expression was determined by normalizing samples to β-actin, 18S rRNA, 
GAPDH, β2M, and HPRT housekeeping genes.  Muc5AC expression was also assessed as 
described above in selected tissues.  Data was analyzed using the comparative CT method 
(∆∆CT).  All primer/probe sets were commercially available and obtained from Applied 
Biosystems.  For human cells, RNA was isolated and NPSR1/GPRA expression quantified as 
described above, with the following exceptions.  Cells or biopsy-derived samples were first 
lysed by addition of Trizol reagent (Gibco), and RNA was extracted according to 
manufacturer’s instructions prior to purification using the Qiaprep Rneasy mini kit (Qiagen).  
Samples were run in duplicate and normalized to GAPDH expression.  
 
Statistical Analysis  
Data are presented as the means +/- standard error of the mean (SEM).  A Random 
Effects Model followed by the Tukey-Kramer Honestly Significant Difference (HSD) was 
utilized to assess dose response data.  Analysis Of Variance (ANOVA) followed by Tukey-
Kramer HSD for multiple comparisons was performed on complex data sets.  Statistical 
significance for single data points was assessed by the Student’s two-tailed t-test. A p-value 
of less than 0.05 was considered statistically significant. 
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 Results 
Targeted disruption of the Gpra gene 
 NPSR1/GPRA is highly conserved: both the structure of the gene and the primary 
structure of the protein are highly similar between mice and humans.  Previous data has 
demonstrated that an Asn107Ile polymorphism is found at higher frequency in the affected 
human population (20).  However, in all the mouse genomes examined, including inbred and 
wild derived strains, the amino acid encoded at position 107 corresponds to Ile.  
Interestingly, this Ile is also present in the rat, dog, cow, and chimp Npsr1/Gpra genes.  Thus, 
the gain-of-function mutation associated with asthma in humans is the common, if not the 
only allele present in other species. Therefore, mice express the form of NPSR1/GPRA 
associated with disease in humans.  However, we reasoned that if a modest increase in 
activity of this receptor leads to enhanced disease in humans, complete loss of expression 
might attenuate disease in a mouse model of asthma.   
A targeting vector was designed which would disrupt the normal expression of this 
gene (Figure 4.1A).  Homologous recombination of the targeting plasmid with the 
endogenous gene removes the majority of exon 4 while leaving the splice acceptor site intact.  
Exon 4 encodes the majority of the 3rd transmembrane spanning domain and a portion of the 
i2 intracellular loop.  Therefore, this deletion removes regions of the GPRA protein that are 
critical for ligand binding. A variety of studies have demonstrated that loss of the 3rd 
transmembrane domain of G-protein coupled receptors prevents ligand coupling and induces 
major conformational changes.  Examination of the litters resulting from the intercross of 
heterozygous animals revealed the presence of animals homozygous for the mutant allele at 
expected frequencies (Figure 4.1B).   Southern analysis of DNA prepared from tail biopsies 
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 from these animals verified that the recombination event had resulted in the deletion of the 
majority of exon 4, as no hybridization was detected with a probe specific for this region of 
the Npsr1/Gpra gene.  No gross anatomical or morphological differences were observed in 
GPRA deficient mice. GPRA deficient mice demonstrated normal blood cell composition 
and blood chemistry (Table E4.1).  Analysis of leukocyte populations from the thymus, 
spleen, and lymph nodes with T cell, B cell, and macrophage markers revealed no aberrations 
in development of the immune system in the GPRA deficient animals (Figure E4.1). 
 To verify that the recombination event had indeed resulted in the alteration of the 
Npsr1/Gpra transcript, RNA was prepared from the brains of GPRA-/- and wild type animals 
and analyzed by northern blot (Figure 4.1C).   The Npsr1/Gpra mRNA present in 
preparations from GPRA-/- animals is of lower molecular weight, but similar in abundance, to 
the native mRNA present in wild type mice (Figure 4.1C).   To verify that the RNA transcript 
from the GPRA deficient mice lacks the coding information included in the region of the 
gene lost during the homologous recombination event, cDNA was prepared from the control 
animals and mice homozygous for the mutation.  The region of the transcript extending from 
exon 2 to exon 5 was then amplified, cloned, and sequenced.  This analysis indicated that the 
transcript present in the mutant animals consisted of a splice variant lacking exons 3 and 4.  
Because the mouse codon orthologous to isoleucine 107 is located in exon 3 of the mouse 
gene, an additional consequence of this splice variant formation is the loss of this codon in 
the mutant mice.  This splice variant has recently been identified in a human lung epithelial 
carcinoma cell line (NCI-H358) and was termed GPRA-F (AY310332)(33).  Transfection of 
this transcript into COS1 cells yielded a protein; however, analysis of these transfected cells 
showed that GPRA-F failed to properly integrate into the cell membrane and is not a 
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 functional GPCR (35).  We therefore refer to the mice homozygous for the mutant allele as 
GPRA-/- mice.    
 
Airway mechanics in naïve GPRA-/- mice after exposure to bronchoconstricting agents   
Previous studies reported that GPRA was expressed by airway smooth muscle cells 
(20).  These studies also suggested that the expression of the Asn107Ile variant by these cells 
contributes to the pathogenesis of asthma (20).  To begin to test this hypothesis, we 
determined the impact of complete loss of functional GPRA on basal airflow and basal 
airway mechanics.  In addition, we determined if loss of GPRA modulates the changes in 
breathing patterns or airway mechanics observed upon exposure to bronchoconstricting 
agents such as methacholine (MCh).  We also determined whether bronchoconstriction 
observed after passive anaphylaxis is altered in mice lacking functional NPSR1/GPRA.    
 Breathing patterns of wild type and NPSR1/GPRA deficient mice were analyzed by 
whole body plethysmography (WBP).  Studies were carried out using wild type and GPRA-/- 
mice on three different genetic backgrounds.  The first group of animals analyzed consisted 
of 129/SvEv mice and co-isogenic GPRA-/- animals.  In addition, GPRA-/- mice and wild type 
littermates were generated after the backcross of the mutation onto the C57BL/6 and BALB/c 
genetic backgrounds for three generations.  No difference in baseline Penh was observed in 
any of the GPRA deficient populations, and methacholine elicited a similar increase in Penh 
in the GPRA deficient mice compared to their genetically matched controls (Figure E4.2 A, 
B, and C; respectively).  
We next determined if changes in airway mechanics could be observed in naïve 
GPRA-/- mice.  For this analysis, we utilized a computer-controlled small animal ventilator, 
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 highly sensitive pressure transducers, and software (Flexivent) to record airway opening 
pressures, volume, and airflow.  Changes in lung mechanics were determined using the 
constant phase model.  Three different parameters were compared: airway resistance (Raw), 
tissue resistance (G), and tissue elastance (H).  No difference in these parameters was 
observed between 129/SvEv and co-isogenic GPRA-/- naïve unchallenged mice (Figure 4.2).  
Exposure of the mice to MCh resulted in an increase in all three parameters, in particular, 
airway and tissue resistance.  The magnitude of these changes did not differ significantly 
between the wild type and mutant mouse lines.   Similar studies comparing GPRA-/- BALB/c 
and C57BL/6 mice to their respective genetically matched controls also failed to identify a 
role for NPSR1/GPRA in changes in lung mechanics in response to methacholine (data not 
shown).  Exposure of the mice to serotonin (5-HT) also resulted in an increase in Raw, G, and 
H.  However, similar to the MCh responses, the magnitude of these changes did not differ 
significantly between the wild type and mutant mouse lines (data not shown).    
Activation of mast cells by IgE and antigen results in release of potent 
bronchoconstricting agents including leukotrienes, prostaglandins, serotonin, and histamine.  
As these mediators contribute to the reversible airway obstruction characteristic of asthma, it 
was of interest to determine whether loss of GPRA altered the changes in lung mechanics 
measured after mast cell degranulation (Figure 4.3).  Passive anaphylaxis was induced in 
GPRA-/- 129/SvEv mice and in co-isogenic controls by injection of animals with monoclonal 
antibody to DNP.  Twenty-four hours later, mice were anesthetized, tracheostomized, and 
mechanically ventilated.  After establishment of baseline airway mechanics, mice received 
antigen (DNP) i.v., and the change in airway mechanics was measured.  Passive anaphylaxis 
resulted in a large increase in airway resistance (Raw) (Figure 4.3A).  A robust increase in Raw 
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 was also observed in the GPRA deficient mice, but the magnitude of this change did not 
differ from the co-isogenic control animals.  A smaller change in tissue resistance (G) and 
elastance (H) is observed after induction of passive anaphylaxis (data not shown).  Again, no 
difference was observed in these parameters between GPRA-/- and control animals.  As 
expected, the airway mechanics of mice that received either antibody or antigen alone did not 
change significantly from baseline (Figure 4.3A), nor was there a significant change in lung 
mechanics observed upon treatment of mast cell deficient KitW-sh/KitW-sh mice with antigen 
and antibody (Figure 4.3B).   
 
GPRA deficient mice demonstrate normal allergic airway inflammation responses  
 Sensitization of mice with ovalbumin followed by exposure of the animals to aerosols 
of antigen results in development of lung inflammation, which models some aspects of 
asthma.  GPRA expression in the lung was reported to increase 7 fold after induction of a 
similar model of allergic lung disease (20).  It was therefore reasonable to assume that 
functions of GPRA in the lung might be highlighted in animals with this disease.  Allergic 
lung disease was induced in 129/SvEv and co-isogenic GPRA-/- mice, and the development 
of inflammation and changes in airway mechanics were assessed in the two groups twenty-
four hours after the final exposure to antigen (Figure 4.4).   
  The total number of cells present in the BALF was significantly increased in both the 
wild type and GPRA-/- mice following OVA challenge.  However, no significant difference 
was noted between the wild type and GPRA-/- mice (Figure 4.4A).   Furthermore, no 
difference could be identified in the total leukocyte composition of the BALF assessed by 
morphological criteria (data not shown).  IL-13 levels are increased in the BALF after 
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 induction of allergic airway disease and are critical to the development of AHR and goblet 
cell metaplasia/hyperplasia.  IL-13 levels were assessed via ELISA in BALF collected from 
OVA immunized and either OVA or saline challenged animals (Figure 4.4B).   A significant 
increase in IL-13 was observed in OVA immunized/OVA challenged mice, irrespective of 
the genotype of the mice (Figure 4.4B).   
 Histological and morphometric assessment of the lungs of mice that were sensitized 
and exposed to antigen revealed similar increases in the number of goblet cells in GPRA 
deficient and wild type mice (Figure 4.4D).    As expected, few PAS+ cells were observed in 
the OVA immunized/saline challenged mice (data not shown).  In mouse models of asthma, 
the induction of pulmonary Muc5ac gene expression correlates with goblet cell 
hyperplasia/metaplasia and the increased production of airway mucus.  To further evaluate 
mucus production in GPRA deficient mice, Muc5ac expression was assessed by quantitative 
rt-PCR (TaqMan) on RNA prepared from the lungs of OVA and saline challenged animals 
(Figure 4.4E).   A significant increase in Muc5ac expression was observed in OVA 
immunized/OVA challenged mice, irrespective of genotype (Figure 4.4E).  However, again 
no difference was observed between the wild type and GPRA deficient mice.  As expected, 
no increase in Muc5ac expression was observed in OVA immunized/saline challenged mice 
(Figure 4.4E).   
In addition to finding an association between GPRA and the asthmatic phenotype, 
recent studies have also suggested an association between polymorphisms in GPRA and 
elevated serum IgE levels (18, 20, 23).  Increased serum IgE is observed in the OVA model 
of allergic lung disease and, not surprisingly, the IgE is specific for ovalbumin.  Total IgE 
levels were assessed via ELISA in serum collected from OVA immunized and either OVA or 
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 saline challenged animals (Figure 4.4C).   As expected, a significant increase in total IgE was 
observed in OVA immunized/OVA challenged mice; however, the magnitude of this increase 
was not significantly different in the GPRA-/- animals (Figure 4.4C).   
 
NPSR1/GPRA deficiency has no effect on the induction of airway hyperresponsiveness 
(AHR) in the OVA model of allergic airway disease 
 As discussed above, no difference was observed in the airway mechanics of the naïve 
NPSR1/GPRA mice in response to constricting agents such as methacholine (Figure 4.2) and 
serotonin (data not shown).  In addition, the increase in airway resistance during passive 
anaphylaxis was not affected by the absence of functional NPSR1/GPRA (Figure 4.3).  
However, it is possible that contribution of this protein to airway physiology becomes 
apparent only in the inflamed lung.  We therefore examined baseline airway mechanics and 
the change in airway mechanics in response to methacholine in 129/SvEv mice and co-
isogenic GPRA-/- animals after induction of allergic airway disease (Figure 4.4, F-H).  None 
of the three described parameters, airway resistance (Raw), tissue or distal lung resistance (G), 
or elastance (H) differed between the GPRA-/- animals and similarly treated controls.    
 
GPRA deficient mice demonstrate normal inflammatory responses in an LPS mediated acute 
model of airway inflammation 
 Endotoxin, a constituent of gram-negative bacteria, and its functional derivative 
lipopolysaccharide (LPS), are ubiquitous in the environment and particularly concentrated in 
several occupational, industrial, and domestic settings.   Several lines of evidence suggest 
that inhalation of LPS causes an inflammatory response and increases airway reactivity in 
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 asthmatics.  This raises the possibility that GPRA could contribute indirectly to the 
development of asthma by altering the sensitivity of individuals to other immunological 
stimuli in the lung such as LPS.  GPRA-/- mice and co-isogenic 129 controls were treated 
with 50 µg of LPS i.t., and the resultant changes in body temperature, breathing patterns 
(Penh), and inflammation were monitored.  Control animals of both genotypes were treated 
with vehicle.  Previous studies indicated that maximum changes in these three parameters are 
observed in 129 mice sixteen to twenty hours after exposure to LPS. As seen in Figure 4.5A 
and B, administration of LPS induced a dramatic drop in body temperature and a significant 
increase in baseline Penh, irrespective of genotype.  LPS exposure results in recruitment of 
neutrophils to the lung.  No significant difference was observed in either the number or 
composition of cells present in the BALF as assessed by morphological criteria (Figure 
4.5C).   
 
GPRA is highly expressed in the CNS with only minimal airway expression 
The inability to discern changes in airway mechanics and in the development of 
allergic lung disease in GPRA deficient mice was surprising given the high levels of GPRA 
expression reported in the lung and the elevation in GPRA expression in this model of 
asthma.  It was therefore of interest to reexamine this finding and verify that this was indeed 
the case in co-isogenic mice on the 129 genetic background, which were utilized in the 
majority of our experiments.  The 2-∆∆Ct method was used for analysis of expression of 
NPSR1 after induction of allergic lung disease.  ∆Ct is defined as the difference between the 
threshold cycle (Ct) of the gene of interest and the internal reference (housekeeping) gene of 
choice.  Internal reference genes are genes whose expression is not expected to change as a 
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 result of the experimental manipulation, such as the induction of allergic lung disease.  
Because their expression remains constant, internal references can be used to normalize 
expression of the gene of interest, NPSR1.  This normalization corrects for differences in 
NPSR1 expression in the allergic lung that might be due to slight variations in quality or 
quantity of RNA between preparations. Before initiating these studies, we first tested a 
number of commonly used internal reference (housekeeping) genes to determine their 
suitability for examination of changes of gene expression in the lung after induction of 
allergic lung disease.  To do this, we examined the number of cycles required to detect 
expression (fluorescence above background) of the gene in the healthy and inflamed lung 
(threshold cycle; Ct).  We found that after approximately 20 cycles, β-actin expression was 
detected in the healthy lung.  However, when RNA was prepared from the inflamed tissue, β-
actin mRNA was less abundant and over 30 cycles were required to detect expression (Ct = 
30) (Figure 4.6A).  The lower abundance of the β-actin mRNA could reflect changes in cells 
of the lung or the fact that much of the RNA present in the inflamed lung is derived from 
infiltrating leukocytes.  Regardless, this change in Ct made β-actin an inappropriate internal 
reference gene when comparing healthy and inflamed lungs.  Likewise, increased threshold 
cycles (Ct) for gapdh, hprt, and β2M were also observed in the inflamed lung, and use of 
these housekeeping genes would, therefore, overestimate increases of the test gene 
expression.  We found that 18S ribosomal RNA was the only RNA whose expression itself 
did not significantly change after induction of allergic airway disease (Figure 4.6A).  To our 
surprise, the levels of Gpra expressed in the naïve lungs were extremely low and these levels 
did not increase in the inflamed lung when 18s was used to normalize expression (Figure 
4.6B).  To reconcile this with previous reports, we next determined whether use of other 
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 internal reference genes could lead to the supposition that expression of GPRA is increased 
in the inflamed mouse lung.  When other housekeeping genes were utilized in the analysis, 
such as β-actin, there was no difficulty in reporting an increase in Npsr1/Gpra expression in 
the lungs of mice with allergic airway disease (Figure 4.6C).   To verify that our primer sets 
were appropriate for the analysis, we examined other tissues, including various regions of the 
brain and the retina.  The relative levels of expression of GPRA in these tissues mimicked 
those reported by Xu et al. during an extensive evaluation of the expression of NPSR1 in the 
mouse (37).  Thus, the primers and conditions used in the studies detect differences in GPRA 
expression between various tissues. While the results shown in Figure 6 were obtained using 
mice on the 129 genetic background subjected to the OVA-challenge model described herein, 
we also failed to observe an upregulation of the GPRA gene and ligand (NPS) in BALB/c 
mice subjected to OVA- and IL-13-challenge models of asthma in which robust 
inflammation, mucus, and airway hyperreactivity endpoints were observed (data not shown). 
 
GPRA is expressed in retina and hypothalamus, but not in human lung cells 
Our expression analysis fails to support the expression of substantial levels of GPRA in 
the mouse lung or the previously reported increase in this expression after induction of allergic 
lung disease.  It was therefore of interest to reexamine the expression of NPSR1/GPRA in 
humans, since expression in humans but not in the mouse would simply suggest that the mouse is 
not the appropriate model for studying the contribution of this gene to asthma.  Initial reports 
indicated that this GPCR is expressed in both epithelial cells and airway smooth muscle cells in 
the lung (20, 35).  Analysis of human airway-derived cell lines and primary cells by quantitative 
PCR failed to detect significant levels of GPRA mRNA in various epithelial (A549, H292, 
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 NHBE), smooth muscle (BSMC) and fibroblast (MRC5, HFL1, NHLF) cell lines and primary 
cells, with the exception of one out of three samples of NHBE cells which showed low but 
significant expression.  In contrast, significant GPRA expression was observed in commercial 
brain, retina, and hypothalamus cDNA libraries (Figure 4.6D). As additional controls, we 
observed high levels of GPRA mRNA in GPRA-A and GPRA-B-transfected CHO cells (not 
shown), ruling out the possibility that the probe and primers used for quantitative PCR in this 
study are specific to only one of the two GPRA isoforms. Since the possibility exists that 
expression of this GPCR is upregulated only in lungs of asthmatics, we also examined mRNA 
levels in cells derived from lung biopsies (graciously provided by F. Goulet, Laval University, 
Quebec, Canada) from both normal controls (n=4) and asthmatics (n=8). These samples, 
containing epithelial cells and fibroblasts, were prepared as previously described (25).  Again, 
there was no significant expression of GPRA in either normal or asthmatic lung, with the 
exception of two of the normal samples that contained significant but very low mRNA levels 
(Figure 4.6D). These data are in contradiction with previous findings (35) showing not only that 
GPRA expression is increased in asthmatics but also that the GPRA-B isoform is ubiquitously 
expressed in a variety of tissues and cell lines. 
 
 
GPRA may participate in an indirect, neurally mediated mechanism of smooth muscle 
constriction 
 High levels of NPSR1/GPRA are expressed in the brain and by neuronal cell lines.  
This raises the interesting possibility that the linkage of the polymorphism in the 
NPSR1/GPRA receptor to asthma reflects a contribution of the nervous system, perhaps 
through cholinergic pathways, to the development of asthma.  To begin to address this 
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 possibility, we examined the change in airway responsiveness of the 129/SvEv GPRA-/- mice 
and their genetic controls to thromboxane.  Previous studies have demonstrated that the 
increase in airway and tissue resistance in the mouse in response to this agent is dependent on 
an intact cholinergic pathway (2).  As seen in Figure 7, we assessed changes in airway 
reactivity utilizing forced oscillatory mechanics (FOM) in the co-isogenic 129Sv/Ev mice.  
As described previously, mice were subjected to aerosolized vehicle (data not shown), 
followed by dose response challenges of U46619 (10-5 – 10-3 M).  U46619 challenge induced 
a robust increase in airway reactivity, regardless of genotype (Figure 4.7).  Increasing doses 
of U46619 generated equivalent increases in G and H (Figures 4.7B and C); however, GPRA 
deficient mice demonstrated a modest but significant attenuation in Raw at the highest 
concentration of U46619 tested (10-3 M)(Figure 4.7A).   This decrease in the Raw response 
and lack of differences in either G or H following U46619 challenge is interesting because it 
suggests a role for GPRA in mediating vagal nerve responses in the conducting airways.  In 
the mouse, airway innervation is higher in the conducting airways and significantly decreases 
towards the peripheral airways.  Thus, these combined data suggest a potential role for 
GPRA in indirect mechanisms affecting airway smooth muscle constriction. 
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 Figure 4.1. Generation of a mouse line with a deletion in the Gpra gene. (A) Restriction 
maps of the endogenous Gpra locus, the Gpra targeting construct, and the targeted locus 
after homologous recombination with the targeting plasmid.  Upon homologous 
recombination, the GPRA∆94-159 construct replaces a 744 bp region of the Gpra gene, which 
includes the majority of exon 4, with the selectable marker gene neomycin (neo).  This 
deletion is predicted to remove the 3rd transmembrane domain and second exoloop of the G-
protein coupled receptor.  Relevant restriction sites are abbreviated as follows: B, BamHI; N, 
NotI; S, SalI; K, KpnI; A, ApaI; M, MfeI.  (B) Southern blot analyses of offspring generated 
by the intercross of mice heterozygous for the Gpra mutant allele.  A 521 bp genomic 
fragment that hybridizes upstream of the targeted region was used as a probe to detect the 
change in BamHI restriction fragment length that occurs with proper integration of the 
targeting construct.  (C) Southern blot analysis of the GPRA∆94-159 mice to confirm the 
deletion of the desired region.  A 631 bp genomic fragment that includes exon 4 was used as 
a probe to confirm the loss of this region in the GPRA∆94-159 homozygous animals. (D) 
Northern analysis of Gpra expression in the brains of wild type and GPRA∆94-159 
homozygous animals.  Abundant Gpra RNA is observed in wild type mice, whereas a 
smaller Gpra transcript resulting from the deletion of exon 4 is seen in RNA prepared from 
GPRA∆94-159 mice.  Analysis with a Cyclooxygenase 2 specific probe indicates equal RNA 
sample loading (not shown).  (E) Analysis of the truncated Gpra mRNA expressed by the 
GPRA∆94-159 animals by rt-PCR.  rt-PCR of RNA from wild type animals yields a fragment of 
604 bp, whereas a fragment of approximately 406 bp was amplified from the homozygous 
mutant cDNAs.  Subsequent cloning and sequencing of the resultant cDNA from the 
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 GPRA∆94-159 animals confirmed that an alternative splicing event joining exon 2 to exon 5 has 
occurred.  If transcribed, this would encode a protein lacking exons 3 and 4. 
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 Figure 4.2 
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 Figure 4.2. Changes in airway physiology of wild type and GPRA-/- mice in response to 
methacholine.  (A) Airway resistance (Raw), (B) tissue damping (G), and (C) tissue elastance 
(H) were assessed in 129/SvEv co-isogenic wild type and GPRA-/- mice in response to MCh.  
The percent change in Raw, G, and H from baseline increased significantly in all animals, 
regardless of genotype.  GPRA+/+ mice, n=15; GPRA-/- mice, n=9.   
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 Figure 4.3                     
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 Figure 4.3.  Mast cell mediated airway anaphylaxis in wild type and GPRA-/- mice.  
Mast cell function and changes in Raw in response to mast cell degranulation were assessed in 
a model of passive systemic anaphylaxis. (A) DNP administration caused a significant 
increase in Raw in all mice regardless of genotype.  No significant increases in either G or H 
were observed (data not shown).  GPRA+/+, n = 4; GPRA-/-, n = 4; Experimental controls, n = 
4 (*p < 0.05; †p < 0.05).  (B) To confirm that this airway anaphylaxis is indeed an assay of 
mast cell function, mast cell deficient mice (KitW-sh/KitW-sh) were also assessed.  The mast 
cell deficient mice failed to demonstrate an increase in Raw in response to DNP 
administration.  Mast Cell Deficient, n = 10; C57BL/6 Wild Type, n = 7; Experimental 
Controls, n = 2 (‡p < 0.001; *p < 0.05).   
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 Figure 4.4 
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 Figure 4.4.  Allergic airway inflammation in wild type and GPRA-/- mice.  Allergic lung 
disease was induced in 129/SvEv co-isogenic wild type and GPRA-/- mice.  (A) Increases of 
similar magnitude were observed in the cellularity and composition of bronchoalveolar 
lavage fluid (BALF) between the OVA-challenged GPRA-/- and wild type mice.  OVA 
GPRA+/+, n = 16; OVA GPRA-/-, n = 14; SAL GPRA+/+, n = 9; SAL GPRA-/-, n = 9.  
Histological scoring of H & E stained lung slices demonstrated a significant increase in 
inflammatory cells present in the lungs of OVA sensitized and challenged mice, regardless of 
genotype (data not shown). (B) A significant increase in total BALF IL-13 levels was 
detected following OVA sensitization and challenge, regardless of genotype.  IL-13 levels 
from the OVA immunized/saline challenged mice were below the detection limits of this 
assay. OVA GPRA+/+, n = 16; OVA GPRA-/-, n = 14; SAL GPRA+/+, n = 9; SAL GPRA-/-, n 
= 9. (C) A significant increase in total serum IgE levels was detected following OVA 
sensitization and challenge, regardless of genotype.  Total serum IgE levels failed to increase 
above baseline levels in the OVA sensitized/saline challenged mice, and no significant 
difference was detected between genotypes.   No significant differences were observed 
between baseline total IgE levels in the serum of naïve GPRA+/+ and GPRA-/- mice (data not 
shown). OVA GPRA+/+, n = 16; OVA GPRA-/-, n = 14; SAL GPRA+/+, n = 9; SAL GPRA-/-, 
n = 9.  (D) Sections through the main bronchiole of the left lobe of the lung were stained with 
PAS/AB, and the volume of PAS/AB-stained mucosubstance per square millimeter of basal 
lamina (Vs) was determined.  A significant increase in airway mucus production was 
observed in mice of both genotypes.  No significant differences in mucus production were 
observed between GPRA+/+ and GPRA-/- mice; however, a slightly larger increase was 
observed in the GPRA-/- mice (p = 0.11).  OVA GPRA+/+, n = 16; OVA GPRA-/-, n = 14; 
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 (saline data not shown).  (E) A significant increase in Muc5AC expression was detected with 
no significant differences observed between GPRA+/+ and GPRA-/- mice.  Relative 
expression was determined by standardizing samples to the 18S housekeeping gene.  OVA 
sensitized/saline challenged mice, n = 3/genotype; OVA sensitized/OVA challenged mice, n 
= 3/genotype.  (F-H) The change in respiratory mechanics, assessed as Raw (F), G (G) and H 
(H), in intubated mice was determined in response to MCh for OVA immunized/OVA 
challenged and OVA immunized/saline challenged wild type and GPRA-/- mice.  Dose 
dependent increases in Raw, G, and H were observed in all mice, regardless of genotype.  
Wild type and GPRA-/- OVA immunized and challenged mice demonstrated an increase in 
airway hyperresponsiveness as determined by increased G and H.  OVA GPRA+/+, n = 16; 
OVA GPRA-/-, n = 14; SAL GPRA+/+, n = 5; SAL GPRA-/-, n = 3. 
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 Figure 4.5 
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 Figure 4.5.  LPS mediated acute lung inflammation in wild type and GPRA-/- mice.  
Acute lung inflammation was induced in C57BL/6 wild type and GPRA-/- mice.  Mice were 
challenged via intratracheal (i.t.) instillation with either LPS (1 mg/ml) or sterile saline.  (A) 
LPS induced a significant drop in body temperature in both wild type and GPRA-/- mice.  
LPS GPRA+/+, n = 14; LPS GPRA-/-, n = 13; SAL GPRA+/+, n = 3; SAL GPRA-/-, n = 3 (**p 
< 0.005; ##p<0.005).  (B) LPS induced a significant increase in baseline Penh in both wild 
type and GPRA-/- mice.  LPS GPRA+/+, n = 14; LPS GPRA-/-, n = 13; SAL GPRA+/+, n = 3; 
SAL GPRA-/-, n = 3 (*p < 0.01; #p<0.01). (C) Increases of similar magnitude were observed 
in the cellularity and composition of bronchoalveolar lavage fluid (BALF) in LPS-challenged 
wild type and GPRA-/- mice. LPS GPRA+/+, n = 11; LPS GPRA-/-, n = 10; SAL GPRA+/+, n = 
3; SAL GPRA-/-, n = 3 (*p < 0.05; §p < 0.05; †p <0.05; #p < 0.05). 
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 Figure 4.6 
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 Figure 4.6.  GPRA expression in human and mouse tissues.  (A) A comparison of 
threshold cycles for common housekeeping genes used to normalize rt-PCR data.  OVA 
inflammation significantly alters housekeeping gene expression.  The 18S gene appeared to 
be the only appropriate housekeeping gene assessed for use in normalizing RT-PCR data 
from the inflamed lung (*p<0.05 compared to naïve lung).  (B) No increase in Gpra 
transcript levels was detected following challenges with 1% Ovalbumin (OVA).  Mice were 
sensitized to OVA and subjected to aerosol challenges with either OVA or saline.  The lung 
and trachea were removed immediately following the final aerosol challenge and total RNA 
was extracted.  Gpra expression was assessed by quantitative RT-PCR (TaqMan) using 
commercially available primer sets.   Whole brains were removed from naïve animals to 
serve as positive controls for real time assessments.  Relative expression was determined by 
standardizing samples to the 18S housekeeping gene.  OVA sensitized/saline challenged 
mice, n = 3; OVA sensitized/OVA challenged mice, n = 3; naïve mice, n=3. (C) Analysis of 
Gpra expression assessed by quantitative RT-PCR and normalized with β-actin. (D) GPRA 
expression in human tissues and cells.  Levels of GPRA cDNA were measured in cDNA 
libraries of brain, hypothalamus, or retina, or in various airway derived cells and cell lines 
following conversion of mRNA to cDNA using reverse transcriptase.  GPRA levels were 
assessed by quantitative PCR (TaqMan) using commercially available primer sets.  Relative 
expression was determined by standardizing samples to GAPDH levels and normalizing to a 
hypothalamus cDNA library.  “Normal” and “asthmatic” refer to cells obtained from biopsies 
of non-asthmatic (n=4) and asthmatic (n=8) individuals, respectively.  For the indicated cells 
and cell lines (labeled as “N.S.”), the measured cycle thresholds were indistinguishable from 
those obtained in identical samples that had not been treated with reverse transcriptase, with 
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 the exception of 1 of 3 NHBE samples and 2 out of 4 “normal” samples, for which very low 
but significant levels were detected. Each bar represents the mean ± S.D. of 2 to 8 
independent samples. A representative experiment is shown. 
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Figure 4.7 
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 Figure 4.7. Changes in airway physiology of wild type and GPRA-/- mice in response to 
a thromboxane A2 analog (U46619).  Raw (A), G (B), and H (C) were assessed in wild type 
and GPRA-/- mice in response to U46619, which induces airway smooth muscle constriction 
through an indirect, neurally mediated mechanism.  The percent change in Raw, G, and H 
from baseline increased significantly in all animals, regardless of genotype.  However, 
GPRA deficient mice demonstrated a significantly attenuated Raw response following 
U46619 challenge.  GPRA+/+ mice, n=17; GPRA-/- mice, n=16 (*p = 0.038). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  214
 Expression and function of NPSR1/GPRA in the lung before and after induction of 
asthma-like disease 
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 Table E4.1 
 
 WBC       
(L 103/min3)
RBC 
(106/min3)
PLT          
(H 103/min3)
HGB       
(g/dl)
HCT        
(%)
GPRA+/+ 2.13 ± 0.33 7.86 ± 2.10 979.67 ± 130.56 12.33 ± 2.92 41.07 ± 11.39
GPRA-/- 1.67 ± 0.12 8.53 ± 0.14 990.67 ± 40.92 13.13 ± 0.26 43.37 ± 0.29
MCV       
(fl)
MCH       
(pg)
MCHC        
(g/dl)
RDW       
(L %)
MPV        
(fl)
GPRA+/+ 51.67 ± 0.88 16.17 ± 0.87 31.27 ± 2.22 14.1 ± 0.25 5.53 ± 0.12
GPRA-/- 51 ± 0.58 15.4 ± 0.21 30.33 ± 0.43 12.9 ± 0.15 5.3 ± 0.06
LYM       
(L 103/min3)
MON       
(L 103/min3)
GRA         
(L 103/min3)
GPRA+/+ 1.37 ± 0.15 0.13 ± 0.07 0.63 ± 0.12
GPRA-/- 1.27 ± 0.12 0.1 ± 0 0.3 ± 3.14 X 10-9 
MON       
(%)
GRA       
(%)
EOS         
(%)
LYM       
(%)
GPRA+/+ 8.23 ± 1.32 22.2 ± 2.80 5.03 ± 0.77 69.57 ± 4.12
GPRA-/- 7.1 ± 0.49 13.87 ± 2.80 3.57 ± 0.35 79.03 ± 1.41
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 Table E4.1. Complete Blood Counts.  The red blood cell, white blood cell and platelet 
composition of both GPRA+/+ and GPRA-/- mice fall within normal reference ranges.  RBC, 
Red blood cells; HGB, Hemoglobin; HCT, Hematocrit; MCV, Mean Corpuscular Volume; 
MCH, Mean Corpuscular Hemoglobin; MCHC, Mean Corpuscular Hemoglobin 
Concentration; RDW, Red Cell Distribution Width; PLT, Platelets Count; MPV, Mean 
Platelet Volume; WBC, White Blood Cells; LYM, Lymphocytes; MON, Monocytes; EOS, 
Eosinophils; GRA, Granulocytes.  All mice are on the 129SvEv coisogenic background. 
GPRA+/+ (n = 4); GPRA-/- (n = 4) 
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 Figure E4.1 
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 Figure E4.1.  FACS Scan Analysis.  No significant differences were detected in the immune 
cell composition between GPRA-/- and GPRA+/+ mice on the 129/SvEv coisogenic 
background.  Thymus:  GPRA+/+ (n = 1), GPRA-/- (n = 1); Spleen:  GPRA+/+ (n = 4), 
GPRA-/- (n = 4); Lymph Nodes:  GPRA+/+ (n = 3), GPRA-/- (n = 3). 
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 Figure E4.2 
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 Figure E4.2.  Methacholine response in conscious, unrestrained wild type and GPRA-/- 
mice.  Changes in enhanced pause (Penh) of GPRA+/+ and GPRA-/- mice in response to MCh 
was assessed in mice backcrossed onto BALB/c (A), 129/SvEv (B) and C57BL/6 (C) 
backgrounds.  Following baseline measurements, the airways were exposed to aerosolized 
vehicle (not shown) followed by increasing doses of aerosolized MCh (12 mg/ml to 50 
mg/ml).  The average Penh increased significantly in all groups of mice regardless of 
genotype or strain.  GPRA+/+ mice:  BALB/c, n = 3; 129/SvEv, n = 15; C57BL/6, n = 9; 
GPRA-/- mice: BALB/c, n = 4; 129/SvEv, n = 7; C57BL/6, n = 7. 
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 Discussion 
Previous studies reported a dramatic increase in the expression of NPSR1/GPRA in 
the mouse lung after induction of allergic lung disease, suggesting that the mouse was likely 
to provide a model for the study of the role of this gene in the pathogenesis of asthma.  As a 
first step to examine the functional significance of GPRA in the development of disease in 
the mouse lung, we generated a mouse lacking the functional receptor.  A deletion mutation 
introduced into the exon encoding a portion of the 3rd transmembrane domain not only results 
in the loss of codons encoding a.a. residues 94 to 159 from the mouse genome, but also 
results in an alteration in the splicing pattern of the gene, such that the major transcript 
remaining in the mutant mouse line is predicted to produce an isoform incapable of 
integration into the cell membrane (previously characterized (35)).  Despite the loss of 
functional NPSR1/GPRA, we detected no difference in the development of allergic lung 
disease in these mice.  Neither qualitative nor quantitative differences in the cellular 
infiltrate, or the development of AHR in response to methacholine, distinguished the mutant 
mice from littermate controls.   
A number of explanations are possible for the failure to observe differences in the 
development of disease between the GPRA-/- and littermate control mice.  First, it is possible 
that, while loss of the receptor has little impact on the development of disease because of 
compensatory pathways, the expression of an allele encoding a gain-of-function mutation in 
GPRA would result in increased signaling and might result in more severe disease.  
Unfortunately, this hypothesis is not easily tested in the mouse.  As discussed above, all 
mouse strains examined to date express the disease associated Gpra allele.  Given our 
difficulty in observing a measurable consequence as a result of the complete loss of GPRA, it 
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 is unlikely that introducing the codon for asparagine at position 107 will alter the 
development of disease in the mouse asthma model.  
 We cannot rule out the possibility that the inflammation models we have chosen for 
testing the role of GPRA lack the sensitivity for discerning the contribution of GPRA to 
disease development.  There are ample examples in the literature that have demonstrated the 
reliance on a particular immunization protocol or on a particular mouse strain for the ability 
to distinguish the role of a particular cell type or molecule in allergic lung inflammation.  For 
example, the contribution of the mast cell to allergic lung disease is only observed in a 
chronic OVA inflammation model when mice are sensitized with antigen free of alum (36).  
Likewise, the dependence of allergic airway disease on the eosinophil (21, 13) was more 
apparent when C57BL/6 mice were used rather than BALB/c.  Further studies with the 
GPRA-/- mice should allow us to rule out these possibilities.   
A third possibility is suggested by our analysis of expression of GPRA in the lung of 
BALB/c, C57BL/6 and 129/SvEv mice before and after induction of airway disease, as well 
as our analysis of expression of the GPRA ligand NPS in select tissues.  In all cases, 
quantitative PCR failed to detect expression of GPRA:  the signal obtained from the tissue 
was observed only after 35-36 cycles and is thus, outside of the range that we believe 
provides reliable detection of expression.  Consistent with these data, northern blot analysis 
of RNA prepared from either naïve lung or lung tissue obtained from mice with allergic 
airway disease failed to detect expression of GPRA (data not shown), although expression in 
RNA prepared from the brain was easily observed.  Our findings are similar to those of Xu et 
al., who observed high levels of GPRA/NPSR1 expression in the brain but very low 
expression in the naïve lungs (37).  A possible explanation for the differences in our results 
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 and those published by Laitinen et al. is the method used in the analysis of the quantitative 
PCR, specifically the choice of the housekeeping genes used to normalize the results.  The 
importance of the choice of housekeeping gene with which to normalize expression in tissue 
with an active and ongoing inflammatory response has been discussed previously (3, 6, 8).  
Consistent with this, we show that the threshold cycle at which the expression of a variety of 
common housekeeping genes, including β-actin and GAPDH, are detected varies 
significantly between OVA and saline challenged lung samples.  Changes in levels of 
housekeeping genes in this model are consistent with previous reports demonstrating that β-
actin, GAPDH, and elongation factor-1-α (EF-1α) are inappropriate for normalizing mRNA 
levels in diseased airways and can lead to erroneous results regarding gene expression in the 
lung (6, 8).  Of the housekeeping genes included in our study, 18s rRNA was the only 
normalizer appropriate for assessing mRNA expression levels in OVA treated lungs.  In fact, 
upon normalizing our data sets to β-actin, we found enhanced GPRA expression in the OVA 
treated lungs similar to that previously reported by Laitinen et al.  While it is possible that 
GPRA is expressed at low levels in the lung epithelia and/or airway smooth muscle, our 
studies do not support the expression at the levels previously reported, nor do they indicate 
that these levels change dramatically in the inflamed lung. This raises the possibility that the 
failure to observe a change in the development of allergic lung disease in the GPRA-/- mice 
reflects a differential expression pattern of this gene in mouse and human.  However, our 
further studies of expression of GPRA in human tissues do not support this interpretation.   
The excitement over this latest asthma candidate gene was based, not only on the 
strong genetic evidence derived from two independent founder populations, but also on the 
expression of the gene in airway epithelial and smooth muscle cells and, importantly, the 
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 changes in expression patterns of two of the isoforms in the airways of asthmatics.  However, 
contrary to the previously published report, we could find no evidence for substantial 
expression of GPRA in normal lung samples or in tissue biopsies from the asthmatic lung by 
quantitative PCR.  The earlier observations were based largely on the expression of GPRA 
detected by antibodies specific for the two isoforms of GPRA.  We cannot rule out the 
possibility that the differences between our findings reflect an extreme disconnect between 
mRNA and protein levels.  However, inconsistent with this interpretation, Laitinen et al. 
present northern analysis of lung tissue demonstrating detection of two, albeit faint, bands 
corresponding to the GPRA isoforms with a GPRA specific probe.   We cannot explain these 
discrepancies.  However, consistent with our studies of the allergic mouse airways, extensive 
analysis of tissues and cell lines fail to support a model in which substantial levels of GPRA 
are expressed by either human epithelium or airway smooth muscle cells.  
While genetic studies identified GPRA as a potential risk factor for asthma, studies by 
Xu and colleagues simultaneously identified GPRA as the neruopeptide S receptor (NPSR).  
These studies demonstrated that NPSR1/GPRA is highly expressed in the brain, with the 
highest levels detected in the hypothalamus.  They further demonstrated that central 
administration of NPS results in increased locomotor activity, altered sleep states, and 
increased anxiolytic-like effects in mice, thus suggesting that NPSR1/GPRA can play a role 
in arousal and anxiety (37).  This raises the interesting possibility that NPSR1/GPRA may 
affect airway function as a result of its role in the nervous system.  A number of reports 
suggest that the pathogenesis of many chronic inflammatory diseases including atopic 
dermatitis (AD), rheumatoid arthritis (RA), and asthma can be modulated by stress and 
emotion.  For example, studies have reported that some asthmatics demonstrate a reduction 
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 in pulmonary function in response to increased anxiety levels evoked by exposure to 
emotionally charged films (27), listening to stressful interactions (17), and participating in a 
sustained stressful life event (final academic examinations)(22).  Increasing evidence 
suggests that the biological basis for these observations involves alterations of the stress 
response, which can contribute to dysfunctional interactions between the neuroendocrine and 
immune systems.  These interactions are likely mediated by the hypothalamo-pituitary-
adrenal axis (HPA axis) via regulation of circulating concentrations of corticosteroid 
hormones, such as corticosterone (reviewed by (10)).  These hormones are potent modulators 
of both immune and neuronal mechanisms.  Interestingly, studies in rats have demonstrated 
that intracerebroventricular (ICV) and paraventricular nucleus (PVN) administration of NPS 
significantly increases plasma levels of adrenocorticotropic hormone (ACTH) and 
corticosterone (30).  A recent study of mice lacking corticotropin-releasing hormone (CRH) 
also demonstrated the ability of this pathway to modulate inflammation in a mouse model of 
allergic lung disease (29).  This raises the possibility that polymorphisms in the 
NPSR1/GPRA gene could alter the activity of the HPA axis and in this manner impact the 
risk for the development of asthma, although increased activity would be predicted to inhibit, 
rather than enhance, inflammatory disorders.     
The high expression of NPSR1/GPRA in the nervous system suggests a second 
possible mechanism by which altered function of this receptor might influence the 
pathogenesis of asthma.  The human airway is highly innervated, and expression of GPRA, 
either on sensory or cholinergic neurons, could influence the tone of the airway smooth 
muscle or the response to stimuli.  Although not specifically addressed, it is possible that 
various neuronal populations in the lung express NPSR1/GPRA.  This expression would be 
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 difficult to detect by analysis of total RNA, but could dramatically impact the pathogenesis 
of asthma and particularly the development of AHR.   In this regard, it was of interest that the 
only difference discerned between the wild type and GPRA-/- mice was an attenuation in 
airway resistance in response to the thromboxane A2 analog U46619.  Analysis of a large 
cohort of 129/SvEv mice and co-isogenic NPSR1/GPRA-/- animals demonstrated a small but 
significant decrease in the change in airway resistance.  The difference appears to be 
confined to the central airways, as no significant difference was observed in the G and H 
parameters, which are sensitive to changes in the distal lung.  Previous studies have 
demonstrated that U46619 facilitates airway smooth muscle constriction through an M3 
muscarinic acetylcholine receptor (M3 mAChR) dependent mechanism (2).  It has been 
suggested that this mechanism likely involves afferent and efferent neural signaling (1, 2, 
15).  This leaves open the possibility that polymorphisms in NPSR1/GPRA could alter 
neurally mediated mechanisms affecting smooth muscle constriction and airway function and 
in this way increase the risk for asthma.  
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